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ABSTRACT OF DISSERTATION

COMPUTATIONAL ANALYSES OF THE UPTAKE AND DISTRIBUTION OF
CARBON MONOXIDE (CO) IN HUMAN SUBJECTS

Carbon monoxide (CO) is an odorless, colorless, tasteless gas that binds to hemoglobin
with high affinity. This property underlies the use of low doses of CO to determine
hemoglobin mass (MHb) in the fields of clinical and sports medicine.

However,

hemoglobin bound to CO is unable to transport oxygen and exposure to high CO
concentrations is a significant environmental and occupational health concern. These
contrasting aspects of CO—clinically useful in low doses but potentially lethal in higher
doses—mandates a need for a quantitative understanding of the temporal profiles of the
uptake and distribution of CO in the human body. In this dissertation I have (i) used a
mathematical model to analyze CO-rebreathing techniques used to estimate total
hemoglobin mass and proposed a CO-rebreathing procedure to estimate hemoglobin mass
with low errors, (ii) enhanced and validated a multicompartment model to estimate O2,
CO and CO2 tensions, bicarbonate levels, pH levels, blood carboxyhemoglobin (HbCO)
levels, and carboxymyoglobin (MbCO) levels in all the vascular (arterial, mixed venous
and vascular subcompartments of the tissues) and tissue (brain, heart and skeletal muscle)
compartments of the model in normoxia, hypoxia, CO hypoxia, hyperoxia, isocapnic
hyperoxia and hyperbaric oxygen, and (iii) used this developed mathematical model to
propose a treatment to improve O2 delivery and CO removal by comparing O2 and CO
levels during different treatment protocols administered for otherwise-healthy COpoisoned subjects.
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Chapter 1: INTRODUCTION

1

Inhalation of carbon monoxide (CO) interrupts the efficient mechanism of
hemoglobin (Hb) molecule to transport oxygen. O2 is stored in the lungs as a gas and in
the blood. In the blood it is present in two (Vander et al., 2004) forms: (1) dissolved in
plasma (normally 1.5% or 3 ml in 1 liter blood) and (2) reversibly combined with
hemoglobin (normally 98.5% or 197 ml in 1 liter blood). Each hemoglobin molecule can
bind to four oxygen molecules forming fully-saturated oxyhemoglobin (HbO2). Hb is
present in the red blood cells and O2 transport to the tissues occurs primarily in the HbO2
form, as there are about 280 million Hb molecules in each red blood cell. CO is an
odorless, colorless, tasteless gas that has a much higher binding affinity for hemoglobin
and competes with O2 for the same binding sites on Hb. Hb binds CO ~220 times more
strongly than it binds O2, to form carboxyhemoglobin (HbCO). In the presence of CO,
the oxygen dissociation curve shifts to the left resulting in increased affinity of Hb for O2.
This increased affinity prevents unloading of O2 from Hb and impairs O2 delivery to the
tissues. Thus inhalation of CO can decrease the oxygen-carrying capacity of hemoglobin
and impair tissue oxygenation.
In addition to Hb, CO also binds to myoglobin (Mb). Mb is a monomeric heme
protein present in the muscle tissue and each myoglobin molecule can bind to one O2
molecule forming oxymyoglobin (MbO2). Mb is an oxygen store and also binds to CO to
form carboxymyoglobin (MbCO). Mb binds CO ~36 times more strongly than it binds
O2. Thus, inhalation of CO can decrease the oxygen-storing capacity of myoglobin and
impair tissue oxygenation.
Exposure to CO concentrations exceeding permissible exposure levels (average of
50 ppm over 8 hrs) is a significant environmental and occupational health concern (EHC,
1979; Raub et al., 1999). There are approximately 4000 deaths and over 40,000
emergency department visits resulting from CO exposures in the United States each year
(Raub et al., 2000; Tucker and Eichold, 2005). CO toxicity causes mortality primarily
due to the effects of severe hypoxia by attaching itself to Hb and Mb and reducing the
oxygen carrying capacity of these heme proteins. Both the therapy (i. e., normobaric vs.
hyperbaric oxygen) and the duration of treatment are determined by the percent of
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%HbCO in the blood and the state of consciousness of the patient when admitted to the
hospital. Unfortunately, the %HbCO provides limited information regarding the total
body burden of CO and the severity of the CO exposure because %HbCO correlates only
weakly with extravascular CO content, and because a given %HbCO could have been
achieved via an infinite variety of exposure conditions.
Although high doses of CO are toxic, techniques involving rebreathing relatively
low concentrations of CO have been used with moderate success in both clinical and
sports medicine to measure total hemoglobin mass, a value which provides information
regarding adaptation to exercise training and various illnesses (Heinicke et al., 2001;
Garvican et al., 2010; Schmidt and Prommer, 2005, 2010). As is the case with CO
poisoning, the accuracy of CO-rebreathing methods is dependent on the ability to account
for all the CO in the body, which %HbCO levels alone do not provide.
It would be difficult, and in some cases impossible, to obtain the information
necessary to accurately determine the total body burden of CO in a patient (CO poisoned
victim) or a study subject (hemoglobin mass determination). The total body burden of CO
is the amount of CO present in the blood (%HbCO), lungs, nonmuscle tissue and muscle
tissue (%MbCO). Determination of total body burden of CO is diffcult mainly because
non-invasive measurements of MbCO are not possible. Use of a mathematical model,
however, greatly improves the ability to address this question of assessing the total body
burden of CO. I hypothesize that “using a validated mathematical model to accurately
estimate the amount of CO bound to myoglobin during and after CO inhalation will (i)
allow improving the accuracy of CO-rebreathing methods to determine hemoglobin mass
and (ii) aid in suggesting treatments ensuring fast CO removal from the body, after CO
poisoning.”
Our laboratory has developed mathematical models that predict the uptake,
distribution, and elimination of CO under a variety of exposure conditions (Bruce and
Bruce, 2003,2006; Bruce et al., 2008). In my MS thesis, I enhanced the most recent
model (Bruce et al., 2008) by adding a separate myocardial compartment and assessing
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the effects of exercise on myocardial oxygen content in the presence of CO (Erupaka et
al., 2010). My doctoral dissertation comprises three projects, where each project is
designed to accomplish the Specific Aims listed below.
The first Specific Aim of my Doctoral dissertation was to use this enhanced
model (Erupaka et al., 2010) to evaluate two commonly used CO rebreathing methods
(Burge and Skinner, 1995; Schmidt and Prommer, 2005) to estimate hemoglobin mass
(MHb) and to propose an alternative method with lower errors than the methods currently
in use. The main aim of this project was to use a validated mathematical model to
simulate the two commonly used CO rebreathing protocols (Burge and Skinner, 1995;
Schmidt and Prommer, 2005) for a population of healthy subjects and then analyze the
simulation results to determine any potential sources of errors in estimation of MHb. As a
process of validation experimentally measured %HbCO levels (Garvican et al., 2010)
from healthy human subjects during the two CO rebreathing protocols were compared
with the model estimated %HbCO levels. Also, a new standardized CO rebreathing
method to determine MHb with lower errors than the methods currently in use has been
proposed and modifications to the existing CO rebreathing methods to improve
estimation of MHb have been suggested. Methods to accomplish the first Specific Aim are
discussed in detail in chapter 2 of this dissertation.
The second Specific Aim was to further enhance the earlier model
(Erupaka et al., 2010) in order to be able to model the effects of poikilocapnic
normobaric (NBO2), isocapnic normobaric (INBO2) and poikilocapnic hyperbaric
(HBO2) oxygen therapy on brain oxygen levels. To achieve this aim it was necessary to
enhance the model by adding a separate brain tissue compartment and to include control
of ventilation, cardiac output, and brain blood flow with changes in O2 and CO2 levels. In
order to understand the role of CO2 during isocapnic and poikilocapnic treatment
protocols, mass balance equations for CO2 were added for all the compartments in the
model. The main aim of this project was to enhance my earlier model and validate it for
various conditions of changing O2 or CO2 concentrations like hypoxia, hyperoxia,
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hyperbaric oxygen, hypercapnia and hypocapnia. Methods to accomplish the second
Specific Aim are discussed in detail in chapter 3 of this dissertation.
The third Specific Aim was to use this enhanced and validated model to predict
PO2’s in the brain, heart and skeletal muscle tissues, and to compare the rates of CO
removal in CO-poisoned patients treated with NBO2, HBO2 or INBO2. The main aim of
this project was to compare NBO2, HBO2 and INBO2 therapies, to determine the best
treatment strategy to be administered, ensuring fastest CO removal and O2 delivery after
healthy subjects were exposed to varying concentrations and durations of CO poisoning.
Methods to accomplish my third Specific Aim are discussed in detail in chapter 4 of this
dissertation.
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Chapter 2: Computational Analyses of Carbon monoxide (CO) Rebreathing
Methods to Estimate Hemoglobin Mass in Humans

Contents of this chapter will be submitted as a manuscript
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INTRODUCTION
Determination of total hemoglobin mass (MHb) is important in the fields of
clinical and sports medicine (Garvican et al., 2010; Heinicke et al., 2001; Schmidt and
Prommer, 2005). Routine measurements of MHb are made to determine the effects of
adaptation to exercise training, environmental stresses, illness and trauma. Radioactive
methods and dilution techniques are the most popular procedures to measure MHb.
Determinations of MHb from the radioactive methods are reliable but have the
disadvantage of being radioactive. The radioactivity is due to injection of radioactive
markers like 51Cr or 11CO-labeled RBC’s. The dilution techniques to determine MHb are
less harmful due to the usage of safe doses of carbon monoxide (CO), Evans blue dye or
indocyanine green as markers. Recently Gore et al. (2005) had concluded that the
determination of MHb using the CO rebreathing dilution technique has an error
comparable to that of the radioactive methods and also errors lower than that obtained
from other dilution techniques.
In the CO rebreathing methods, a known volume of CO ( VCO t ) is rebreathed in
100% O2. The duration of rebreathing is different for the various CO rebreathing
protocols (Burge and Skinner, 1995; Garvican et al., 2010; Hutler et al., 2000, Schmidt
and Prommer, 2005). However, the two commonly used CO rebreathing techniques to
determine MHb were described by Burge and Skinner in 1995 and by Schmidt and
Prommer in 2005. In these methods during the process of CO rebreathing, CO leaves the
alveolar space and enters the vascular space via diffusion. In the vascular space, Hb binds
CO to form HbCO. Depending on the CO rebreathing protocol, administered CO can
leave the vascular space either by diffusion to the extravascular compartments containing
heme pigments like myoglobin (Mb), cytochrome c oxidase, etc or to the lungs (from
where CO is exhaled after the period of rebreathing). When equilibration of arterial and
venous HbCO levels occurs, CO is assumed to be well mixed in the vascular space. In the
CO rebreathing techniques, mixing time is determined as the time at which the %HbCO
levels obtained from two or more blood sites (arterial, capillary or venous) are equal.
Experimentally, the best one can do with current analyses of HbCO is to determine the
time at which the differences between %HbCO levels is ≤ 0.1%. The CO rebreathing
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methods are based on the principle that, after mixing of CO in the vascular space is
complete, the MHb equals to the ratio of the volume of CO bound to Hb (VCOHb) and the
maximal capacity of Hb to bind to CO (Equation 2.1).
M Hb = K iVCOHb i

100
.............................................2.1
1.58ΔHbCOi

where,
K=1 (as all values are in BTPS)
VCOHb= VCO t -VCO Lungs + rebreathing system at end of rebreathing (VCO L+S) VCO exhaled between end of rebreathing and time of blood sampling (VCO ex)VCO bound to myoglobin at Tsample (VCOMb)
∆HbCOi= Change in %HbCO between time T0 and Tsample for blood compartment
‘i’. where i= arterial (ar), capillary (cot, cm), venous (vm)
T0 = Start time of the experiment
Tsample = Sampling time
1.58= Hufners constant in BTPS (Gorelov, 2004)
A prerequisite to accurately calculate the MHb using these methods is to ensure
that mixing of CO in the vascular space is complete (trueTmix). Due to the measurement
limitations of %HbCO and dependence of determinations of trueTmix on these values, MHb
is calculated from blood samples taken at 1-2 min away from
referred to as sampling time, Tsample. Optimal values for

true

Tmix. This time is

true

Tmix or Tsample to calculate MHb

are often debatable in the CO rebreathing methods (Gore et al., 2006, Schmidt and
Prommer, 2005). Depending on the CO rebreathing method applied, estimated values of
the

true

Tmix (referred as Tmix in the text) range from 2-12 minutes (Burge and Skinner,

1995; Garvican et al., 2010; Schmidt and Prommer, 2005). Duration of CO rebreathing,
volume of CO administered, site of blood sampling and variability among subjects may
be some of the factors contributing to a wide range of Tmix values obtained from various
CO rebreathing methods (Burge and Skinner, 1995; Garvican et al., 2010; Gore et al.,
2006; Schmidt and Prommer, 2005). Also the %HbCO values at Tsample are influenced by
the site of sampling and diffusion of CO from vascular space to extravascular tissues or
to the lungs (Garvican et al., 2010). In a given subject for a CO rebreathing method,
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sampling for %HbCO from different blood sites (arterial, capillary, venous) before
complete mixing of CO in the vascular space results in different estimates of MHb
(Garvican et al., 2010). Thus the reliability and accuracy of MHb estimation is dependent
on the blood sites sampled for %HbCO measurements (Equation 2.1) and determination
of Tmix.
Another prerequisite for accurate estimation of MHb from CO rebreathing methods
is to be able to account for the entire volume of CO at Tsample that has been administered
at the start of the experiment (T0). Thus the estimation of MHb is dependent on the
calculation of the volume of CO bound to hemoglobin, VCOHb and %HbCO (Equation
2.1). However, the calculation of VCOHb is dependent on the measurements of (i) the
volume of CO in the lungs and the rebreathing system at the end of rebreathing (VCO
L+S), (ii) the volume of CO exhaled from the end of rebreathing to Tsample (VCO ex), and
(iii) the volume of CO bound to Mb at Tsample (VCOMb). Thus, any errors in determination
of VCO L+S, VCO ex, or VCOMb may lead to either an overestimation or underestimation of
total hemoglobin mass, MHb (Garvican et al., 2010; Steiner and Wehrlin, 2010).
Prior to 2007, estimation of MHb from CO rebreathing methods assumed no loss
or minimal loss of CO (1% of VCO t ) to Mb (Burge and Skinner, 1995; Hutler et al., 2000;
Gore et al., 2006; Schmidt and Prommer, 2005). In 2003, Bruce and Bruce used their
multicompartment model to simulate a CO rebreathing method (Burge and Skinner,
1995) and concluded that Mb in the muscle tissue is a reservior for binding CO. Inspired
by the findings of this model, recently Prommer and Schmidt (2007) have derived a
formula to estimate VCOMb and concluded that ~2% of VCO t is bound to Mb. This formula
was derived on the assumption that there is constant flux of CO from blood to the tissues
containing Mb. The errors introduced in determination of MHb due to using this formula
are not known. In the recent CO rebreathing experiments (Garvican et al., 2010; Steiner
and Wehrlin, 2010), using Prommer and Schmidt’s formula (2007) to determine VCOMb
resulted in higher estimates of MHb from Burge and Skinner’s method (1995) when
compared to Schmidt and Prommer’s method (2005). The inability to account for the loss
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of CO from Hb to Mb present in muscle tissues will lead to an overestimation of total
MHb.
The existing CO rebreathing methods result in different estimates of MHb for a
given subject (Garvican et al., 2010; Steiner and Wehrlin, 2010), thus questioning the
reliability and accuracy of these methods to determine MHb. Differences in the estimates
of MHb from these methods makes it difficult to compare results from different studies
which measure MHb to determine the effects of adaptation to exercise training, altitude
and other blood related illnesses. In order to evaluate a CO rebreathing method which
estimates MHb with low errors, it would be better to compare the estimates of MHb with a
known value of MHb (AMHb). The commonly used CO rebreathing methods make various
assumptions in calculating VCO L+S (Burge and Skinner, 1995), VCO ex (Schmidt and
Prommer, 2005), or VCOMb (Prommer and Schmidt, 2007). Errors in determination of
VCOL+S, VCO ex, or VCOMb due to these assumptions may lead to either an overestimation
or underestimation of total hemoglobin mass, or, possibly, to compensating errors
(Equation 2.1). Also, it is important to know if the differences in MHb from different CO
rebreathing methods are due to the variations in these methods to estimate MHb or due to
errors in the underlying concepts of CO dilution techniques to determine MHb.
Thus the main aim of this study is to use a validated mathematical model to
simulate the two commonly used CO rebreathing protocols (Burge and Skinner, 1995;
Schmidt and Prommer, 2005) for a group of healthy subjects and then analyze the
simulation results to determine any potential sources of errors in estimation of MHb
( Mˆ Hb ). As a process of validation experimentally measured %HbCO levels (Garvican et
al., 2010) in nine healthy human subjects from three different blood compartments
(arterial, capillary and venous), during the two CO rebreathing protocols were compared
with the model estimated %HbCO levels. In addition the model estimated MHb was
compared to the experimentally determined MHb. Also, a new CO rebreathing method to
determine Mˆ Hb with low errors, independent of the site of sampling has been proposed
and modifications to the existing CO rebreathing methods to improve estimation of MHb
have been suggested. In addition the blood sampling site and the values for Tmix and
10

Tsample, to obtain low errors in Mˆ Hb independent of the CO rebreathing method used to
estimate MHb have been determined.

METHODS
Model description
The mathematical model used in this study has been described in detail previously
(Erupaka et al., 2010). This validated model was capable of predicting time varying
%HbCO levels, carboxymyoglobin (%MbCO) levels and O2 tensions in various tissue
and blood compartments for a variety of CO exposures (Erupaka et al., 2010). The major
features of this model are the expansion of a standard single lumped compartment
representation of skeletal muscle tissues into two tissue subcompartments interacting with
three vascular subcompartments (Bruce et al., 2008) and an addition of a cardiac
compartment (Erupaka et al.,2010) with an architechture similar to that of the skeletal
muscle. This model (Erupaka et al., 2010) was shown to reproduce experimental data
from transient CO exposure (Benignus et al., 1994) and one of the CO rebreathing
method (Burge and Skinner, 1995). The %HbCO predicted by the model for arterial
(%HbCOar) and skeletal muscle venous (%HbCOvm) blood compartments were in
agreement with the experimentally measured arterial and venous %HbCO values (Bruce
and Bruce, 2008; Erupaka et al., 2010). %HbCOvm is the %HbCO of the blood exiting
from the third vascular subcompartment of skeletal muscle tissue. In addition to arterial
and antecubital venous blood sites, the two common sites of measurement for capillary
blood samples in CO rebreathing protocols are finger tips or ear lobe. In the current
model, a blood site equivalent of measurements made from pre-warmed finger tip is
assumed to be the %HbCO in blood entering the second vascular subcompartment of
skeletal muscle tissue (%HbCOcm). As fingers contain Mb, this blood site is assumed to
surround the skeletal muscle subcompartment of the model. A model equivalent of
%HbCO measurements made from the ear lobe is assumed to be that from the venous
vascular compartment of the nonmuscle tissue (%HbCOcot).
To determine Mˆ Hb from the model, equations 2.2-2.4 were added to the model
(See Table 2.1-2.2 for details). For Garvican’s data set, MHb was also estimated using
11

equation 2.1a in equation 2.1. In the model, VCOMb is calculated from the tissue volumes
and MbCO concentrations of skeletal and cardiac muscle subcompartments (Equation
2.2). VCOex and VCO L+S are calculated using equations 2.3-2.4. VCO exhaled calculated
in the model would be the equivalent of collecting the expired CO over a specified
duration of time in an experiment, e.g., VCO ex is the volume of exhaled CO collected
from the end of rebreathing to Tsample. VCO L+S calculated in the model would be the
equivalent of measuring volume of CO in the lungs and rebreathing system at a specific
time, depending on the CO rebreathing method e.g., VCO L+S at Tsample or VCO L+S at the
end of rebreathing.
VCOHb = ∑ Vbi i[ HbCO ]i ............................2.1a

where,
Vbi and [HbCO]i are the blood volume and concentration of Hb bound to CO in vascular
compartment ‘i’. i= arterial (ar), three vascular subcompartments of skeletal muscle
(bm1,bm2,bm3), three vascular subcompartments of cardiac muscle (bc1,bc2,bc3), other
tissue venous blood compartment (vot) and mixed venous blood compartment (mx).

⎧Vm1 i MbCOm1 + Vm2 i MbCOm2
⎫
VCOMb = ⎨
⎬ ............................2.2
⎩+Vcm1 i MbCOcm1 + Vcm2 i MbCOcm2 ⎭
where,
Vm1 and Vm2 are tissue volumes of skeletal muscle subcompartments. Vcm1 and Vcm2 are
tissue volumes of cardiac muscle subcompartments. MbCOm1 and MbCOm2 are MbCO
concentrations in skeletal muscle subcompartments at Tsample. MbCOcm1 and MbCOcm2
are MbCO concentrations in cardiac muscle subcompartments at Tsample.
Tsample

VCO ex =

∫

VA iC ACO(t ) dt.....................................................2.3

Tend of rebreathing

where,

V

A

= Measured alveolar ventilation

CACO(t)= Alveolar CO concentration
VCO ex is zero in protocol B.
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.

VCO L + S = (VRS + VLV )iC ACOt =T ..........................................2.4
where,
VRS= Volume of rebreathing system or spirometer
VLV= Lung volume = Functional residual capacity for protocol B and residual volume for
protocol P
CACO= Alveolar CO concentration at time ‘T’
T= Tsample for protocol B and end of rebreathing time (2 min) for protocol P.
Simulation Description
This study comprised simulations of two commonly used CO rebreathing methods
on two different data sets (See section “Data sets used for simulations of CO rebreathing
protocols” for details). The first data set was provided by Garvican et al. (2010) and was
used for model validation. The second data set was provided by Benignus et al. (1994)
and was used to analyze potential sources of errors in calculation of Mˆ Hb from the CO
rebreathing methods.
To validate the model and assess its predictive power to estimate %HbCO levels
and MHb in different blood compartments, I used the mathematical model to simulate the
CO rebreathing experiments of Garvican et al. (2010) in nine healthy (2 female, 7 male),
recreationally-active, human subjects. Each subject was individually simulated using the
subject specific parameters provided by the investigators, Garvican et al. (2010). The
model estimated %HbCOar, %HbCOcm, and %HbCOvm for each subject were compared
with their respective experimentally measured %HbCO levels, for the two CO
rebreathing methods described in their study (Garvican et al., 2010).

If the model

predicted mean ± SD values of %HbCO from all the nine subjects were within the 95%
confidence limits of the experimental data, then the model was considered to be capable
of reproducing the experimental data. Garvican et al. (2010) also provided us with the
best estimates of MHb for each subject and these values were considered as AMHb for this
data set. MHb from four different blood compartments was estimated from the model
using the predicted %HbCO levels and VCOHb (Equation 2.1a). Errors in estimation of
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MHb from the two CO rebreathing protocols at different time points were calculated by
comparing the model calculated MHb and AMHb. It was assumed that, irresepective of the
blood site sampled obtaining errors less than 2% would imply that the model is capable
of estimating the experimentally determined MHb, AMHb. As Garvican’s data was used to
validate the model for prediction of %HbCO’s and Mˆ Hb ’s in various blood
compartments, this data set was not used for detailed analysis of determining potential
sources of errors in the CO rebreathing methods.
Data (Benignus et al., 1994) from fifteen healthy, male human subjects with
known MHb, (AMHb) were used to simulate the two CO rebreathing studies. AMHb for each
subject was calculated as the product of blood volume (measured by Na251CrO4 dilution
method) and hemoglobin concentration (measured by IL-282 CO-oximeter) provided by
the investigators. To allow detailed analysis of CO rebreathing methods to estimate MHb,
this study comprised simulations of the methods described by Burge and Skinner in 1995
(which I refer to as protocol B) and by Schmidt and Prommer in 2005 which was later
modified by Prommer and Schmidt in 2007 (which I refer to as protocol P). The volume
of CO administered for a given subject was the same in both the protocols, i.e. 1 ml of
CO/Kg of body weight (BW). For protocols B and P, the model was used to determine
the uptake and distribution of CO in each subject. The time varying %HbCO’s from the
arterial, capillary other tissue, capillary muscle and muscle venous blood compartments
(symbolized by %HbCOar, %HbCOcot, %HbCOcm, %HbCOvm) and alveolar CO
concentrations (CACO) were calculated by the model for protocols B and P. The
simulation results of each subject were analyzed to calculate Mˆ Hb and then compared to
the AMHb. In this study, Mˆ Hb was determined using (i) the exact values from the model
for VCO L+S, VCO ex, and VCOMb ( Mˆ Hb thus calculated will be referred as

M

Mˆ Hb ) and (ii)

approximated values based on the published formulas for calculating VCO L+S, VCO ex,
and VCOMb ( Mˆ Hb thus calculated will be referred as E Mˆ Hb ).

M

Mˆ Hb was calculated and

compared to AMHb of the subjects to ensure that any errors in calculation of Mˆ Hb are
probably due to the assumptions made in the methods of calculating it in the experiments
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rather than to the errors in the predicted data (VCOHb, VCO L+S, VCO ex, and VCOMb) from
the model. Also, E Mˆ Hb was compared to AMHb to determine the potential possibility of
errors in estimation of MHb from the existing CO rebreathing methods. The major sources
leading to errors in calculation of Mˆ Hb from the two CO rebreathing methods were
determined on comparing the values of VCO L+S, VCO ex, and VCOMb used to calculate
M

Mˆ Hb and

E

calculation of

Mˆ Hb (See section “Estimation of hemoglobin mass” for details on
M

Mˆ Hb and

E

Mˆ Hb ).

It was assumed that if the errors obtained on

comparison of AMHb with the Mˆ Hb calculated from the model are less than 2%, it would
imply that the errors in calculation of

E

Mˆ Hb are not due to errors in the underlying

concepts of CO rebreathing methods or due to the errors in calculation of

M

Mˆ Hb . See

Table 2.1 for symbols and definitions.
Simulated CO rebreathing protocols
This study comprised (i) simulations of CO rebreathing methods as described by
Garvican et al. (2010) in healthy, recreationally-active subjects to validate the model and
(ii) simulations of protocol B and protocol P in healthy subjects (Benignus et al., 1994) to
allow detailed analysis of CO rebreathing methods to estimate MHb. ACSLTM version
11.8 was used for implementing the model and running the simulations. ACSL is a
computer language designed for modelling and evaluating the performance of systems
described by time-dependent, nonlinear differential equations. Simulations were
performed in double precision and a 12 min stabilization period was initiated with every
simulation run for the baseline simulation to reach a steady state. For the duration of
rebreathing, the rebreathing system or the spirometer and the lungs form a closed circuit.
To simulate rebreathing, the lung volume was augmented by the volume of the
rebreathing system or spirometer and alveolar ventilation was set to zero.
To validate the model, CO rebreathing methods described by Garvican et al.
(2010) were simulated. The CO rebreathing methods in their study are similar to
protocols B and P described below, but with some changes in the CO dose administered.
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To simulate protocol B, each subject rebreathed 1 ml of CO/Kg of body weight in
~99% O2 for a duration of 40 mins. Also oxygen flow rate equal to the metabolic uptake
was added to the rebreathing bag to avoid hypoxia as a result of underfilling of the bag.
In this protocol the subject is on 100% O2 prior to rebreathing. The lung volume was
augmented by the volume of the rebreathing system of 3.5 L.
To simulate protocol P, each subject rebreathed 1 ml of CO /Kg of BW in ~ 99%
O2 for 2 mins. Prior to CO rebreathing, the subject is on room air. CO rebreathing was
followed by 13 mins of normal breathing on room air. The lung volume was augmented
by the volume of the rebreathing system of 2 L.
Estimation of hemoglobin mass (MHb)
In the study conducted by Garvican et al. (2010), the investigators have provided
information regarding (personal communication) the sampling time and blood site at
which the best estimates of MHb were obtained in their subjects for the two CO
rebreathing methods. The best estimates of MHb from their study were used as the MHb
for the model simulations and were considered as AMHb to allow comparison with

M

Mˆ Hb

or E Mˆ Hb . For the Burge and Skinner method, AMHb was obtained at a Tsample of 12.5 min
in four subjects and at 10 min in five subjects. The blood sampling site was arterial blood
in 8 subjects and capillary blood in 1 subject. For the Schmidt and Prommer method
A

MHb, was obtained at Tsample of 7.5 min (2 subjects), 10 min (4 subjects) and 12.5 min (3

subjects). The blood sampling site was arterial blood in 6 subjects and capillary blood in
3 subjects. For the two CO rebreathing protocols,

M

Mˆ Hb for these subjects was calculated

using the model equations 2.1-2.4 at the Tsample and the blood sites specified by the
investigators. Also MHb was estimated using the model predicted %HbCO levels and
VCOHb from equation 2.1a. This calculation was done to determine lower bounds on errors
produced by these methods for estimating MHb.

E

Mˆ Hb for all the subjects were calculated

using the formulas (Equations 2.5-2.7) described by Garvican et al. (2010) at the
specified Tmix, Tsample and blood site. In their study the formula to calculate VCO ex was
different from Equation 2.6, as alveolar ventilation ( V ) was estimated from a regression
A
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equation and the alveolar CO concentration (CACO) was measured at a different time
point. For the two CO rebreathing methods, the values obtained for E Mˆ Hb and

M

Mˆ Hb

were compared with AMHb.
For all the 15 healthy, male subjects of Benignus et al. (1994), MHb for protocols
B and P was estimated from %HbCO calculated by the model for four blood
compartments: arterial, venous blood of nonmuscle tissue (approximation of earlobe
blood), blood flowing into the capillary subcompartment of muscle tissue (approximation
of arterialized fingertip capillary blood) and muscle venous blood (symbolized by
subscripts ar, cot, cm and vm respectively). For a given protocol to determine the Tmix for
each subject; the time dependent pairwise differences (Figure 2.1) between %HbCO’s of
arterial, capillary (cot, cm) and venous blood compartments were plotted along with a
reference line at ±0.1. The time at which ∆%HbCO last crosses the 0.1 reference line was
considered as the Tmix. The criterion of 0.1 reference line to determine Tmix was chosen
due to the 0.1% detection limit of CO oximeter to measure %HbCO. After the Tmix was
determined in each subject for a given protocol, Tsample was calculated as 1.5 min from
Tmix.
To estimate MHb from equation 2.1, the %∆HbCO for each of the four blood sites
and the volume of CO bound to Hb (VCOHb) were calculated. The %∆HbCO value for a
specific blood compartment is calculated using the model predicted %HbCO’s of that
blood compartment at T0 and Tsample (%HbCOTsample - %HbCOTo). However, the VCOHb
(Table 2.2) was calculated using (i) model equations 2.2-2.4 (MVCOHb) and also using (ii)
the formulas published (EVCOHb) by the authors of protocols B and P (Schmidt and
Prommer, 2005; Prommer and Schmidt, 2007; Burge and Skinner, 1995) which are
described below and in Table 2.2. The authors of protocol B (Burge and Skinner, 1995)
used equation 2.5 to estimate VCO L+S and the authors of protocol P (Schmidt and
Prommer, 2005) used equation 2.6 to estimate VCO exhaled. VCOMb was estimated using
equation 2.7 in both the protocols (Prommer and Schmidt, 2007; Garvican et al., 2010).
Thus for a given protocol B or P,

M

Mˆ Hb is the MHb estimated using MVCOHb and E Mˆ Hb is

the MHb estimated using EVCOHb (Table 2.2). For the CO rebreathing methods, I assumed
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that if the errors obtained on comparison of AMHb with
then

M

M

Mˆ Hb or E Mˆ Hb are less than 2%,

Mˆ Hb or E Mˆ Hb will be considered as a good estimate of MHb.

VCO L + S =

2.2
iVCO t ...................................2.5
100

where,
VCO t = Total volume of CO administered
VCO ex = VA iΔT iC ACOt = 20 ...........................2.6

where,

V

A

= Assumed alveolar ventilation = 5L/min

∆T= Tsample - 2
CACO= Alveolar CO concentration at t=20 min

=V
V
COMb
COMb

•
Tmix −Tsample

Tsample
Tsample − Tmix

...........................2.7

where,
⎛
⎞
= ⎜V
-V
−
V
L + S -V
ex ⎟
COMb Tmix −Tsample ⎜ COt CO
CO ⎟
⎝
⎠Tsample
⎛ ΔHbCO
Tsample
⎜
⎜⎜ ΔHbCO
Tmix
⎝

⎞⎛
⎞
⎟i⎜ V
-V
L + S -V
ex ⎟
⎜
⎟
CO
⎟⎟ COt CO
⎠Tmix
⎠⎝

Data sets used for simulations of CO rebreathing protocols
Garvican et al. (2010) have compared uptake kinetics of CO in the CO
rebreathing methods which were proposed by Burge and Skinner (1995), and Schmidt
and Prommer (2005). This data set was used to validate my model. In this experiment
(Garvican et al.,2010), the investigators have measured time varying %HbCO levels from
three different blood sites (ar,cm,vm), age, body weight, height, volume of CO dose
administered, and Hb concentrations in nine healthy, recreationally-active subjects. Two
of their nine subjects were females. The %HbCO were taken from arterial (forearm),
capillary (finger tips) and venous (forearm) blood sites at different time points of the
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experiment. For the two CO rebreathing methods, the investigators have also provided
information regarding (personal communication) the sampling time and blood site at
which the best estimates of MHb were obtained in these subjects. The blood volume was
calculated from experimentally determined MHb and the Hb concentrations by Garvican
et al., 2010. For any given subject, these calculated blood volumes were differrent for the
two CO rebreathing methods. In the simulations of this study, using the blood volume
values from the Burge and Skinner method showed better agreement between the model
predictions of %HbCO levels and the experimental data. Thus in the simulations, values
for blood volume, MHb (AMHb) and Hb concentrations for all the subjects were used from
Burge and Skinner’s method. In the simulations, the rebreathing bag volume, ambient
temperature and ambient pressure were set to the experimentally measured values. Total
body oxygen consumption was calculated as 3.2 ml/Kg and cardiac output was estimated
from the regression equation (Equation C.3 in Appendix C of Erupaka et al., 2010).
Previous models from our lab were developed to simulate healthy human subjects (Bruce
and Bruce, 2008; Erupaka et al., 2010). In literature it was found that the capillary
density, mitochondrial content, heart rate and stroke volume at rest in untrained subjects
differed statistically from the healthy endurance trained human subjects (Andersen and
Henriksson, 1977; Brodal et al., 1977; Ingjer, 1979; Kalliokoski et al., 2001; Sagiv et al.,
2007; Tibes et al., 1977; Zoladz et al., 2005). Other parameters at rest like muscle blood
volume, muscle blood flow, cardiac output, metabolic rate or ventilation, did not differ
statistically between the trained and untrained groups (Kalliokoski et al., 2001; Sagiv et
al., 2007; Tibes et al., 1977). Thus to simulate CO rebreathing methods in healthy,
recreationally-active subjects, the muscle diffusion coefficient of CO (DMCO) and
capillary density of the skeletal muscle was increased by 34% (Brodal et al., 1977;
Zoladz et al., 2005). The DMCO was varied in proportion to muscle mass, with a value of
DMCO of 0.302 ml/min/Torr/Kg of muscle mass. As the subjects are assumed to be
trained, a heart rate of 51 beats/min was used (Kalliokoski et al., 2001; Sagiv et al., 2007;
Tibes et al., 1977) to estimate myocardial oxygen consumption and myocardial blood
flow (Erupaka et al., 2010). Values for all other parameters that were not provided by the
investigators and were not significantly affected with exercise training, were those used
in and referenced in my previous publication (Erupaka et al., 2010).
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Benignus et al. (1994) exposed fifteen healthy, male human subjects to high
concentrations of CO for short durations. This data set was used to analyze and determine
sources of errors in the CO rebreathing methods to estimate MHb. Previous versions of the
model were able to reproduce experimental data of arterial and venous %HbCO from all
the subjects for the transient CO exposure simulations (Bruce and Bruce, 2003; Bruce
and Bruce, 2006; Bruce et al., 2008). In this experiment (Benignus et al., 1994),
measurements of age, body weight, height, blood volume, hemoglobin concentration,
cardiac output, ventilation, initial %HbCO and lung diffusivity coefficient of CO were
provided by the investigators for each subject.

A

MHb for each subject was calculated as

the product of blood volume and hemoglobin concentration measurements. The blood
volume in this study was measured by Na251CrO4 dilution method. Total body oxygen
consumption was calculated as 3.2 ml/Kg. DMCO was varied in proportion to muscle
mass, with a value of DMCO of 0.225 ml/min/Torr/Kg of muscle mass. Values for all
other parameters that were not provided by the investigators have been referenced in my
previous publication (Erupaka et al., 2010).
Determination of effects of Tmix, Tsample and sampling blood site on estimation of MHb
In order to determine the effects of Tmix on estimation of MHb,

M

Mˆ Hb (the MHb

estimated using the exact values from the model for VCO L+S, VCO ex, and VCOMb) was
calculated for each CO rebreathing protocol from four blood compartments (ar, cot, cm,
vm) for Benignus’s subjects by varying the Tmix. In calculations of

M

Mˆ Hb , Tmix was

assumed as 1, 3, 5, 7, 9, 11, 13, 15 and 38 minutes and the difference between Tsample and
Tmix was always 1.5 min. For each subject, the calculated

M

Mˆ Hb at a different Tsample

(based on the Tmix value) was compared with the known hemoglobin mass of the subject,
A

MHb and the error in estimation of MHb was calculated from four different blood

compartments. For a given CO rebreathing method, the errors in calculation of MHb from
different blood sites and Tmix were plotted for these subjects. The minimal value of Tmix
and the blood sampling site at which low errors in estimation of MHb were obtained
independent of the CO rebreathing method applied, was determined. In this study I also
looked at the effects of changing various factors like Mb concentration, VCO t , DMCO (the
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muscle diffusion capacity of CO), duration of rebreathing, muscle blood flow and muscle
blood volume on Tmix in one of the Benignus’s subjects (S112, Benignus et al., 1994).
Also, to determine the effects of Tsample on estimation of MHb,

M

Mˆ Hb was

calculated from four different blood compartments (ar, cot, cm, vm) for protocols B and
P for Benignus’s subjects by varying the Tsample realtive to Tmix.

M

Mˆ Hb were calculated at

Tsample’s which were 1.5, 3, 5, 7, 9 and 11 minutes from the determined Tmix of each
subject. For a given CO rebreathing protocol, the Tmix for each subject was determined
based on the time at which the difference between the %HbCO’s from all the blood
compartments was ≤ 0.1%.

M

Mˆ Hb at different Tsample’s were compared with AMHb and the

errors in estimation of MHb from different blood sites and Tsample were plotted for these
subjects. The blood sampling site and the minimal value of Tsample at which low errors in
estimation of MHb were obtained independent of the CO rebreathing method applied, was
determined.

RESULTS

Model behavior
The time course of %HbCO levels from all the blood sites for protocol B and
protocol P for a single subject are shown in Figure 2.2. In both the protocols, arterial
blood %HbCOar peaks within the first 2 minutes and then decreases. The capillary blood
%HbCO rises initially and then reaches a plateau. Venous blood %HbCOvm increased
slowly and then reaches values similar to that of capillary blood %HbCOcm in both the
methods. Peak %HbCOar level is higher in protocol P than in protocol B. Mixing of CO
(based on determination of Tmix as shown in Figure 2.1) in blood occurred by ~11 min in
protocol B and by ~5 min in protocol P for the Benignus’s subjects. The above described
uptake kinetics of CO are qualitatively in agreement with the peak %HbCO levels and the
mixing times are quantitatively in agreement with the Tmix values reported in
experimental results of protocol B and protocol P (Burge and Skinner, 1995; Schmidt and
Prommer, 2005).
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Model Validation
The mathematical model was used to simulate the CO rebreathing experiments
described by Garvican et al. (2010) in nine (2 female, 7 male) healthy, recreationallyactive subjects. Each subject was individually simulated using the subject specific
parameters provided by the investigators and the time varying %HbCO levels in blood
were predicted by the model for the two CO rebreathing methods. The model is able to
reproduce the experimental measurements of the time varying %HbCO levels made in
three different blood compartments (%HbCOar, %HbCOcm, %HbCOvm) during the two
commonly used CO rebreathing methods (Figure 2.3-2.4). On the one hand, the model
predicted mean %HbCO ± SD values from the arterial (ar), capillary (cm) and venous
(vm) blood compartments at different time points are within the 95% confidence limits of
the experimental data for both the CO rebreathing methods. On the other hand, individual
comparison of model predicted %HbCO levels from all the three blood compartments (ar,
cm, vm) with the experimentally measured %HbCO levels at respective time points
showed a good agreement for both the CO rebreathing methods in 6 of the 9 subjects.
However, in three of the nine subjects, the rise in %HbCO levels of the blood
compartment “vm” during the initial five minutes was faster than the experimental data
for both the methods (Figure 2.16). After five minutes, the model predicted %HbCO
levels were similar to the experimentally measured values. In these three subjects I was
able to match the model predicted %HbCOvm levels with the experimental values by
decreasing the muscle blood flow and increasing the blood volume of muscle vascular
subcompartment 3 (Vbm3). In all the three subjects the muscle blood flow was decreased
by 20% and the blood volume Vbm3 was increased by 20% of the total mixed venous
blood volume (Figure 2.16). However even prior to changing the values of muscle blood
flow and Vbm3 in 3 of the 9 subjects, the model predicted mean %HbCO levels from all
the three blood compartments are in good agreement with the mean %HbCO levels made
from the experiments of Garvican et al. (2010) for the Burge and Skinner method (Figure
2.3) and the Schmidt and Prommer method (Figure 2.4). Thus, the model is able to
reproduce the experimental measurements of time varying %HbCO levels from three
different blood compartments and predicts the uptake and distribution of CO during the
commonly used CO rebreathing methods.
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Model estimates of MHb ( M Mˆ Hb ) from the CO rebreathing methods
M

Mˆ Hb , the MHb estimated using the exact values from the model (Equations 2.1-

2.4, Table 2.2) for VCO L+S, VCO ex, and VCOMb was calculated for the data sets of
Garvican et al., 2010 (9 healthy-2 female and 7 male, recreationally-active subjects) and
Benignus et al., 1994 (15 healthy, male subjects).

For the two CO rebreathing methods,

M

Mˆ Hb for Garvican’s subjects was

calculated using the Tsample and the blood sites specified by the investigators. In my
simulations of this study the values for the known MHb, AMHb for Garvican’s subjects
were used from the Burge and Skinner’s method of the experiments of Garvican et al.
(2010).

M

Mˆ Hb calculated from these subjects underestimated AMHb by 0.32±0.8% in the

Burge and Skinner method and by 2.2±0.49% in the Schmidt and Prommer method. In
the simulations of Schmidt and Prommer method, using the MHb estimated from Schmidt
and Prommer method of the experiments of Garvican et al. (2010), did not change the
errors obtained in calculation of

M

Mˆ Hb (2.18±0.46%).

In addition, Equation 2.1 was used to calculate time varying MHb using the model
estimated VCOHb (Equation 2.1a) and %HbCO’s from four different blood compartments.
For the Burge and Skinner method (Figure 2.5A) irrespective of the blood site sampled,
errors less than 2% in estimation of MHb occurred at ~ 16 min. Estimates of MHb were
close to the actual MHb values from arterial (ar) and capillary other tissue (cot) blood sites
at ~ 9 min. The estimates of MHb from all four blood sites were never equal, suggesting
incomplete mixing of CO in blood. For the Prommer and Schmidt method (Figure 2.5B)
irrespective of the blood site sampled, errors less than 2% in estimation of MHb occurred
at ~ 7 min. Estimates of MHb were close to the actual MHb values from all the blood sites
at ~ 9 min. Also, the estimates of MHb from all four blood sites were similar at ~ 9 min,
suggesting complete mixing of CO in blood. These results suggest that the model is
capable of calculating MHb from both the CO rebreathing methods with ~ 0 errors at the
capillary and arterial sampling blood sites and sampling time of ~ 9 min.
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M

Mˆ Hb for the data set of Benignus et al. (1994) was calculated for the two CO

rebreathing protocols B and P using equations 2.1-2.4 (Table 2.2) for arterial (ar),
capillary other tissue (cot), capillary muscle (cm) and muscle venous (vm) blood
compartments. Tmix for each subject was determined based on the time at which the
differences between %HbCO’s from all the blood compartments was ≤ 0.1% (See
methods, Figure 2.1). Tsample was considered 1.5 min away from Tmix. AMHb for the data
set of Benignus et al. (1994) was calculated for each subject as the product of blood
volume (measured by Na251CrO4 dilution method) and Hb concentration reported in their
study. The

M

Mˆ Hb calculated for the Benignus’s subjects for both the protocols B and P

are in agreement with the AMHb of these subjects (Table 2.3). The mean errors averaged
across the subjects for

M

Mˆ Hb from the “cm” and “vm” blood sites are slightly larger

(~2%) for protocol B. These errors are due to the sensitivity of MHb to variability in
values of %∆HbCO (Burge and Skinner, 1995; also see discussion), as %∆HbCO values
at Tsample depend on the blood sampling site.
Overall, depending on the site of sampling the values of

M

Mˆ Hb for both the CO

rebreathing methods from the data sets of Garvican et al. (2010) and Benignus et al.
(1994) are within 2% of AMHb. This result ensures that the validated model is capable of
calculating good estimates of MHb ( M Mˆ Hb ) for protocols B and P and that any errors in
calculation of Mˆ Hb are probably due to the method of calculating Mˆ Hb from the existing
CO rebreathing methods. This result also ensures that the errors in estimation of MHb are
not due to errors in the concepts for estimating MHb from CO rebreathing methods.
Experimental estimates of MHb ( E Mˆ Hb ) from the CO rebreathing methods
E

Mˆ Hb is the estimate of MHb which is calculated using the approximated values based on

the published formulas for calculating VCO L+S, VCO ex, and VCOMb. The model
calculated %HbCOar, %HbCOcot, %HbCOcm, and %HbCOvm are assumed to be
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experimental equivalents of %HbCO measurements made from arteries in the forearm,
ear lob, pre-warmed finger tips and veins in the forearm respectively.
For the data set of Garvican et al. (2010), E Mˆ Hb for the two CO rebreathing
methods were calculated using the equations provided by Garvican et al. (2010) for
calculating VCOL+S, VCO ex, and VCOMb at the specified Tmix, Tsample and blood site. In
Garvican’s subjects E Mˆ Hb underestimated AMHb by 2.2± 0.9 % in the Burge and Skinner
method and by 5.8±0.5 % in the Schmidt and Prommer method. As Garvican et al. (2010)
did not measure alveolar ventilation ( V ) in their subjects nor did they provide the
A
regression equation used to estimate V

A

in their study, the V

A

estimated from the model

(See section “Model parameters” for details) was used to calculate VCO ex to
estimate E Mˆ Hb in the Schmidt and Prommer method. Larger errors from the Schmidt and
Prommer method when compared to Burge and Skinner method suggest that the actual
values for MHb for Garvican’s subjects are close to the Mˆ Hb ’s estimated from Burge and
Skinner method. It should be noted the errors in E Mˆ Hb were 5.7±0.7% if the estimates
from Schmidt and Prommer method were considered as AMHb. The errors from Burge and
Skinner method are lower as the arterial blood sites were sampled.
For the data set of Benignus et al. (1994), E Mˆ Hb for the protocols B and P were
calculated from all the four blood compartments (ar, cot, cm, vm) using Equations 2.1,
2.5-2.7 (Table 2.2). Tmix for each subject was determined based on the time at which the
pairwise differences between %HbCO’s from all the blood compartments was ≤ 0.1%
(See methods, Figure 2.1). Tsample was considered 1.5 min away from Tmix. The mean
errors in E Mˆ Hb for protocols B and P from different blood sites are shown in Table 2.4.

E

Mˆ Hb from protocol B overestimates AMHb by greater than 2%. The largest error

is seen at the blood sites “cm” and “vm”. The major source of overestimation of AMHb is
due to the inaccuracy in estimating VCOMb.

E

Mˆ Hb uses Prommer and Schmidt’s formula
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(Prommer and Schmidt, 2007) to calculate VCOMb. Estimation of VCOMb using Prommer
and Schmidt’s formula is also dependent on the site of sampling (Table 2.2, 2.4). Their
formula is based on the assumption that there is constant flux of CO from blood to
muscle tissue. As seen in Figure 2.6, the flux of CO from blood to muscle tissue varies
with time. This assumption of constant CO flux results in the underestimation of the
actual volume of CO bound to myoglobin (Figure 2.7) in protocol B. This
underestimation of VCOMb leads to overestimation of VCOHb, thereby resulting in an over
estimation of AMHb. This underestimation of VCOMb is more prominently seen at blood
site “vm”. Accurate estimation of VCOMb results in

M

Mˆ Hb close to

A

MHb, whereas

underestimation of VCOMb results in E Mˆ Hb greater than AMHb (Figure 2.8).

E

Mˆ Hb from protocol P results in estimates close to AMHb from blood sites “ar”,

“cot” and “cm”. However, E Mˆ Hb from blood site “vm” is overestimated by 4.9%. The
estimation of VCOMb is greatly dependent on the site of blood sampling as the estimated
VCOMb depends (Equation 2.7) on the ratio of %HbCO at Tsample and %HbCO at Tmix.
Since this ratio is often less than one, VCOMb is often overestimated (Figures 2.7, 2.9). In
protocol P, VCOMb is overestimated from blood sites “ar”, “cot” and “cm” and
underestimated from site “vm” (Figure 2.9). In addition to inaccurate estimation of
VCOMb, this protocol also underestimates the volume of CO exhaled up to Tsample (Figure
2.10). At the blood sites “ar”, “cot” and “cm”, overestimation of VCOMb is compensated
with the underestimation of Vco exhaled, thereby resulting in E Mˆ Hb close to AMHb from
these blood sites. However at the blood site “vm”, underestimation of both VCOMb and
Vco exhaled results in overestimation of AMHb. Thus the values of E Mˆ Hb in protocol P
are close to AMHb based on compensatory errors from the blood sites “ar”, “cot” and
“cm” (Table 2.4).

Errors > 2% in estimation of

E

Mˆ Hb suggest that these errors are due to

inaccuracies in the methods of calculating VCOL+S, VCO ex, or VCOMb. The sources of
errors in calculation of E Mˆ Hb could be due to the errors in calculations of VCOL+S, VCO
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ex, or VCOMb. In protocol P the sources of errors could either be due to the assumptions
made in VCO ex (Equation 2.6), VCOMb (Equation 2.7) or both, as VCOL+S in this protocol
is measured and not estimated. In protocol B the sources of errors could either be due to
the assumptions made in VCO L+S (Equation 2.5), VCOMb (Equation 2.7) or both, as VCO
ex in this protocol is 0. To determine the errors in Mˆ Hb due to the errors in estimation of
VCO ex and VCOL+S, E Mˆ Hb was calculated from the blood site “vm” for the protocols P
and B using the model calculated VCOMb (Equation 2.2) instead of using Equation 2.7 to
estimate VCOMb. Calculating E Mˆ Hb from blood site “vm” using Equation 2.6 to estimate
VCO exhaled and using the model calculated VCOMb (Equation 2.2), results in a maximum
error of 0.8% in

E

Mˆ Hb for protocol P. Calculating E Mˆ Hb from blood site “vm” using

Equation 2.5 to estimate VCO L+S and using the model calculated VCOMb (Equation 2.2),
results in a maximum error of 1.2% in E Mˆ Hb for protocol B. These errors are smaller
compared to the errors obtained in E Mˆ Hb using Equation 2.7 to estimate VCOMb (Table
2.4). Thus, detailed analysis of all the simulations suggests that the major source of error
leading to inexact calculation of E Mˆ Hb in both the protocols is due to the inaccuracy in
estimating volume of CO bound to myoglobin rather than the errors in estimation of VCO
ex and VCOL+S. Also, using the blood sites “ar”, “cot” or “cm” to calculate E Mˆ Hb results
in lower errors and using blood site “vm” as a sampling site in the CO rebreathing studies
may lead to larger errors in calculation of E Mˆ Hb .
Improving CO rebreathing protocols
Protocol B offers the advantage of calculating MHb close to the actual values, if
the VCOMb were estimated accurately. However the long duration of rebreathing and a
longer Tmix are a disadvantage of this protocol. Protocol P has a shorter Tmix and
rebreathing duration but the estimates of VCOMb and Vco exhaled are inaccurate. The
errors in estimates of MHb from protocols B and P are also dependent on the site of blood
sampling. Thus, there is a need to determine a CO rebreathing method with a shorter Tmix
which estimates MHb without compensating errors and has lower errors irrespective of the
sampling blood site. In the quest to develop such a method, the validated model was used
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to estimate MHb from four different blood sites (ar, cot, cm, vm) for varying durations (2,
3.5, 5, 7.5, 10 min) of CO rebreathing in 100% O2 (Figure 2.11). In addition, the effects
of administering 100% O2 before or after CO rebreathing versus room air breathing on
estimation of MHb was also tested. Based on these simulation results, a new protocol was
defined.
New Protocol: In this protocol (Figure 2.12A), 1 ml/Kg of CO in 3 L of oxygen is
rebreathed for 3.5 min followed by 17 min of room air breathing. Prior to rebreathing, the
subject is on 100% O2. This new protocol (protocol N) was simulated for the Benignus’s
(15 healthy male) and Garvican‘s (9-2 female and 7 male, healthy, recreationally-active
subjects) subjects and E Mˆ Hb was determined. In 3 of the 9 Garvican’s subjects, the model
predicted fast uptake of CO in the blood compartment “vm” during the initial 5 minutes
of two mostly used CO rebreathing methods when compared to the experimental data.
The muscle blood volume of third vascular subcompartment of skeletal muscle and
muscle blood flow were adjusted in these subjects to match the experimental data (Figure
2.16). To simulate protocol N in these 3 subjects, the adjusted values for muscle blood
volume in the third vascular subcompartment and muscle blood flow were used. Tmix was
determined from the methods described previously (Figure 2.1). The Tmix for this
protocol is ~5 min in Benignus’s subjects and ~6.5 min in Garvican’s subjects. The
uptake kinetics of CO in all the blood compartments for this protocol are shown in Figure
2.12B. Tsample was considered as 1.5 min away from Tmix. In actual practice, the volume
of CO exhaled should be collected over the duration of experiment and the volume of CO
in the lungs and rebreathing system should be measured at the end of CO rebreathing.
The volume of CO bound to myoglobin is estimated from a regression
relationship based on the model calculated VCOMb (Figure 2.13a, Equation 2.8a). In order
to develop this regression relation, the model calculated VCOMb (in ml, BTPS), Tsample (in
minutes) and VCO t (in ml, BTPS) from Benignus’s and Garvican’s subjects were used.
VCOMb is estimated as a function of Tsample and VCO t (Equation 2.8). VCOMb is the
dependent variable and Tsample, VCO t are the independent variables. To develop a
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regression equation to estimate VCOMb for protocol N, the muscle blood flow (decreased
by 20% of average value) and blood volume of the third skeletal vascular compartment
(increased by 20% of mixed venous blood volume) was changed in 3 of the 9 Garvican’s
subjects. The regression equations to estimate VCOMb were developed for this protocol
using a DMCO of 0.225 ml/min/Torr/Kg of muscle mass for Benignus’s subjects and
0.302 ml/min/Torr/Kg of muscle mass for Garvican’s subjects. In one typical subject
(S112, Benignus et al., 1994), when the DMCO was increased by 50%, the regression
equation (Equation 2.8a) underestimated VCOMb by 0.62 ml (relative to the correct value
of 2.53 ml) and a decrease in DMCO by 50% resulted in an overestimation of VCOMb from
the regression equation by 0.65 ml. S112 was chosen for analysis of variations in DMCO
on the regression equations proposed, as the value for VCOMb calculated from the
regression equation (Equation 2.8) for this subject was close to the value for VCOMb from
the model. The effects of changes in ventilation (+50%) on estimation of VCOMb from the
regression equations were negligible. The errors in

E

Mˆ Hb are less than 1% from this

protocol (Table 2.5, Figure 2.2.13) from any blood sampling site. Thus, protocol N
results in lower errors in estimation of

E

Mˆ Hb compared to protocols B and P without

involving any compensatory errors (Figure 2.14).
⎧0.223iTsample + 0.024iVCOt - 1.129 ; For Protocol N
⎪
= ⎨0.400iTsample + 0.057iVCOt - 4.685 ; For Protocol B
V
COMb
⎪
; For Protocol P
⎩0.091iTsample + 0.013iVCOt

2.8a ⎫
⎪
2.8b ⎬
⎪
2.8c ⎭

2.8

The major source of error in calculation of E Mˆ Hb , from protocols B and P are due
to errors in the estimation of VCOMb. Independent of the site of sampling, low errors in
estimates of MHb from protocols B and P can be obtained by using the suggested
regression equations (Equation 2.8b-c).
Protocol B: A regression equation to estimate VCOMb is developed for this protocol based
on the model estimates of VCOMb from 24 (Benignus’s and Garvican’s subjects) healthy
humans (Figure 2.13A, Equation 2.8b). To develop this regression relation, the model
calculated VCOMb (in ml, BTPS), Tsample (in minutes) and VCO t (in ml, BTPS) from these
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subjects (Benignus et al., 1994; Garvican et al., 2010) were used. VCOMb is the dependent
variable and Tsample, VCO t are the independent variables. For Benignus’s subjects, Tsample
was 1.5 min away from the model determined Tmix (See methods, Figure 2.1) and for
Garvican’s subjects Tsample provided by the investigators were used. The DMCO values
used for the two data sets simulated (Benignus et al., 1994; Garvican et al., 2010) were
same as those used in protocol N. In one typical subject (S112, Benignus et al., 1994), the
effects of changing DMCO on estimation of VCOMb from the regression equation were
analyzed. When the DMCO was increased by 50%, the regression equation (Equation
2.8b) underestimated VCOMb by 0.93 ml from its actual value and a decrease in DMCO by
50% resulted in an overestimation of VCOMb from the regression equation by 1.2 ml from
its actual value. The errors in calculation of E Mˆ Hb are less than 1.1% (independent of
blood site sampled) when the regression equation is used (Equation 2.8b, Table 2.5). For
this protocol, it would also be recommended that the volume of CO in the rebreathing
system be measured at the Tsample instead of estimating it form Equation 2.5.
Protocol P: A regression equation to estimate VCOMb is proposed to improve the
estimation of MHb from this CO rebreathing method, based on the model estimates of
VCOMb from 24 healthy subjects (Figure 2.13C, Equation 8c). To develop this regression
relation, the model calculated VCOMb (in ml, BTPS), Tsample (in minutes) and VCO t (in ml,
BTPS) from the subjects of Benignus et al. (1994) and Garvican et al. (2010) were used.
VCOMb is the dependent variable and Tsample, VCO t are the independent variables. For
Benignus’s subjects, Tsample was 1.5 min away from the model determined Tmix and for
Garvican’s subjects Tsample provided by the investigators were used. In one typical subject
(S112, Benignus et al., 1994), when the DMCO was increased by 50%, the regression
equation (Equation 2.8c) underestimated VCOMb by 0.54 ml from its actual value and a
decrease in DMCO by 50% resulted in an overestimation of VCOMb from the regression
equation by 0.61 ml from its actual value. In this protocol, the effects of changes in
ventilation on estimation of VCOMb from the regression equation were negligible and it
would be suggested that the volume of CO exhaled be measured up to Tsample. Errors less
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than 1% (Table 2.5) without involving any compensatory errors are obtained when the
regression equation (Equation 2.8c) is used to calculate E Mˆ Hb .
Predicted values for Tmix, Tsample, and sampling blood sites to estimate MHb with low
errors: In this study additional analysis of the simulations of the three CO rebreathing
protocols (B, P, and N) was done to determine the effects of Tmix, Tsample, and the
sampling blood site on estimation of MHb.
Effects of mixing time (Tmix): In order to determine the effects of Tmix on
estimation of MHb,

M

Mˆ Hb was calculated for protocols B, P and N from arterial (ar),

capillary other tissue (cot), capillary muscle (cm) and muscle venous (vm) blood
compartments by assuming different values for Tmix.

M

Mˆ Hb , the MHb estimated using the

exact values from the model (Equations 2.1-2.4, Table 2.2) for VCO L+S, VCO ex, and
VCOMb was calculated for the Benignus’s subjects. In calculations of

M

Mˆ Hb , Tmix was

assumed as 1, 3, 5, 7, 9, 11, 13, 15 and 38 minutes. The difference between Tsample and
Tmix was always 1.5 min. For each protocol, the errors in calculation of

M

Mˆ Hb from

different blood sites and Tmix was plotted for all the subjects (Figure 2.17-2.18). The error
at each Tsample was calculated on comparing

M

Mˆ Hb with AMHb. In protocol B, low errors

in estimation of MHb were obtained from blood sites “ar” and “ot” at a minimum value of
Tmix of 7.5 min (Tsample = 9 min). The minimum value of Tmix to obtain low errors in
M

Mˆ Hb from blood sites “cm” and “vm” was 38 min (Tsample = 39.5 min). Thus, in this

protocol estimation of MHb from a blood sample taken from an artery or an ear lobe at 9
min, would result in an lower error than taking a blood sample from a vein or finger tip at
40 mins. Similar error analysis for protocols P (Figure 2.18) and N (Figure not shown for
protocol N) were done. Error analysis for protocols P and N revealed that low errors in
estimation of MHb were obtained irrespective of the blood site sampled at a minimum
value of Tmix of 5.0 min (Tsample = 6.5 min) and 6.5 min (Tsample = 8 min), respectively.
These results suggest that irrespective of the protocol, site of blood sampling and
intersubject variability, a minimum value of Tmix after which the effects of Tmix on
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estimation of MHb are minimal is 7.5 min. Results of the simulations to look at the
effects of changing various factors like myoglobin concentration, VCO t , DMCO, duration
of rebreathing, muscle blood flow and muscle blood volume on Tmix are reported in the
discussion sections of this chapter in the section “Mixing time of CO in the vascular
space”
Effects of sampling time (Tsample): To determine the effects of Tsample on estimation of
MHb,

M

Mˆ Hb was calculated for protocols B, P and N from four blood compartments (ar,

cot, cm, vm) for Benignus’s subjects by varying the Tsample.

M

Mˆ Hb was calculated at

Tsample’s which were 1.5, 3, 5, 7, 9 and 11 minutes from the determined Tmix of each
subject (Figure 2.15, shown for protocol N). Tmix for each subject for a given CO
rebreathing protocol was determined from the model using the methods described
previously (Figure 2.1). Error analysis for protocols P (Figure not shown) and N (Figure
2.15) suggested that low errors in estimation of MHb were obtained irrespective of the
blood site sampled, when the difference between Tmix and Tsample was between 1.5-3 min.
For protocol B (Figure not shown), low errors in estimation of MHb were obtained from
blood sites “ar” and “cot” when the difference between Tmix and Tsample was between 1.53 min. In protocol B to obtain low errors in estimation of MHb from blood sites “cm” and
“vm”, the difference between Tmix and Tsample was between 8-10 min. Summarizing
results on error analysis of MHb with changes in Tmix, and Tsample from different blood
sites in these 15 healthy subjects (Benignus et al., 1994) and using the information from
the plateaus observed in %HbCO’s of blood compartments of the experimental data from
9 healthy, recreationally-active subjects (Garvican et al., 2010); a minimal value of Tsample
to obtain low errors in Mˆ Hb can be suggested. It is suggested that low errors in Mˆ Hb can
be obtained for any protocol at a Tsample of 9 min using a blood sample from ear lobe,
finger tip, or an artery in the forearm.

Effects of blood sampling site: In this study

M

Mˆ Hb was calculated from four blood

compartments for all three CO rebreathing protocols (B, P and N) at different Tmix and
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Tsample values. Low errors in Mˆ Hb were obtained when the blood was sampled from
arterial (assumed to represent blood sample from an artery in a fore arm), capillary other
tissue (assumed to represent blood sample from an ear lobe) and muscle capillary
(assumed to represent blood sample from a finger tip) sites (Table 2.5, Figure 2.13,
Figure 2.17-2.18).
In general analysis of protocols B, P and N suggest that, using a sample taken
from blood sites “ar”, “cot” or “cm” at 9 min and estimating VCOMb from the proposed
regression equations (Equation 2.8) will ensure estimation of MHb with low errors.
DISCUSSION

The main aim of this study was to use a validated mathematical model to
determine any potential sources of errors in estimation of MHb ( Mˆ Hb ) from the existing
CO rebreathing methods. After validating the model, my goal was to evaluate any
potential errors in these methods and to suggest modifications that mitigate those errors.
The validated mathematical model was used to simulate the two commonly used CO
rebreathing methods in healthy human subjects. For these methods, Mˆ Hb was determined
using the exact values from the model for VCO L+S, VCO ex, and VCOMb ( M Mˆ Hb ) and
using the approximated values based on the published formulas for calculating VCO L+S,
VCO ex, and VCOMb ( E Mˆ Hb ). The errors in estimation of MHb were calculated by
comparing the values of

M

Mˆ Hb and E Mˆ Hb to the known hemoglobin mass of the subjects,

A

MHb. On comparison, it was found that the values of

M

Mˆ Hb were in agreement with

MHb independent of the sampling blood site while the values from E Mˆ Hb were dependent

A

on the sampling blood site and E Mˆ Hb either inaccurately estimated (overestimation or
underestimation) AMHb or was close to AMHb based on compensating errors. Inaccuracies
in estimation of volume of CO bound to myoglobin was found to be the major source of
error in calculation of E Mˆ Hb from the existing CO rebreathing methods. In this study, I
also propose a new CO rebreathing method which I predict will estimate MHb with small
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errors. Also, for experimentalists who wish to use the existing CO rebreathing methods, I
suggest modifications to these methods for calculating E Mˆ Hb with low errors.
Model Limitations
Model validation of %HbCO levels: The model was validated by comparing the model

predicted and experimentally measured values of %HbCO (%HbCOar, %HbCOcm,
%HbCOvm) from three blood sites (arterial, capillary, venous). The experiments of
Garvican et al. (2010) were simulated, and the predicted mean %HbCO ± SD values from
all the three blood compartments at different time points were within the 95% confidence
limits of the experimental data (Figures 2.3-2.4). However, individual comparison of
%HbCO vs. time revealed that in 3 of the 9 subjects the model predicted faster uptake of
CO in the muscle venous compartment, and higher %HbCOvm, during the initial few
minutes of both the CO rebreathing protocols (Figure 2.16). After ~5 minutes, the
predicted %HbCOvm was in agreement with the experimental values. Model prediction of
fast uptake of CO in the muscle venous compartment would result in a smaller predicted
Tmix in these subjects when compared to the experimentally determined Tmix. This
behavior of the model would suggest an erroneously small Tmix for ~33% of the
population when compared to the data obtained from experiments. I was able to match
the predicted %HbCOvm with experimental values by decreasing the muscle blood flow
by 20% and increasing blood volume in the third vascular compartment of the muscle
(Vbm3) by 20% of the mixed venous blood volume (Figure 2.16). In these 3 subjects,
changing the values for muscle blood flow and Vbm3 did not affect the values of
%HbCOvm after 5 minutes or the uptake of CO in other blood compartments.
In my model, I used average values reported in the literature (Bruce and Bruce,
2008; Erupaka et al., 2010) for blood flow and Vbm3 (as the values for these parameters
were not provided by the investigators). The blood flow rates are heterogeneous at
different compartments of vasculature and, for some subjects, may be lower than the
average values used for the integrated muscle compartment in the model. In addition to
this, the coefficient of variation in muscle blood flow or any physiological parameter
might be 20%. On this basis, decreasing the muscle blood flow to match the experimental
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data of 3 subjects may be justifiable. Also, Vbm3 is assumed to be larger by up to 20% of
the mixed venous blood volume in some subjects than the average values used in the
model. Thus, when the volume of this compartment was increased, the model matched
the slower uptake of CO by muscle observed in the experimental data. The regression
equations to estimate VCOMb for protocols B, P, and N were developed using the
simulations from Garvican’s subjects, including the 3 for whom the values of blood flow
and Vbm3 were changed. Thus this limitation of the model to predict uptake of CO in the
muscle venous compartment for some subjects should not affect the regression equations
proposed.
Model parameters: Values for parameters in the model where either provided by the

investigators, or estimated from regression equations developed from healthy populations
(Bruce and Bruce, 2008; Erupaka et al., 2010). For some parameters which were not
provided to us by the investigators or estimating the value from a regression equation was
not possible (like estimating alveolar ventilation), average values from the literature for
healthy populations were used. In my simulations using the same average value for all the
subjects for some parameters like alveolar ventilation, the muscle diffusion capacity of
CO (DMCO) and lung volume, may affect the model calculated values of VCOMb, VCO
S+L and VCO ex. Thus whenever possible, in all my simulations intersubject variability
was taken into account while estimating the values for unknown parameters which were
not provided to us by the investigators (Garvican et al., 2010; Benignus et al., 1994).
Like in cases where the subject specific values for alveolar ventilation were not measured
(Garvican et al., 2010), the ventilation in each subject was adjusted so that an arterial PO2
of 98 Torr was obtained on breathing room air at the control or steady state. For
Garvican’s subjects, Mˆ Hb calculated using equations 2.1a-2.4 were in agreement with
A

MHb for both the CO rebreathing methods. However, for Schmidt and Prommer method

E

Mˆ Hb underestimated AMHb by ~6%. In addition to inaccurate estimation of VCOMb,

assumptions made in estimation of alveolar ventialtion may have contributed to larger
errors in

E

Mˆ Hb from Schmidt and Prommer method when compared to Burge and

Skinner method. The values for DMCO may differ among the subjects, thus the DMCO
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was varied as a function of muscle mass to take into account differences in muscle mass
of subjects (Garvican et al., 2010, Benignus et al., 1994). An average value of lung
volume was used for simulating the three CO rebreathing protocols (B, P and N) in all the
subjects (Bruce and Bruce, 2003; Erupaka et al., 2010). To determine the effects of
changes in lung volume on estimation of MHb, protocol N was simulated in Benignus’s
subjects with changing the lung volume as a function of age, body weight and height of
the subject (Petersen et al., 1975). For each subject

M

Mˆ Hb was calculated (Equations 2.1-

2.4) using the estimated value of lung volume as a function of age, body weight and
height. No significant differences were found in the values of
compared to the

M

M

Mˆ Hb (results not shown)

Mˆ Hb calculated using the same average value of lung volume in

different subjects. For protocols B and P, the effects of changing the lung volume (as a
function of age, body weight and height) on calculation of

M

Mˆ Hb were not analyzed in

this study. The small or no influence of lung volume on estimation of MHb has also been
confirmed by the experiments and calculations of Steiner and Wehrlin (2010).
Effects of various factors on estimation of hemoglobin mass, Mˆ Hb
Volume of CO bound to myoglobin: Analysis of simulations of all three protocols in

Benignus’s subjects reveals that ~ 6%, 2%, and 3% of VCO t is bound to myoglobin in
protocols B, P, and N respectively. On average if VCOMb is ignored in the estimation of
VCOHb, then protocols B, P, and N overestimate MHb by ~7% (Tsample = 12 min), 2.2%
(Tsample= 6 min), and ~3.3% (Tsample=7 min), respectively. If a larger Tsample (say
Tsample=12 min) is used in protocols P and N then the error in Mˆ Hb due to ignoring VCOMb
may be slightly greater by ~1%, but would not be as large as the error in protocol B. In
protocols P and N, CO is exhaled after rebreathing ends causing a decrease in the amount
of CO entering the tissues and resulting in lower values for VCOMb at any Tsample when
compared to protocol B. Thus at any given Tsample when compared to protocol P, VCOMb is
larger in protocol B. Also, when compared to protocol P the underestimation of VCOMb is
larger in protocol B, thus resulting in a higher estimate of MHb from protocol B for any
subject. Thus in the existing CO rebreathing methods when compared to protocol P, Mˆ Hb
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is always greater from protocol B either due to ignoring VCOMb (Gore et al.,2006;
Schmidt and Prommer,2005; Steiner and Wehrlin,2010) or due to underestimating the
volume of CO bound to Mb using the Prommer and Schmidt’s formula (Equation 2.7)
(Garvican et al., 2010; Schmidt and Prommer,2007), which either ways results in an
overestimation of MHb. However in protocol B, if the volume of CO bound to myoglobin
is accounted accurately, then the estimates of MHb are close to the values of AMHb (Figure
2.8, Table 2.5).
Prommer and Schmidt (2007) make an assumption that there is continuous flow
of CO from Hb to Mb at a constant rate. Certainly there is continuous flow of CO from
Hb to Mb (Bruce and Bruce, 2003), but the rate of flow of CO is not constant (Figure
2.6). This assumption results in inaccuracies in calculation of VCOMb which may combine
with other errors to either result in overestimation of MHb (Table 2.4), underestimation of
MHb (See results) or correct estimation of MHb based on compensatory errors (Table 2.4).
Also the formula (Equation 2.7) proposed by Prommer and Schmidt (2007) is greatly
influenced by the choice of (i) site of sampling due to the use of %HbCO levels and (ii)
values for Tmix, and Tsample due to the two assumptions made while developing their
formula.
In protocol B, the %HbCOcm or %HbCOvm levels rise slowly, resulting in a larger
Tmix (Figure 2.2a). In this protocol assuming that negligible amount of CO is bound to
Mb at Tmix results in underestimation of VCOMb. Thus, using Prommer and Schmidt’s
formula (Equation 2.7) to estimate VCOMb overestimates MHb in protocol B. In protocol P
using Prommer and Schmidt’s formula to estimate VCOMb from venous blood results in an
overestimation of MHb, which is due to the underestimation of VCOMb from their
assumption of constant CO flux. Estimation of MHb from other blood compartments is
based on compensatory errors. Also, the errors in estimation of VCOMb from different
blood compartments are evident due to the effects of incomplete circulatory mixing
(Figure 2.5). For protocol P, my modeling results agree with findings of Prommer and
Schmidt (2007) that ~2% of VCO t is bound to Mb. In this article (Prommer and Schmidt,
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2007), it should be noted that the ear lobe was the sampled blood site and the precise
volume of CO exhaled was measured.
In this study, I proposed regression equations to estimate VCOMb from Tsample and
VCO t for different protocols using VCOMb values calculated by the model for Benignus’s

(healthy) and Garvican’s (healthy, recreationally-active) subjects. In the case of
Garvican’s subjects, volume of CO bound to Mb will be greater compared to Benignus’s
subjects because Tsample and VCO t are larger in recreationally-active subjects. Though this
result cannot be proven experimentally, it is suggested by the fact that the recreationallyactive populations will have more muscle mass, resulting in larger amount of myoglobin
being available to bind to CO. The regression equations to estimate VCOMb were
developed for each protocol using a DMCO of 0.225 ml/min/Torr/Kg of muscle mass for
Benignus’s subjects and 0.302 ml/min/Torr/Kg of muscle mass for Garvican’s subjects.
For all the protocols, I analyzed the effects of changing DMCO (±50%) on estimation of
VCOMb from the regression equation (see Results). For protocols P and N, the effects of
changes in ventilation on estimation of VCOMb from the regression equations were
negligible.
Mixing time of CO in the vascular space (Tmix): The mixing times of protocol B and

protocol P are in agreement with articles published in the literature (Burge and Skinner,
1995; Gore et al., 2006; Schmidt and Prommer, 2005). These articles used approximated
methods to determine Tmix, where as my model allowed a more complete analysis of
mixing, as it was based on pairwise differences from five blood sites (Figure 2.1). In
order to determine the effects of Tmix on estimation of MHb,

M

Mˆ Hb was calculated for

protocols B, P and N from various blood compartments for Benignus’s subjects by
varying the Tmix. Analysis of these results suggested that irrespective of the protocol, site
of blood sampling and intersubject variability, a minimum value of Tmix after which the
effects of Tmix on estimation of MHb are minimal is 7.5 min.
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The simulations discussed in this paragraph were not presented in the results
section. In this study I also looked at the effects of changing various factors like
myoglobin (Mb) concentration, VCO t , DMCO, duration of rebreathing, muscle blood flow
and muscle blood volume on Tmix in one of the Benignus’s subjects (S112, Benignus et
al, 1994). An increase in concentration of Mb resulted in a larger Tmix for any CO
rebreathing protocol. Thus, untrained (sedentary) subjects and populations with lower
muscle mass will have a smaller Tmix when compared to trained (athletes, recreationallyactive) subjects and populations with larger muscle mass. Administering smaller doses
of CO resulted in lower values for %HbCO and smaller Tmix in any CO rebreathing
protocol because of the 0.1% HbCO threshold criterion to determine Tmix. One of the
major reasons for obtaining a larger Tmix in CO rebreathing methods is due to the slow
diffusion of CO from the vascular space to the tissue spaces containing myoglobin. The
rate of diffusion of CO from the vascular space to the myoglobin containing tissues is
dependent on the DMCO and the pressure gradients of CO between the blood and tissue
compartments. It is however suggested that the minimum dose of CO to be administered
is 1 ml/Kg for men and 0.8 ml/Kg for women, to allow measurements of %HbCO. When
compared to trained subjects the amount of CO injected into the rebreathing bag is
smaller in untrained subjects, thus resulting in untrained subjects having a smaller Tmix
when compared to the trained subjects. Also, women will have a lower Tmix when
compared to men as the dose of CO administered in the CO rebreathing studies is smaller
in women than men. For any CO rebreathing protocol, a lower value for DMCO results in
a smaller Tmix. When a smaller value of DMCO is used, the amount of CO flowing into
the tissues from the vascular space is smaller and thus mixing of CO takes place faster in
the vascular space. As the CO flux from the vascular space to the muscle tissues is
dependent on DMCO, using a lower DMCO value results in a smaller Tmix than using a
higher DMCO value. A CO dilution technique with longer duration of CO rebreathing has
larger Tmix when compared to a CO rebreathing method involving smaller durations of
CO rebreathing. Depending on DMCO value, the volume of CO diffusing from the blood
compartments to the muscle tissue compartment is directly proportional to the duration of
CO rebreathing method. Longer the duration of rebreathing, larger is the volume of CO
flowing into the muscle tissues from the vascular space and slower is the mixing of CO in
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the vascular space- thus resulting in a larger Tmix. Thus for any given subject, protocol B
has the largest Tmix followed by protocol N and protocol P. Populations with lower
muscle blood flow tend to have a larger Tmix when compared to populations with normal
or lower blood flows. An increase in muscle blood volume also results in an increase in
Tmix. Thus a variation in one or more than one of these various factors may explain the
range of values reported for Tmix in the literature. These results also suggest that trained
populations may have a larger Tmix than untrained populations.
Blood sampling site:

M

Mˆ Hb and

E

Mˆ Hb were calculated in Benignus’s subjects for the

three CO rebreathing protocols B, P and N (Tables 2-4) from the arterial (ar-artery in fore
arm), capillary other tissue (cot-ear lobe), capillary muscle (cm-finger tip) and muscle
venous (vm- vein in forearm) blood compartments. Errors in

M

Mˆ Hb from blood

compartments “ar” and “cot” of protocol B and all other compartments of protocol P
were less than 1%. Errors in

M

Mˆ Hb from blood sites “cot” and “vm” in protocol B were

<2%. The reason for slightly larger errors in

M

Mˆ Hb from compartments “cot” and “vm”

in protocol B is due to the sensitivity of MHb to changes in %∆HbCO (Equation 2.1) and
due to incomplete mixing of CO in blood (Figure 2.2a). A variation of ∆HbCO by ±0.1%
will result in a variation of MHb by ∓12 g . Despite a difference of ~0.1% between the
%HbCO’s, considering a sample from blood site “cot” or “vm” one can expect that the
A

MHb will be overestimated or underestimated by ~12g (Figure 2.2a). In protocol P,

E

Mˆ Hb was lower from blood sites ar, cot and cm when compared to E Mˆ Hb from blood

site vm. These results are due to incomplete mixing of CO in blood and are in agreement
with other studies (Garvican et al., 2010; Gore et al., 2006). Suggested sampling sites to
obtain low errors in estimation of MHb for protocol B are arterial or ear lobe blood sites.
For protocols P and N, arterial, ear lobe or finger tips are the suggested blood sites to
obtain low errors in MHb. Based on the analysis of simulation results from all the blood
compartments and experimental data (Garvican et al., 2010), despite low errors in

M

Mˆ Hb

or E Mˆ Hb (Table 2.3, 2.5) from protocol B, P and N, blood site “vm” is not suggested as it
is not a reliable sampling site.
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Irrespective of the protocol, low errors in estimation of MHb were obtained from
arterial, capillary other tissue and muscle capillary sites (Table 2.5). My results for
suggested reliable sampling sites for protocols B and P are in agreement with the
preferred sampling blood sites of Garvican et al. (2010). For a given CO rebreathing
method, Garvican et al. (2010) chose their blood site in each subject based on the least
coefficient of variation in MHb at different time points. Suggestions for reliable sampling
blood sites from my study are more credible than theirs as reliable sampling blood sites
were determined based on obtaining lowest errors in estimates of MHb, when compared to
A

MHb from three different CO rebreathing methods and four different blood sites in 24

(15 Benignus’s and 9 Garvican’s subjects) healthy humans. Thus, suggestions for reliable
blood sampling sites to obtain low errors in estimation of MHb based on experimental data
and analysis of simulations are ear lobe or pre warmed finger tips. If obtaining samples
from ear lobe or finger tips is not possible, then arterial blood should be sampled.
Considering the difficulties in obtaining samples from arterial blood sites, despite low
errors arterial blood site is reserved as the next best site for sampling. Though all the
protocols estimate MHb with errors less than 2% using %HbCO values from venous blood
(Table 2.3, Table 2.5), it is suggested that venous blood sites should be avoided because
this compartment takes more time to reach equilibration with other compartments. Usage
of one of the suggested blood sampling sites will improve the reliability and accuracy of
the CO rebreathing methods to estimate MHb and allow standardization of the method.
Sampling time: To determine the effects of Tsample on estimation of MHb,

M

Mˆ Hb was

calculated for protocols B, P and N from various blood compartments for Benignus’s
subjects by varying the Tsample relative to Tmix. Summarizing the simulation results from
Benignus’s subjects and using the information of plateaus attained in %HbCO levels
from the experimental data of Garvican’s subjects, it is suggested that low errors in Mˆ Hb
can be obtained for any protocol at a Tsample of 9 min using a blood sample from ear lobe,
finger tip, or an artery in the forearm. Using finger tips for blood sampling may have
slightly larger errors (Table 2.3, Table 2.5) compared to using ear lobe or arterial blood
sites in protocol B. Sampling at the suggested Tsample will allow determination of Mˆ Hb
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with low errors and also avoid taking multiple samples which will decrease the cost of
the experiment, inconvenience to the subject and duration of the experiment.
Effects of plasma skimming: Due to a process known as plasma skimming the red blood
cells (RBC) are not evenly distributed within the vascular tree and the hematocrit in the
microvascular beds is considerably lower than that of the larger vessels (Burge and
Skinner, 1995). Plasma skimming is a phenomenon in which, due to low flow rates in the
microvascular beds like capillaries, the RBC’s stick together, thus increasing the
viscosity, and remaining at the centre of the vessel. Thus, the blood closest to the vessel
wall has lower hematocrit and the fraction of blood volume that is occupied by the RBC’s
is lower in the microvascular beds when compared to larger blood vessels. As an effect of
plasma skimming, it would be expected that Mˆ Hb calculated using %HbCO
measurements from a capillary blood site may be an overestimate of the actual
hemoglobin mass. However, this process of plasma skimming should not effect the
estimation of MHb from a specific blood site, if the blood is sampled for %HbCO after
mixing of CO is complete and the %HbCO’s from all the blood compartments are similar
or equal. As it is difficult to determine the true Tmix, using the suggested sampling time of
9 min should allow accurate estimation of MHb. Though the process of plasma skimming
is not implemented in the model, it should be noted that the model was able to predict the
%HbCO’s from different blood compartments, which were in agreement with the
experimental data. Also the techniques using tagged RBC’s (CO,
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Cr) have been

reported to accurately estimate the RBC volume, but underestimate the plasma and blood
volume (Burge and Skinner, 1995). Thus, a correction factor as proposed by Burge and
Skinner (1995) may have to be applied to estimate blood volume using the CO
rebreathing methods.

Proposed new CO rebreathing method

In this study I have proposed a new CO rebreathing method (Figure 2.12A) to
estimate MHb with low errors irrespective of the site of sampling. In this section I
summarize the procedure to determine Mˆ Hb using this new method. Prior to CO
rebreathing the subject breathes 100% O2 for approximately 5 minutes. The initial
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%HbCO levels from ear lobe, pre warmed finger tip or an artery in fore arm should be
measured. The subject then rebreathes CO in 100% O2 for 3.5 min. A known volume of
CO is injected into the rebreathing system (3 L) at the beginning of CO rebreathing. The
time at which CO is injected into the rebreathing circuit is considered as the experiment
start time (T0). The volume of CO administered is based on the gender and fitness level
of the subject (Schmidt and Prommer, 2005). The concentration of CO in the rebreathing
system at the end of rebreathing (3.5 min from T0) is measured in ml, ATPD and then
converted to BTPS. The volume of CO exhaled from end of rebreathing to Tsample (9 min
from T0) is measured in ml, BTPS. The %HbCO levels at Tsample are measured from the
arterial, capillary other tissue, or capillary muscle blood compartments. VCOMb (in ml,
BTPS) is estimated using the proposed regression equation (Equation 2.8a, Figure
2.13A). The VCO administered ( VCO t ) is in ml, ATPD and should be converted to BTPS.
Tsample is in minutes. MHb is calculated using equation 2.1.
Modifications to the existing CO rebreathing methods
Protocol B: In this method, inaccuracies in estimation of VCOMb result in larger errors in
Mˆ Hb when compared to other CO rebreathing methods. Also, the long duration of CO

rebreathing in 100% O2 (40 min) causes inconvenience to the subjects. Thus the main
disadvantages of this method are inaccurate estimation of VCOMb, larger Tmix and long
durations of rebreathing. However, using the regression equation (Equation 2.8b, Figure
2.13b) suggested in this study to estimate VCOMb will lower the errors in E Mˆ Hb (Table
2.5) when compared to using the Prommer and Schmidt’s formula (Equation 2.7, Table
3) or ignoring VCOMb. Despite larger Tmix, making a measurement from arterial or ear lobe
(other tissue capillary) blood sites at a sampling time of 9 min, will allow determination
of Mˆ Hb with low errors (Figure 2.17). Also the duration of the experiment can be
decreased to 9 minutes as low errors in Mˆ Hb are obtained at the suggested sampling site
and time. In addition to the suggested modifications, this method is complemented with
other advantages like there will be no additional errors introduced in

E

Mˆ Hb due to

inaccuracies in measurement of VCO ex (as CO is not exhaled in this method). In this
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method despite intersubject variability, the magnitude of the size of error in calculation
of Mˆ Hb is low from any blood site (Figure 2.17). Thus this method can be anticipated to
determine Mˆ Hb with low errors for a range of subjects. Also I suggest that the VCO L+S
be measured at the suggested sampling time, instead of calculating it from Equation 2.5.
Protocol P: The advantages of this method are that it has a smaller Tmix, smaller duration
of CO rebreathing and lower volume of CO bound to myoglobin when compared to other
rebreathing methods. However, the choice of 2 min duration of rebreathing in this
method was not based on experimental or mathematical model driven results. Also, the
model was able to validate the %HbCO’s measured from different blood compartments
for the Schmidt and Prommer’s experiment conducted by Garvican et al. (2010), using
the blood volumes calculated for the Burge and Skinner’s method in the same
experiment. This result suggests that the estimates of MHb from Schmidt and Prommer’s
method were inaccurate. In this CO rebreathing method, the values of E Mˆ Hb are based
on compensatory errors in calculation of VCOMb and VCO ex (Table 2.4). To avoid errors
in

E

Mˆ Hb , it is suggested that VCO ex should be measured during the experiment and

VCOMb should be calculated using the regression equation proposed in this study for
protocol P (Equation 2.8c, Figure 2.13c). Unlike protocol B, in this method the
magnitude of the size of error in calculation of Mˆ Hb from any blood site is dependent on
the intersubject variability (Figure 2.17). The subject specific factors like ventilation, age,
fitness level, body weight, blood volume, or DMCO, to which the magnitude of error is
sensitive, is not known and have not been analyzed in this study. Also the choice of
duration of CO rebreathing in protocol N is based on results (low errors in MHb) obtained
from simulation analysis.

CONCLUSIONS

In this study a validated mathematical model was used to determine any potential
sources of errors in estimation of MHb ( Mˆ Hb ) from the existing CO rebreathing methods.
Inaccuracies in estimation of volume of CO bound to myoglobin was found to be the
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major source of error in calculation of Mˆ Hb from these methods. Using the regression
equations developed in this study to estimate the volume of CO bound to myoglobin will
allow estimation of MHb with low errors from any CO rebreathing method. Also
estimating MHb using the new CO rebreathing method (Protocol N) or from the existing
CO rebreathing methods with the suggested modifications for estimation of volume of
CO bound to myoglobin, sampling time, and blood site, will allow estimation of MHb
with low errors and allow comparison of hemoglobin mass determined from different
studies using different CO rebreathing methods possible.
SUMMARY

Routine measurements of hemoglobin mass (MHb) are made to study the
alterations in oxygen delivery during exercise training and acclimatization to altitude.
Carbon monoxide (CO) rebreathing technique is a popularly used method to determine
MHb in humans. The two commonly used CO rebreathing methods to determine MHb
were proposed by Burge and Skinner (1995) and Schmidt and Prommer (2005). The
potential sources of errors in determination of MHb from these methods are not known.
The main aim of this study was to use a validated mathematical model to simulate the
commonly used CO rebreathing methods and determine any potential sources of errors in
estimation of MHb using these methods. For the two CO rebreathing methods, my
previously published mathematical model (Erupaka et. al., 2010) was validated for
experimentally measured %HbCO and MHb from arterial, capillary and venous blood
sites of human subjects (Garvican et al., 2010). The validated model was used to simulate
the existing CO rebreathing methods in 24 human subjects with a known MHb. MHb in
these subjects was also estimated using the approximations made in the existing CO
rebreathing methods for calculating volume of CO bound to myoglobin, volume of CO
exhaled and the volume of CO in the rebreathing system. On analysis of my simulations,
it was found that inaccuracies in estimation of volume of CO bound to myoglobin was
the major source of error in determination of MHb. To determine MHb with low errors
from the CO rebreathing methods, the validated mathematical model was applied in this
study to propose a new CO rebreathing method and suggest modifications to the existing
CO rebreathing methods.

45

Table 2.1: Symbols and their definitions
Symbol

Definition

Blood sites

Blood sites sampled for determination of hemoglobin mass

%HbCO

ar

Arterial blood site (artery in forearm)

cm

Muscle tissue capillary blood site (finger tip)

cot

Nonmuscle tissue capillary blood site (ear lobe)

vm

Muscle tissue venous blood site (vein in forearm)

Percent carboxyhemoglobin level
%HbCOar

%HbCO in arterial blood

%HbCOcot %HbCO in capillary blood of nonmuscle tissues
%HbCOcm %HbCO in capillary blood of skeletal muscle tissues
%HbCOvm %HbCO in venous blood of skeletal muscle tissues
MHb

Hemoglobin mass

A

Known value of MHb from experiments (Input parameter to the model)

Mˆ Hb

Estimated MHb

MHb

Mˆ Hb

Mˆ Hb estimated using the values from the model

Mˆ Hb

Mˆ Hb estimated using the approximations from the experiments

M

E

Tmix

Estimated mixing time of CO in vascular space

Tsample

Blood sampling time

VCOHb

Volume of CO bound to hemoglobin

VCOMb

Volume of CO bound to myoglobin

VCO L+S

Volume of CO in the lungs and rebreathing system at Tsample

VCO ex

Volume of CO exhaled
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Table 2.2 : Estimation of hemoglobin mass ( M Mˆ Hb , E Mˆ Hb )
Variable

Model
Protocol B

Mˆ Hb
VCOHb

M

M

Experiment

Protocol P

Mˆ Hb = K i M VCOHb i

Protocol B

100
1.58ΔHbCOi

E

E

VCOHb = VCOt - VCO L+S - VCO ex - VCOMb

Protocol P

Mˆ Hb = K i EVCOHb i

100
1.58ΔHbCOi

VCOHb = VCOt - VCO L+S - VCO ex - VCOMb

VCOt

Total volume of CO administered

Total volume of CO administered

VCO L+S

Equation 2.4

Equation 2.4

Equation 2.5

Equation 2.4

VCO ex

0

Equation 2.3

0

Equation 2.6

VCOMb

Equation 2.2

Equation 2.2

Equation 2.7

Equation 2.7
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Table 2.3: Mean values with standard deviations of various variables and
M

mean errors in calculation of

Mˆ Hb from Benignus’s subjects (15 healthy

male humans) for simulations of protocols B and P.
Variable

Protocol B

Protocol P

11.5 ± 2.561

3.54 ± 0.159

13 ± 2.561

5.04 ± 0.159

Actual hemoglobin mass (AMHb )(g)

779.9 ± 167.8

779.9 ± 167.8

VCO administered (ml)

83.88 ± 13.44

83.88 ± 13.44

VCO Lung + rebreathing system (ml)

1.279 ± 0.161

1.116 ± 0.339

0.0

1.440 ± 0.342

VCOMb (ml)

5.174 ± 1.683

1.581 ± 0.382

VCOHb (ml)

77.43 ± 12.62

79.74 ± 13.05

∆HbCO (%)*

6.411 ± 0.899

6.718 ± 1.053

mean % error+

0.118 ± 0.151

-0.865 ± 0.363

∆HbCO (%)*

6.415 ± 0.900

6.732 ± 1.055

mean % error+

0.057 ± 0.140

-0.974 ± 0.365

∆HbCO (%)*

6.307 ± 0.899

6.716 ± 1.056

mean % error

1.619 ± 0.079

-0.769 ± 0.365

∆HbCO (%)*

6.291 ± 0.906

6.601 ± 1.055

mean % error+

1.883 ± 0.209

-0.392 ± 0.402

Tmix
Tsample

Vco exhaled (ml)

Arterial

CapillaryOT

CapillaryM

+

VenousM

* All ∆HbCO% are the values estimated by the model at Tsample.
+

%errors in estimates of MHb calculated from the model ( M Mˆ Hb ) compared to AMHb
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Table 2.4: Mean values with standard deviations of estimated VCOMb
using Equation 2.7 and errors in calculation of E Mˆ Hb from
Benignus’s subjects for simulations of protocols B and P.
Blood site

Protocol*

VCOMb (ml)

mean % error+

Arterial

B

3.134 ± 0.603

2.051 ± 1.599

CapillaryOT

B

3.201 ± 0.619

1.901 ± 1.582

CapillaryM

B

2.154 ± 0.590

4.870 ± 1.378

VenousM

B

1.896 ± 0.550

5.479 ± 1.288

Arterial

P

1.872 ± 0.568

-0.056 ± 0.37

CapillaryOT

P

2.120 ± 0.613

-0.474 ± 0.41

CapillaryM

P

2.031 ± 0.723

-0.159 ± 0.49

VenousM

P

-1.749 ± 0.77

4.958 ± 0.702

*See Table 2.3 for Tmix, Tsample, actual MHb (AMHb),VCO administered, and ∆HbCO%. The
volume of CO exhaled is 0 ml and 0.513 ± 0.088 ml for protocols B and P respectively.
The volume of CO in the lungs and rebreathing system is 1.845± 0.296 ml in protocol B
and 0.513 ± 0.088 ml in protocol P.
+

%errors in estimates of MHb calculated from the experiments ( E Mˆ Hb ) compared to AMHb
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Table 2.5: Mean values with standard deviations of errors in E Mˆ Hb from
Benignus’s subjects for simulations of protocols B, P and N.
Blood site

Protocol N*

Protocol B

Protocol P

mean % error+

mean % error+

mean % error+

Arterial

-0.249 ± 0.502

-0.694 ± 1.026

0.322 ± 0.504

CapillaryOT

-0.305± 0.488

-0.755 ± 1.014

0.212 ± 0.486

CapillaryM

-0.730 ± 0.576

0.793 ± 0.897

0.419 ± 0.485

VenousM

-0.056 ± 0.453

1.053 ± 0.774

0.801 ± 0.424

*The mean values for Tmix, Tsample, volume of CO exhaled, and volume of CO in the
lungs + rebreathing system for the new protocol are 4.54 ± 0.19, 6.04 ± 0.19, 1.00 ± 0.15
and 1.26 ± 0.26 respectively. VCOMb for all protocols are estimated from the regression
equations.
+

%errors in estimates of MHb calculated from the E Mˆ Hb (as described below) compared

to AMHb.

E

Mˆ Hb was calculated using estimations of VCOMb from the regression equations

(Equation 2.8) and VCO L+S (Equation 2.5), VCO exhaled (Equation 2.6) from the
experiment formulas.
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Figure 2.1: Determination of Tmix in (A) protocol B and (B) protocol P. The pairwise
differences in %HbCO within four different blood compartments were plotted at different
times. The time at which the %HbCO difference line crosses the reference line was
determined as the mixing time, Tmix.
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Figure 2.2: Uptake kinetics of CO in (A) protocol B and (B) protocol P. The %HbCO
levels in different vascular compartments of the model arterial (ar), capillary muscle
(cm), capillary other tissue (cot), muscle venous (vm) and mixed venous (vmx).
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Figure 2.3: Comparison of model predicted %HbCO with experimental data from three
blood sites: (A) arterial-ar, (B) capillary muscle –cm, (C) venous muscle-vm, for Burge
and Skinner method. The solid lines with error bars are the model predicted mean
%HbCO with ±SD, from individual simualtions of 9 subjects. Mean %HbCO from the
experiments is represented with symbol ‘ • ’. The dashed lines are the 95% confidence
limits of the experimental data.
.
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Figure 2.4: Comparison of model predicted %HbCO with experimental data from three
blood sites: (A) arterial-ar, (B) capillary muscle –cm, (C) venous muscle-vm,

for

Schmidt and Prommer method. The solid lines with error bars are the model predicted
mean %HbCO with ±SD, from individual simualtions of 9 subjects. Mean %HbCO from
the experiments is represented with symbol ‘ • ’. The dashed lines are the 95% confidence
limits of the experimental data.
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Figure 2.5: Mean % error in estimated Hb mass using exact data from the model (i. e.,
VCOHb) vs. time for blood sampled from arterial (—), capillary other tissue (–·–·),
capillary muscle (····) and muscle venous (– –) blood sites for (A) Burge and Skinner
method and (B) Prommer and Schmidt method. Value at each time point represents mean
percent error from simulations of Garvican’s 9 subjects. The red solid line is the zero
line.
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Figure 2.6: CO flux from blood to muscle tissues in the two commonly used CO
rebreathing methods. CO flux (ordinate) from blood to muscle tissue in protocol B (solid
line) and Protocol P (dashed line) is not constant.
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Figure 2.7: Comparison of model calculated VCOMb (abcissa) with Prommer and
Schmidt’s estimated VCOMb (ordinate) in (A) arterial, (B) capillary other tissue, (C)
capillary muscle and (D) muscle venous blood sites for protocol B. Dashed lines are the
identity lines. Each point represents one subject.
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Figure 2.8: Errors in estimation of MHb. Comparison of the actual known MHb, AMHb with
MHb estimated using the exact values from the model, M Mˆ Hb and MHb estimated using the
approximations used in the existing CO rebreathing methods, E Mˆ Hb for samples taken
from different blood sites (A) arterial, (B) capillary other tissue, (C) capillary muscle and
(D) muscle venous for protocol B. Dashed lines are the zero reference lines. Each point
represents one subject.
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Figure 2.9: Comparison of model calculated VCOMb (abcissa) with Prommer and
Schmidt’s estimated VCOMb (ordinate) in (A) arterial, (B) capillary other tissue, (C)
capillary muscle and (D) muscle venous blood sites for protocol P. Dashed lines are the
identity lines. Each point represents one subject.
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Figure 2.10: Comparison of model calculated VCO exhaled (abcissa) with Prommer and
Schmidt’s estimated VCO exhaled (ordinate) in protocol B. Dashed line is the identity
line. Each point represents one subject.
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Figure 2.11: Effects of varying durations of CO rebreathing in 100% O2 and the ambient
conditions before or after CO rebreathing on errors in estimation of MHb. Errors in
estimates of MHb (y-axis) from various blood compartments for different durations of
rebreathing shown on x-axis (2, 3.5, 5, 7.5, 10 min) are represented by (A) ‘ ’ on
breathing room air before and after CO rebreathing in 100% O2, (B) ‘◊’ breathing 100%
O2 before CO rebreathing in 100% O2 followed by breathing room air (C) ‘{’ breathing
100% O2 before and after CO rebreathing in 100% O2 and (D) ‘’breathing room air
before CO rebreathing in 100% O2 followed by 100% O2. Dashed lines are the zero
reference lines.
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New Protocol (Protocol N):
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100% O2 Rebreathing

17 min normal
breathing in RA

in 100% O2

Figure 2.12A: Protocol N
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Figure 2.12B: Uptake kinetics of CO in protocol N for one typical subject. The %HbCO
levels in different vascular compartments of the model arterial (ar), capillary muscle
(cm), capillary other tissue (cot), muscle venous (vm) and mixed venous (vmx).
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Figure 2.13: Proposed regression equations to estimate VCOMb for calculation of MHb
from (A) Protocol N, (B) Protocol B and (C) Protocol P. Model calculated VCOMb as
abscissa and regression estimated VCOMb as ordinate. R is the regression coefficient and E
is the error in the estimate. Dashed lines are the identity lines. Each point represents one
subject.
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Figure 2.15: Effects of Tsample on estimation of MHb in protocol N. Errors in calculation of
M

Mˆ Hb (ordinate) from (A) arterial, (B)capillary-other tissue, (C) capillary muscle and

(D)muscle venous blood compartments are plotted at different times (abcissa) in
Benignus’s subjects. Each line represents one subject.
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Figure 2.16: Model fit of a healthy, recreationally-active female human subject from
Garvican et al.(2010). The %venous HbCO levels in the (A) Burge and Skinner methods
and (B) Schmidt and Prommer method from the experiment of Garvican et al., 2010 (o),
model fit using average values for blood volume of venous blood compartment of the
muscle and muscle blood flow (dashed line) and model fit using the increased blood
volume of venous blood compartment of the muscle and decreased muscle blood flow
(solid line). The venous blood compartment volume was increased by 20% of mixed
venous blood volume and the muscle blood flow was decreased by 20%.
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Figure 2.17: Effects of Tmix on estimation of MHb in protocol B. Errors in calculation of
M

Mˆ Hb (ordinate) from (A) arterial, (B)capillary-other tissue, (C) capillary muscle and (D)

muscle venous blood compartments are plotted at different times (abcissa) in Benignus’s
subjects. Each line represents one subject.
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Figure 2.18: Effects of Tmix on estimation of MHb in protocol P. Errors in calculation of
M
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Chapter 3: Enhanced Mathematical Model

Contents of this chapter will be submitted as a manuscript
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INTRODUCTION

The third specific aim is to compare the current treatment strategies available to
treat CO poisoned victims and determine the best treatment strategy ensuring fastest CO
removal and O2 delivery after CO poisoning. As stated in chapter 1, the best approach to
accomplish this aim would be to use a validated mathematical model capable of
estimating CO burden (%HbCO, %MbCO), O2 levels and CO2 levels in different blood
(arterial, capillary, venous) and tissue (brain, heart, skeletal muscle, nonmuscle)
compartments for various CO exposures and treatment sessions in healthy populations.
Understanding the O2 and CO2 dynamics (transport and utilization of O2 or CO2 from and
within blood vessels and tissues) in the brain, heart and skeletal muscle during different
treatments plays a key role in designing treatments. This is because brain, heart and
skeletal muscle (during exercise) tissues are highly oxidative organs and produce
metabolites like CO2. Limitation of O2 supply below a certain level to these organs due to
CO leads to collapse of vital cell functions, accumulation of metabolites and eventually
cell death (Erecińska and Silver, 2001; Folbergrová et al., 1990; Zauner et al., 2002).
The major limitations of the previously developed model (Erupaka et al., 2010)
are that the brain tissue is represented as a part of the lumped other tissue compartment
and the model lacks control of ventilation and regulation of blood flow in conditions of
changing O2 or CO2 concentrations. Thus due to these major limitations, this model
cannot be applied to compare O2 levels in the brain compartment during different
treatments and to understand the role of CO2 during isocapnic (arterial PCO2 maintained
at a constant level) and poikilocapnic (uncontrolled arterial PCO2) treatments. There are
other whole body mathematical models developed in the literature but have limitations
(Stuhmiller and Stuhmiller, 2005; Ursino et al., 2001; Wolf and Garner¸ 2007; Zhou et
al., 2007). Many of these models cannot be applied because mass balance of CO or
regulation of blood flow has not been incorporated in these models for conditions like CO
exposure or HBO2 (Ursino et al., 2001; Wolf and Garner¸2007; Zhou et al., 2007).
Models which have incorporated CO mass balance equations ignore the fact that a
significant amount of CO can diffuse into the muscle tissues (Stuhmiller and
Stuhmiller,005). Thus, the best available mathematical model that can applied to

70

implement the third specific aim is the model developed in our lab (Erupaka et al., 2010).
However, this model should be enhanced by adding the necessary features and validated
for various conditions of changing O2 and CO2 concentrations to allow simulations of
various treatment protocols.
The mathematical model described in this chapter is an expansion of the previous
model (Erupaka et al., 2010). This previously developed and published model (Erupaka
et al., 2010) was upgraded by adding a cardiac compartment to the original model of
Bruce et al. (2008). Significant enhancements made to the previous upgraded model
(Erupaka et al., 2010) are addition of: (i) brain compartment (Figure 3.1), (ii) mass
balance equations for CO2, (iii) control of ventilation, (iv) regulation of blood flow:
cardiac output, cerebral blood flow, myocardial blood flow, skeletal muscle tissue and
non-muscle tissue blood flow with changes in arterial O2 saturation (SO2), PO2, PCO2,
%HbCO and (v) Bohr effect on O2 dissociation curve and Haldane effect on CO2
dissociation curve.

METHODS

ACSL 11.8 was used to implement this model. For numerical integration, RungeKutta-Fehlberg variable step size algorithm with error flagging was used and the
maximum allowable step size was 0.001 min. Simulations were performed in double
precision and a 30 minute stabilization period was initiated with every simulation run for
the baseline simulation to reach a steady state. New algorithms were added to implement
Bohr effects and previously used algorithms (described as special functions in Erupaka et
al., 2010) were modified.

Model Description

Addition of brain compartment: A brain compartment (Figure 3.1) comprising three
vascular subcompartments (bb1,bb2,bb3) and two tissue subcompartments (b1,b2) was
added to my previously published model (Erupaka et al., 2010). This concept of two
tissue subcompartments with three vascular subcompartments was introduced, validated
and published for the skeletal muscle by Bruce et al. (2008). Later this concept was
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extended to the cardiac muscle tissue by Erupaka et al. (2010). In this chapter, the same
concepts of a two tissue subcompartments described by Bruce et al. (2008) were
implemented to add a brain tissue compartment to the model. The brain tissue in my
previous model (Erupaka et al., 2010) was lumped with the nonmuscle tissues. A separate
brain compartment was implemented to estimate extent of CO induced hypoxia during
CO exposure and O2 delivery during different therapy protocols. Also, knowledge of O2
and CO2 (CO2 mass balance equations described later in the text) levels in the brain will
enable better control of ventilation in the model. The structure of the brain compartment
(Figure 3.1) is similar to that of the skeletal and cardiac muscle compartments of previous
models developed in our lab (Bruce et al., 2008; Erupaka et al., 2010). The relative
volumes of brain tissue subcompartments and blood subcompartments were chosen by
trial and error from various volume distributions, which were tested to optimize the
model predictions for brain blood and brain tissue PO2’s in various conditions (Table 3.13.2). The mass balance equations for O2 and CO for the brain compartment (Eqs. 3.13.10) are similar to that of the cardiac and skeletal muscle tissue (Appendix A of Erupaka
et al., 2010), except that the brain tissue compartments do not contain myoglobin. After
adding the brain compartment, the brain tissue and venous PO2’s were validated for
conditions of hypoxic hypoxia, CO hypoxia, hyperoxia and hyperbaric oxygen (See
section “Model Validation”). The O2 and CO mass balance equations written for brain
compartment are as described below:

Brain Tissue Subcompartment 1, (b1):

(

)

d
d
dCb1O2 (t ) Fluxb1O2 (t ) Db′O2 ⋅ Cb 2O2 (t ) − Cb1O2 (t ) MRb1O2 (t )
=
+
−
dt
Vb1
Dxb
Vb1

(

………… (3.1)

)

d
d
dCb1CO(t ) Fluxb1CO(t ) Db′CO ⋅ Cb 2CO(t ) − Cb1CO(t )
……………………(3.2)
=
+
dt
Vb1
Dxb

Cb1O2(t) and Cb1CO(t) are the tissue concentrations of O2 and CO in brain tissue
subcompartment, b1 of volume Vb1. Fluxb1O2 (t ) and Fluxb1CO(t ) are the O2 and CO
fluxes

from

blood

to

brain

tissue

subcompartment

1.

Cbd1O2 (t ), Cbd2O2 (t ), Cbd1CO(t ), and Cbd2CO(t ) are the dissolved O2 and CO concentrations
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in tissue subcompartments 1 and 2, respectively. Dxb is the mean intercapillary distance
in the brain tissue. Db′O2 and Db′CO are the intertissue brain diffusion coefficients for O2
and CO. MRb1O2 (t ) is the metabolic rate of O2 in tissue compartment b1.

Brain Tissue Subcompartment 2, (b2):

(

)

d
d
dCb 2O2 (t ) Fluxb 2O2 (t ) Db′O2 ⋅ Cb1O2 (t ) − Cb 2O2 (t ) MRb 2O2 (t )
………(3.3)
=
+
−
V
dt
Vb 2
Vb 2
Dxb ⋅ ⎛⎜ b 2 ⎞⎟
⎝ Vb1 ⎠

(

)

d
d
dCb 2CO(t ) Fluxb 2CO(t ) Db′CO ⋅ Cb1CO(t ) − Cb 2CO (t )
…………………(3.4)
=
+
V
dt
Vb 2
Dxb ⋅ ⎛⎜ b 2 ⎞⎟
⎝ Vb1 ⎠

Cb2O2(t) and Cb2CO(t) are the tissue concentrations of O2 and CO in brain tissue
subcompartment, b2 of volume Vb2. Fluxb 2O2 (t ) and Fluxb 2CO(t ) are the O2 and CO
fluxes from blood to brain tissue subcompartment 2. MRb 2O2 (t ) is the metabolic rate of
O2 in tissue compartment b2.
Brain Blood compartment 1, (bb1):

Vbb1

dCbv1O2 (t )
= Qb (t ) ⋅ ( Car O2 (t ) − Cbv1O2 (t ) ) − O2 Fluxb1 (t ) ………………… …(3.5)
dt

Vbb1

dCbv1CO(t )
= Qb (t ) ⋅ ( Car CO(t ) − Cbv1CO (t ) ) − COFluxb1 (t ) ……………… (3.6)
dt

Cbv1O2(t) and Cbv1CO(t) are the blood concentrations of O2 and CO in brain vascular
subcompartment 1, bb1 of volume Vbb1. Qb (t ) is the brain blood flow and Car O2 (t ) ,
Car CO(t ) are the concentration of O2 and CO in the arterial blood. O2 Fluxb1 (t ) and
COFluxb1 (t ) are the O2 and CO fluxes from blood compartment 1 to brain tissue
subcompartment 1.

Brain Blood compartment 2, (bb2):

Vbb 2

dCbv 2O2 (t )
= Qb (t ) ⋅ ( Cbv1O2 (t ) − Cbv 2O2 (t ) ) − O2 Fluxb 2 (t ) …………………(3.7)
dt
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Vbb 2

dCbv 2CO(t )
= Qb (t ) ⋅ ( Cbv1CO(t ) − Cbv 2CO(t ) ) − COFluxb 2 (t ) ………… …(3.8)
dt

Cbv2O2(t) and Cbv2CO(t) are the blood concentrations of O2 and CO in brain vascular
subcompartment 2, bb2 of volume Vbb2. O2 Fluxb 2 (t ) and COFluxb 2 (t ) are the O2 and CO
fluxes from blood compartment 2 to brain tissue subcompartment 2.

Brain Blood compartment 3, (bb3):

Vbb 3

dCbv 3O2 (t )
= Qb (t ) ⋅ ( Cbv 2O 2(t ) − Cbv 3O2 (t ) ) − O2 Fluxb 3 (t ) ……… …………(3.9)
dt

Vbb 3

dCbv 3CO(t )
= Qb (t ) ⋅ ( Cbv 2CO(t ) − Cbv 3CO(t ) ) − COFluxb 3 (t ) ……… …….(3.10)
dt

Cbv3O2(t) and Cbv3CO(t) are the blood concentrations of O2 and CO in brain vascular
subcompartment 3, bb3 of volume 3 to brain tissue subcompartment 1. O2 Fluxb 3 (t ) and
COFluxb 3 (t ) are the O2 and CO fluxes from blood compartment 1 to brain tissue
subcompartment 1.

Auxiliary equations for brain tissue (b1, b2) and blood (bb1, bb2, bb3)
subcompartments:
Vb1 = Fvb ⋅ Vbt
Vb 2 = (1 − Fvb ) ⋅ Vbt

Vb1 , Vb 2 are the tissue volumes of brain tissue subcopartment 1 and 2,
respectively. Vb1 is the product of brain tissue volume distribution fraction, Fvb
and total brain tissue volume, Vbt
Vbb = volfracb ⋅Vbt
Vbb is the total blood volume in the vascular compartments of brain tissue. It is
the product of the fraction of volume of brain tissue compartment attributed to
blood , volfracb and Vbt
Vbb1 = Fvb ⋅ Vbb
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Vbb 2 = (1 − Fvb ) ⋅ Vbb

Vbb 3 = Dbvb _ on ⋅Vbb1
Vbb1 , Vbb 2 , Vbb 3 are the blood volumes of arterial, capillary and venous
subcompartments of brain tissue.
MRbO2 = 1.21i MRbO2/gram iVbt

⎧( MRbO2 ) ⋅
⎪⎪
MRb1O2 (t ) = ⎨
⎪( MRbO2 ) ⋅
⎪⎩

(

Vb1
Vb1 +Vb 2

)

(

Vb1
Vb1 +Vb 2

)

(

Vb 2
Vb1 +Vb 2

)

(

Vb 2
Vb1 +Vb 2

)

⎧( MRbO2 ) ⋅
⎪⎪
MRb 2O2 (t ) = ⎨
⎪( MRbO2 ) ⋅
⎪⎩

if Pb1O2 (t ) ≥ 26 ⎫
⎪⎪
⎬
⎛
⎞
Pb1O2 (t )
⋅⎜
⎟ if Pb1O2 (t ) < 26 ⎪
⎪⎭
⎝ K bO2 + Pb1O2 (t ) ⎠
if Pb 2O2 (t ) ≥ 26 ⎫
⎪⎪
⎬
⎛
⎞
Pb 2O2 (t )
⋅⎜
⎟ if Pb 2O2 (t ) < 26 ⎪
⎪⎭
⎝ K bO2 + Pb 2O2 (t ) ⎠

MRbO2 , MRb1O2 (t ) , MRb 2O2 (t ) are the metabolic oxygen consumptions of an
average brain tissue, brain tissue subcompartment 1, and brain tissue
subcompartment 2, respectively. MRO2 of the tissue compartment decreases as a
function of tissue PO2, after a tissue PO2 of 26 Torr.
Fluxb1O2 (t ) = O2 Fluxb1 (t ) + O2 Fluxb 3 (t )
Fluxb 2O2 (t ) = O2 Fluxb 2 (t )
O2 Fluxb1 (t ) = Dbb1O2 (t ) ⋅ ( PabO2 (t ) − Pb1O2 (t ) )

Dbb1O2 (t ) =

PSb1O2 (t ).SO2 .Vb1
1.04

PabO2 (t ) , (Erupaka et al, 2010; Appendix A, See Section 2.7, special functions
(F.5))
PSb1O2 (t ) = PSbav _ rest ⋅

Qb (t )
Qb 0

Qb 0 = Qb / gram iVbt
O2 Fluxb 2 (t ) = Dbb 2O2 (t ) ⋅ ( PbbO2 (t ) − Pb 2O2 (t ) )

Dbb 2O2 (t ) =

PSb 2O2 (t ) ⋅ SO2 ⋅Vb 2
1.04
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PSb 2O2 (t ) = PSbcap _ rest ⋅

Qb (t )
Qb 0

PabO2 (t ) , PbbO2 (t ) (Erupaka et al., 2010; Appendix A, See Section 2.7, special
functions (F.5))
Fluxb1CO(t ) = COFluxb1 (t ) + COFluxb 3 (t )
Fluxb 2CO(t ) = COFluxb 2 (t )
COFluxb1 (t ) = Dbb1CO (t ) ⋅ ( Pab CO(t ) − Pb1CO(t ) )
PabCO(t ) = 0.5 ( Par CO(t ) + Pbv1CO(t ) )
COFluxb 2 (t ) = Dbb 2CO(t ) ⋅ ( Pbb CO(t ) − Pb 2CO(t ) )
PbbCO(t ) = 0.5 ( Pbv1CO(t ) + Pbv 2CO(t ) )
COFluxb 3 (t ) = Dbb 3CO (t ) ⋅ ( PcbCO (t ) − Pb1CO(t ) )
PcbCO (t ) = 0.5 ( Pbv 2CO (t ) + Pbv 3CO (t ) )

⎛ Db O (t ) ⎞
Dbb1CO(t ) = DB CO ⋅ ⎜ b1 2 ⎟
⎝ Dbb 2O2 (t ) ⎠
⎛ Db O (t ) ⎞
DB CO (t ) = DM CO ⋅ ⎜ b 2 2 ⎟
⎝ Dbm 2O2 (t ) ⎠

Dbb 2O2 (t ) =

PSb 2O2 (t ) ⋅ SO2 ⋅Vb 2
1.04

PSb 2O2 (t ) = PSbcap _ rest ⋅

Qb (t )
Qb 0

Dbb 2CO(t ) = DB CO
Dbb 3O2 (t ) = Dbb1O2 (t ) ⋅ Dbvb _ on
⎛ Db O 2(t ) ⎞
Dbb 3CO(t ) = DB CO ⋅ ⎜ b 3
⎟
⎝ Dbb 2O 2(t ) ⎠

Cbd1O2 (t ) = Cb1O2 (t )
Cbd1CO(t ) = Cb1CO(t )
Cb1O2 (t ) = SO2 ⋅ Pb1O2 (t )
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Cb1CO(t ) = SCO ⋅ Pb1CO(t )
All other equations are similar to those of skeletal and cardiac tissue
compartments (Appendix A of Erupaka et al., 2010), except that there is no O2 or CO
bound to myoglobin in brain tissue compartments. See Table 3.1 and Appendix A of
Erupaka et al. (2010) for definitions of all other parameters and variables.
Addition of mass balance equations for CO2: Mass balance equations for CO2 in all
compartments were added to model transport and production of CO2 from and within
various blood vessels, lungs and various tissues. This modification was added to allow
control of ventilation and regulation of blood flow with changes in CO2 levels. Addition
of this feature to the model will also allow evaluation of the role of CO2 in managing a
treatment after CO poisoning occurs. The mass balance equations for CO2 are similar to
that of O2 (Appendix A of Erupaka et al., 2010), except that CO2 is produced as a
metabolite on O2 utilization. In the blood compartments Hb binds to CO2 to form
carbaminohemoglobin (HbCO2). Thus the total CO2 in any vascular compartment is
expressed as dissolved CO2, in the form of bicarbonate and as bound to Hb while the total
CO2 in any tissue compartment is expressed as dissolved CO2 and in the form of
bicarbonate ( HCO3− ) (Stuhmiller and Stuhmiller, 2005; Ursino et al., 2001; Wolf and
Garner¸ 2007; Zhou et al., 2007).
Mass balance equations for CO2 in Lung ( Alveolar ( L )) compartment :
VL

dC ACO2 (t )
V (t )
= ( PI CO2 (t ) - PACO2 (t ) ) × A - CO2 fluxLB (t ).......................3.11
dt
PB

CO2 fluxLB (t ) = Q(t ) ⋅ (1 − SF ) ⋅ ( Cep CO2 (t ) − Cmx CO2 (t − d v ) )

VL is the lung volume, VA is the alveolar ventilation, Q is the cardiac output, SF is the
pulmonary shunt fraction (SF=0 for HBO2 conditions), CiCO2 is the concentration in
compartment ‘i’ and PiCO2 is the partial pressure of CO2 in compartment ‘i’. Like the
mass balance equations of oxygen (Appendix A of Erupaka et al., 2010), I assume that
the end pulmonary PCO2 (PEPCO2) is equal to the alveolar PCO2 (PACO2).
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Mass balance of CO2 in any vascluar compartment ' i ' :
Vbi

dCi CO2 (t )
= Qi (t ) ⋅ Ciin CO2 (t ) − Ciout CO2 (t ) − CO2 Fluxi (t )................3.12
dt

(

Ci CO2 (t ) =
dissolved
HCO3−

dissolved

)

Ci CO2 (t ) +

HCO3−

Ci CO2 (t ) +

HbCO2

Ci CO2 (t )

Ci CO2 (t ) = SbCO2 i PCO
i
2

( pH i − 6.1)
Ci CO2 (t ) = Sb CO2 i PCO
i
2 i10

HbCO2

Ci CO2 (t ) = 0.2413C Hb +(0.31CHb i(1-Si O 2 ))

CO2 Fluxi (t ) = 0 for arterial and mixed venous blood compartments

Vbi is the blood volume of compartment ‘i’, SbCO2 is solubility of CO2 in blood, SiO2 is
the O2 saturation of blood compartment ‘i’ (0≤SiO2≤1), pHi is the pH in the blood
compartment
HbCO2

‘i’

and

CHb

is

the

concentration

of

Hb.

Calculation

of

Ci CO2 (t ) indirectly depends on PiCO2, as SiO2 is calculated at every time step (0.001

min) taking into account the effects of PiCO2, pHi and %HbCOi (Bohr effect on the
oxygen dissociation curve).
Mass balance of CO2 in any tissue of two subcompartments (i1, i 2) :

(

)

d
d
dCi1CO2 (t ) Fluxi1CO2 (t ) Di′CO2 ⋅ Ci 2CO2 (t ) − Ci1CO2 (t ) MRi1CO2 (t )
=
+
+
.............3.13
dt
Vti1
Dxi
Vti1

Ci1CO2 (t ) =
dissolved
HCO3−

dissolved

Ci1CO2 (t ) +

HCO3−

Ci1CO2 (t )

Ci1CO2 (t ) = St CO2 i Pi1CO2

Ci1CO2 (t ) = St CO2 i Pi1CO2 i10( pHti1 −6.1)

The mass balance equation for CO2 is given for the first tissue subcompartment. Vti1 is
the volume of tissue compartment ‘i1’, Di′CO2 is the intertissue diffusion coefficient of
CO2 , Dxi is the intercapillary distance in the tissue compartment, StCO2 is the solubility
of CO2 in tissue, MRi1CO2 is the rate of CO2 production in tissue subcompartment i1, and
pHti is pH in the tissue compartment ‘i’.
Auxiliary equations for CO2 mass balance equations:
Fluxb1CO2 (t ) = CO2 Fluxb1 (t ) + CO2 Fluxb 3 (t )
Fluxb 2CO2 (t ) = CO2 Fluxb 2 (t )
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CO2 Fluxb1 (t ) = Dbb1CO2 (t ) ⋅ ( PabCO2 (t ) − Pb1CO2 (t ) )
PabCO2 (t ) = 0.5 ( Par CO2 (t ) + Pbv1CO2 (t ) )
CO2 Fluxb 2 (t ) = Dbb 2CO2 (t ) ⋅ ( PbbCO2 (t ) − Pb 2CO2 (t ) )
PbbCO2 (t ) = 0.5 ( Pbv1CO2 (t ) + Pbv 2CO2 (t ) )
CO2 Fluxb 3 (t ) = Dbb 3CO2 (t ) ⋅ ( Pcb CO2 (t ) − Pb1CO2 (t ) )
PcbCO2 (t ) = 0.5 ( Pbv 2CO2 (t ) + Pbv 3CO2 (t ) )

MRi CO2 (t ) = MRi O2 (t )i RQi
Di CO2 (t ) = 18i Di O2 (t )
MRot CO2 (t ) = MRCO2 (t ) − ( MRB CO2 (t ) + MRCM CO2 (t ) + MRM CO2 (t ))
MRotCO2(t), MRCO2(t), MRBCO2(t), MRCMCO2(t) and MRMCO2(t) are the rates
of CO2 production in the non-muscle tissue, whole body, brain tissue, cardiac
muscle and skeletal muscle, respectively. Values for RQi and fac are given in
table 3.1. The diffusion coefficient for CO2 ( Di CO2 (t ) ) is reported to be at least
18 times greater than that of O2 ( Di O2 (t ) ) in the normoxic and normocapnic
conditions (Zhou et al., 2007). In my model this relation of a constant ratio
between Di CO2 (t ) and Di O2 (t ) is assumed to be valid for all conditions like
hyperoxia, hypoxia, hypercapnia, CO hypoxia, hypocapnia etc.
After implementing the mass balance equations for CO2, tissue and blood PCO2
from various compartments were validated for situations of normoxic normocapnia,
hypercapnia, hyperoxia, and hyperbaric oxygen (See section “Model Validation”).
Addition of control of ventilation: The uptake and removal of CO is dependent on the
ventilation of the subject. For the same duration and concentration of CO exposure, a
subject with higher ventilation will inhale more CO and will have higher %HbCO levels
at the end of exposure, when compared to a subject with lower ventilation. In CO
exposure studies of humans (Chiodi et al., 1941) and animals (Doblar et al., 1977;
Santiago ans Edelman, 1976), it has been observed that the ventilation does not change
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significantly from the control values at least up to a %HbCO of 55. But during treatment
with normobaric oxygen (NBO2), isocapnic NBO2 or hyperbaric oxygen (HBO2), the
ventilation would be significantly different from the control values (Becker et al., 1996;
Fisher et al., 1999; Lambertsen et al., 1952, 1953; Nishimura at al., 2007). Inhalation of
O2 results in a decreased brain blood flow due to cerebral vasoconstriction. Decreased
brain blood flow causes an increase in brain tissue PCO2. Increases in brain tissue PCO2
are sensed by the central chemoreceptors and the respiratory centers in the brain send
signals to cause an increase in ventilation. Higher ventilation during treatment (NBO2,
isocapnic NBO2, or HBO2) for a CO poisoned patient would mean that more CO will be
exhaled, thereby resulting in faster removal of CO from the body. Thus to appropriately
estimate uptake and removal of CO during an exposure and treatment, it is essential to
implement control of ventilation in my model.
Many mathematical models (Duffin et al., 2000; Longobardo et al., 2002;
Stuhmiller and Stuhmiller, 2005; Ursino et al., 2001; Topor et al., 2004; Wolf and
Garner¸ 2007; Zhou et al., 2007) have implemented control of ventilation as the sum of
peripheral ( VPERI ) and central ventilation ( VCENT ). But the gains or threshold used in their
equations were specific to situations like hypoxic hypoxia, sleep stages or hyperoxia.
Also most of these models estimated minute ventilation (Duffin et al., 2000; Longobardo
et al., 2002; Stuhmiller and Stuhmiller, 2005; Ursino et al., 2001; Topor et al., 2004;Wolf
and Garner¸ 2007). In my model, I need to estimate alveolar ventilation ( VA ) during
normoxia, CO hypoxia, NBO2, isocapnic NBO2, and HBO2. Thus to implement
ventilation control in my model, I used the concepts of Garner and Wolf (2007) and
implemented alveolar ventilation as the sum of peripheral and central component (Eqs.
3.14-3.16). Tidal volume, dead space and minute ventilation were estimated from
regression equations based on alveolar ventilation (Bruce et al., 2011, under review).
Minute ventilation was calculated in the model to allow comparison of model estimates
of ventilation with the experimental data. The parameters in the equations for control of
ventilation (Wolf and Garner¸ 2007) were first adjusted to match normoxic values of
ventilation. Later the values of the parameters were fine tuned to match hypoxic,
hypercapic and hyperoxic (NBO2, isocapnic NBO2, and HBO2) data. The details of the
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experiments used to determine the gains and threshold of the ventilation control equations
(Eqs. 3.14-3.16) are described in the “model validation” section of this chapter. The
equations for the control of ventilation are:
VA (t ) = VCENT (t ) + VPERI (t )......................................................................3.14
VCENT (t ) = 2.07i( Pbt CO2 (t ) − 46)............................................................3.15
⎛
⎞
360
− 5.04 ⎟i FCO 2 (t )...3.16
VPERI (t ) = 0.72i( PcbCO2 (t ) − 37.8) + ⎜
⎝ PcbO2 (t ) − 26.2
⎠
k
Pbt CO2 (t ) = Pb 2CO2 (t + Dc ) ; Dc = c
Q(t )
4 −1
⎧⎛
⎫
⎞
P
CO
t
(
)
⎛
⎞
⎪⎜ 5 − 4 ⎜ cb 2 ⎟ ⎟ for ⎜⎛ PcbCO2 (t ) ⎟⎞ ≤ 1⎪
40
40
⎪⎜
⎪
⎝
⎠ ⎟⎠
⎝
⎠
FCO 2 (t ) = ⎨⎝
⎬
⎪⎛ PcbCO2 (t ) ⎞3
⎪
⎛ PcbCO2 (t ) ⎞
> 1⎪
for ⎜
⎪⎜
⎟
⎟
40
40
⎠
⎝
⎠
⎩⎝
⎭
kp
PcbCO2 (t ) = Par CO2 (t + D p ) ; D p =
Q(t )

where,
Pb2CO2(t) is the PCO2 of the brain tissue in subcompartment 2 and ParCO2(t) is the
arterial PCO2. Dp and Dc are the peripheral and central time delays. See Table 3.1 for
values of kc and kp. Q(t ) is the cardiac output.

Addition of regulation of blood flow: Cardiac output ( Q ) and blood flow to various
tissues is regulated constantly with changes in arterial PO2, PCO2 and %HbCO levels
(low or high O2 and CO2, high CO). Cardiac output and blood flow to other vital organs
like brain and heart is reported to increase with increasing %HbCO levels (Benignus et
al., 1992; Chiodi et al., 1941; Doblar et al., 1977; Einzig et al., 1980; Kleinert et al.,
1980; Koehler et al., 1984; Langston et al., 1996; Paulson et al., 1973; Rucker et al.,
2002; Santiago et al., 1986; Zhu and Weiss, 1995). In NBO2 or HBO2 conditions and
hypocapnia, cardiac output and brain blood flow is reported to decrease due to peripheral
vasoconstriction (Floyd et al., 2003; Lambertsen et al., 1953; Ohta, 1986; Topor et al.,
2004; Zhou et al., 2007; Weaver et al., 2009). During hypoxic hypoxia and hypercapnia,
cardiac output and brain blood flow ( QB ) is reported to increase due to peripheral
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vasodilatation (Topor et al., 2004; Wolf and Garner¸2007; Zhou et al., 2007). Thus to
model dynamics of O2, CO2 and CO during exposure and various treatments, regulation
of blood flow should be implemented.
Regression equations were developed to predict changes in cardiac output (Figure
3.2) and brain blood flow (Figure 3.3) with increases in %HbCO levels (Benignus et al.,
1992; Chiodi et al., 1941; Doblar et al., 1977; Koehler et al., 1984; Langston et al., 1996;
Paulson et al., 1973; Rucker et al., 2002; Santiago et al., 1986). Piecewise linear
regression fits were made to predict percent changes in cardiac output (Figure 3.2d) and
brain blood flow (Figure 3.3) as a function of %HbCO. The previous model (Erupaka et
al., 2010) was developed to simulate CO exposures <30% HbCO levels. But, the current
model being developed is intended to simulate CO exposures greater than 30% HbCO
levels. The previous regression equation developed in my model (Equation C5 of
Appendix C, Erupaka et al., 2010) underestimated the changes in cardiac output with
increases in %HbCO levels >30. Chiodi et al. (1941) reported that the changes in cardiac
output are statistically different for %HbCO levels >30. To predict appropriate percent
changes in Q for %HbCO levels greater than 26%, a regression equation was developed
(Figure 3.2) using the data from Chiodi et al. (1941). The regression statistics for this
equation are R2=0.901 and the error in the estimate, Ĕ=7.94. To predict changes in
cardiac output for %HbCO levels less than or equal to 26%, an equation of the form
y=mx+c was calculated for a line formed from two data points. The first data point
(1%,0.572%) for this line was from the old regression equation (Equation C5 of
Appendix C, Erupaka et al., 2010) at 1% HbCO and the second data point (26%,1.772)
was from the new regression relation at 26% HbCO. The value of 26% HbCO level was
chosen to avoid discontinuity in the regression relation developed. To predict percent
changes in QB with changes in %HbCO, data from animals (Doblar et al., 1977; Koehler
et al., 1984; Langston et al., 1996; Santiago et al., 1986) and humans (Benignus et al.,
1992; Paulson et al., 1973; Rucker et al., 2002) were used (Figure 3.3). The regression
statistics for this equation for % HbCO levels ≤ 23 are R2=0.951, Ĕ=3.37 and for
%HbCO levels >23 are R2=0.898, Ĕ=9.622. The value of 23% HbCO level was chosen to
avoid discontinuity in the regression relation developed to predict brain blood flow.
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Equations for regulation of Q and QB during hypoxia, hypercapnia and
hypocapnia were used from the model of Zhou et al. (2007). For conditions of NBO2,
isocapnic NBO2 and HBO2, Q was estimated using a regression equation as function of
ParO2 and ParCO2. The regression equation was developed in this study using the data
from healthy human subjects (McMohan et al., 2002; Weaver et al., 2009; Whalen et al.,
1965) who were exposed to NBO2, isocapnic NBO2 or HBO2 and Q was measured. The
regression statistics for the equation developed are R2=0.849, Ĕ=0.314. QB for conditions
of high O2 (NBO2, isocapnic NBO2 or HBO2), was estimated from the relationship
developed by Floyd et al. (2003). The coefficients of the regression relation developed by
Floyd et al. (2003) were fine tuned to match the model predicted ventilation to that of the
experiments of Becker et al. (1996) and Lambertsen et al. (1952, 1953).
Regulation of Cardiac Output (Q)
dQ(t )
+ Q(t ) = Q0 + ΔQO2 (t ) + ΔQCO2 (t ) + 0.01(Q0 iQHbCO (t )).......................................3.17
dt
if % S ar O2 (t ) ≤ 99
⎧0.09(97.4 − S ar O2 (t ))
⎫
ΔQO2 (t ) = ⎨
⎬
if % S ar O2 (t ) > 99 or PB > 760 ⎭
⎩-0.001i(Par O 2 (t)-Par0 O 2 (t))
if % Sar O2 (t ) ≤ 99
⎧0.033( Par CO2 (t ) − 40)
⎫
ΔQCO2 (t ) = ⎨
⎬
⎩-0.143i(Par CO 2 (t)-Par0 CO 2 (t)) if % S ar O2 (t ) > 99 or PB > 760⎭
if % HbCO(t ) ≤ 26 ⎫
⎧0.048(% HbCO(t )) + 0.52)
QHbCO (t ) = ⎨
⎬
if % HbCO(t ) > 26 ⎭
⎩1.772(% HbCO(t ) - 25)

τq

Q0 is the resting cardiac output, SarO2(t) is the arterial O2 saturation and ParCO2(t) is the
arterial PCO2. ParO2(t) is the arterial PO2 and PB is the barometric pressure. τ q is the first
order time constant. Par0O2(t), Par0CO2(t) are the arterial PO2 and PCO2 at the control
conditions. The maximal decrease in Q (t) from Q0 during high oxygen conditions is
limited to 15% (Weaver et al., 2009).
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Regulation of Brain Blood Flow (QB )
dQB (t )
+ QB (t ) = ΔQBO , BCO (t ) + 0.01(QB0 iQBHbCO (t ))..................................................3.18
2
2
dt
⎧
⎫
⎪if % S O (t ) ≤ 99
⎪
ar 2
⎪
⎪
⎪QB + 7.7 × 10−3 (97.4 − Sar O2 (t )) + 0.2 × exp(0.033 × Par CO2 ) − 0.75 ⎪
⎪⎪ 0
⎪⎪
ΔQBO , BCO (t ) = ⎨
⎬
2
2
⎪if % S O (t ) > 99 or P > 760
⎪
ar 2
B
⎪
⎪
⎪ QB
⎪
⎪73i 0 -0.0153i(Par O 2 (t)-Par0 O 2 (t))+0.67i(Par CO 2 (t)-Par0 CO 2 (t))+11⎪
⎪⎩ Vbt
⎪⎭

τb

⎧0.718(% HbCO(t )) + 0.52)i ff
QBHbCO (t ) = ⎨
⎩1.487(% HbCO(t ) -17.285)i ff

if % HbCO(t ) ≤ 23 ⎫
⎬
if % HbCO(t ) > 23 ⎭

QB0 is the resting brain blood flow and ff is the adjustment factor introduced, so that the

ventilation does not change from its control state (normoxic,normocapnia) during CO
exposure (See section “model limitations”). τ b is the first order time constant. Vbt is the
brain tissue volume. The maximal decrease in QB (t) from QB0 during high oxygen
conditions

is

limited

to

30%

(Ohta,

1986).

Regulation of cardiac muscle (QCM )
QCM (t ) = QCM 0 i

Q(t )
......................................................3.19
Q0

Regulation of skeletal muscle (QSM )
QSM (t ) = QSM 0 i

Q(t )
......................................................3.20
Q0

Regulation of nonmuscle tissue blood flow(QOT )
QOT (t ) = Q(t ) − (QB (t ) + QCM (t ) + QSM (t ).......................3.21

Addition of Bohr and Haldane effects: In the presence of CO, the oxygen dissociation
curve shifts to the left resulting in an increased affinity of Hb for O2. The leftward shift
causes the sigmoidal curve to become more hyperbolic and impairs unloading of oxygen
to the tissues. P50 is the vascular PO2 at which hemoglobin is 50% saturated. The value of
P50 decreases with increases in %HbCO levels in the blood (Bruce and Bruce, 2003). The
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previous model (Erupaka et al., 2010) accounted for changes in P50 due to increase in
%HbCO levels. In the new model, after implementing mass balance of CO2, it was
necessary to include Bohr effects (PCO2, pH, %HbCO levels, and temperature) on the
oxygen dissociation curve and Haldane effects (O2Hb) on CO2 dissociation curve
(Collier, 1976; Lobdell, 1981; Sharan et al.,1989;Stuhmiller and Stuhmiller, 2005). The
concepts from Sharan et al. (1989) were used to implement Bohr effects on oxygen
dissociation curve (ODC). Algorithms were developed to calculate O2 saturation, P50 and
PO2 in a vascular compartment taking into account the effects of PCO2, pH, %HbCO
levels, and temperature on ODC (Collier, 1976; Lobdell,1981; Sharan et al.,1989). In the
algorithm the dependence of ODC on %HbCO is implemented by calculating the P50,
according to the theory of Collier (1976). To calculate the oxygen saturation (SO2) or
PO2 in any blood compartment, an invertible Adair type equation with high accuracy is
used (Equation 1 of Lobdell, 1981). Later the absolute SO2 is calculated from %HbCO
levels and maximal oxyhemoglobin (HbO2).

Haldane effects (O2Hb) on CO2

dissociation curve were implemented using the relationship published by Stuhmiller and
Stuhmiller (Equation A43, 2005).

The algorithms implementing Bohr and Haldane

effects were validated for various conditions of normoxia, CO hypoxia, hyperoxia,
hypercapnia and hypocapnia (See section “model validation”).
Other modifications: The metabolic rate of O2 consumption in cardiac muscle and
skeletal muscle tissue was constant if the tissue PO2 was greater than 20 Torr and
decreased (Equation 3.22) with decreasing tissue PO2’s for values less than 20 Torr.

⎧( MRi O2 ) ⋅
⎪⎪
MRi1O2 (t ) = ⎨
⎪( MRi O2 ) ⋅
⎪⎩

(

Vi 1
Vi 1 +Vi 2

)

(

Vi 1
Vi 1 +Vi 2

)

if Pi1O2 (t ) ≥ 26 ⎫
⎪⎪
⎬ .........................3.22
⎛
⎞
Pi1O2 (t )
if
P
O
(
t
)
<
26
⋅⎜
⎪
⎟
i1 2
⎪⎭
⎝ K i O2 + Pi1O2 (t ) ⎠

where i1, i2 represent tissue subcompartment 1 and 2 of cardiac or skeletal muscle
tissues. MRiO2 is the metabolic rate of O2 in tissue ‘t’. Pi1O2 is the PO2 in compartment
‘i1”. Vi1 and Vi2 are the tissue volumes of subcompartment i1 and i2. For KiO2 see Table
A4 of Appendix A of Erupaka et al. (2010).

85

The muscle diffusion coefficient of CO (DMCO) was varied in proportion to
muscle mass, with a value of DMCO of 0.225 ml/min/Torr/Kg of muscle mass. Lung
diffusivity of CO (DLCO) varied (Equation 3.23) as a function of alveolar PO2 (PAO2)
and at a PAO2 of 500 Torr, DLCO was half of its value at room air ( D L CO Air ).

D L CO =

1
iD CO .........................3.23
PA O 2 L Air
1+
500

Hypoxic ventilatory depression (HVD) is a bipasic response produced during
hypoxic exposure, where an initial rapid increase in ventilation is not sustained and is
followed by a decline during the first 30 mins of hypoxic exposure. HVD was
implemented in the model using the concepts of Ursino et al. (2001) and Zhou et al.
(2007). The version of the model in which HVD was implemented, was validated for
transient and steady state conditions of hypoxia (Bascom et al., 1992). After
implementing and validating the mechanism of HVD, the model was used to simulate a
short duration CO exposure resulting in ~20% HbCO. At the end of CO exposure the
predicted change in ventilation from the normoxic condition did not agree with the
experimentally measured changes in ventilation (Chiodi et al., 1941; Kizakevich et al.,
2000). As this version of the model was unable to predict appropriate changes in
ventilation during CO hypoxia, the mechanism of HVD was not implemented (See
discussion).

RESULTS
Model validation

After implementing the above described modifications, the capability of the
model to predict brain tissue and venous PO2’s¸ ventilaton, tissue and blood PCO2’s,
tissue and blood pH in various compartments was assessed and compared with
experimental data. The modified model was validated for various conditions. The
conditions simulated were normoxia, hypercapnia, hypocapnia, hypoxic hypoxia, CO
hypoxia, hyperoxia, isocapnic hyperoxia and hyperbaric oxygen. For various simulated
experimental conditions, the model predicted values of various parameters (brain tissue
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and venous PO2, ventilation, blood PCO2, etc) were validated against the experimentally
measured values. Most of the data for validation of brain tissue PO2’s were obtained from
studies on anesthetized animals (Table 3.2), but data for validation of ventilation, blood
PCO2, blood pH and brain venous PO2’s were obtained from studies involving human
subjects (References in the text below and Table 3.2). Developing a validated
mathematical model to estimate O2, CO and CO2 levels in brain, heart and skeletal
muscle tissue during CO exposures and treatments, will allow me to compare O2
delivery, CO removal and CO2 levels during different treatments after a CO exposure.
Validation of brain tissue and blood PO2: Table 3.2 shows the compiled experimental
data for brain tissue and venous PO2’s from different species and conditions of
measurement. Inspired levels of O2 (FIO2) and barometric pressure (PB) in the simulations
were set equal to the reported experimental values or were adjusted to achieve the
measured arterial PO2 (when arterial PO2 was reported in the study). Arterial PO2’s for
the experiments simulated ranged from 21 Torr to 2100 Torr. Alveolar ventilation, brain
blood flow, brain oxygen consumption and brain CO2 production were estimated by the
model for a human subject. For all the simulations, other brain compartment related
parameters (volume distribution fraction, permeability surface area product, etc) are listed
in Table 3.1. The PO2 of the third vascular subcompartment of the brain compartment,
bb3, (Figure 3.1), was compared to sagittal sinus PO2 reported in the experimental data.
The brain tissue O2 tensions in the experiments were mostly reported as mean values with
standard deviations. I considered the reported mean PO2 plus one standard deviation as
the O2 tension of brain tissue subcompartment 1, b1 and the reported mean PO2 minus one
standard deviation as the O2 tension of brain tissue subcompartment 2, b2. During
conditions of high arterial PO2, the tissue PO2 in b2 increased but did not increase in
proportion to the arterial PO2. This result is in agreement with the experimental studies,
where an increase in tissue PO2 was not seen in the majority of tissue during hyperoxia
(Eintrei and Lund, 1986; Lumb and Nair, 2010). Thus for hyperoxic and hyperbaric
conditions, O2 tension of b1 was compared to the reported mean PO2 of the experiments.
Figure 3.4(a-b) shows the comparison of model predictions (brain tissue and sagittal
venous PO2’s) with experimentally measured values. Predicted PO2’s from the model

87

were tested for conditions of normoxia, hypoxia, hyperoxia, hyperbaric oxygen, CO
hypoxia, hypocapnia, and hypercapnia. In Fig. 3.4 (a-b), the model-predicted PO2’s for
brain tissue and venous compartments fit variations in the experimentally measured
PO2’s for a variety of simulation conditions. Also, the model was used to simulate 40
mins of CO exposure to attain 40% HbCO and the brain tissue PO2’s after 40 min of CO
exposure were compared with an experimental study in rat (Hara et al., 2011). The
average brain tissue PO2 after 40 min of CO exposure at 40% HbCO was in agreement
with the experimental result of Hara et al. (2011). Thus, the model predicts
physiologically reasonable brain tissue and vascular O2 tensions over a wide range of
arterial PO2 values.
Validation of tissue and blood PCO2: Model predicted brain tissue and blood venous
PCO2’s were tested for conditions of normoxia (Hoffman, 2001; Lambertsen et al., 1952,
1953,1953,1955; Martinez Tica et al., 1999), hypoxia (Martinez Tica et al., 1999),
hyperoxia (Lambertsen et al., 1952), hyperbaric oxygen (Lambertsen et al., 1953,1955),
hypocapnia (Hoffman, 2001) and hypercapnia (Hoffman, 2001; Lambertsen et al., 1953).
Figure 3.4(c-d) shows the comparison of model predictions (brain tissue and sagittal
venous PCO2’s) with experimentally measured values. In hypoxia, the model-predicted
brain tissue and blood PCO2’s are slight underestimates of the experimental data. Also,
in the condition of normoxia, the skeletal muscle (M) and cardiac muscle (C) tissue PCO2
predicted by the model (M:46.9 Torr, C:50.2 Torr) are in agreement with the
experimental data (M:45.4 Torr, C:54±5 Torr) reported by Hart et al.(2003) and Hoffman
et al. (2001). Model estimated tissue PCO2’s in the cardiac muscle during hypocapnia and
hypercapnia closely matched the trend in the data reported by Hoffman et al. (2001).
Figure 3.5 shows that the model predicted arterial and mixed venous PCO2’s and pH
measurements for normoxia, hyperoxia and hyperbaric oxygen are in agreement with the
data. Considering the limited availability and variability of experimental data for blood
and tissue PCO2 tensions, the model closely represents the trends in the data.
Validation of PO2 and PCO2 for hyperbaric oxygen: Weaver et al. (2009) exposed 10
healthy subjects to air and oxygen at 0.85, 3, 2.5, 2, 1.3 and 1.2 ATA. Cardiac output,

88

whole body metabolic rate, arterial and venous blood gas, pH measurements, heart rate
and many other variables were measured at the end of exposure to each pressure. I used
the model to simulate their experiment for an average subject from their data (mean age,
weight, height etc). Average values for heart rate, cardiac output and metabolic rate were
given as the input to my model at the specified atmospheric pressures. Model predicted
arterial PO2 (ParO2), PCO2 (ParCO2), pHar and venous PO2 (PmxO2), PCO2 (PmxCO2), pHmx
were compared to the experimental data at 0.85 ATA air, 0.85 ATA O2, 3 ATA O2, 2.5
ATA O2, 2 ATA O2, and 1.2 ATA O2, respectively (Figure 3.5). The model predicted gas
tensions in the arterial and mixed venous blood compartments were compared with the
arterial and venous measurements of the experimental data. It is seen from Figure 3.5 that
the model estimates are in agreement with the experimentally measured values. Also, the
model-predicted tissue PO2 in the skeletal muscle compartment at 2 ATA are in
agreement with the value reported by Hart et al. (2003)
Overall the model is well validated to predict tissue and blood O2 and CO2
tensions in brain, heart and skeletal muscle for a variety of conditions like nomoxia,
hypoxic hypoxia, CO hypoxia, hyperoxia, hyperbaric oxygen, hypocapnia and
hypercapnia.
Validation of ventilation: Model predicted ventilation was validated for various situations
like normoxia, hypoxia, isocapnic hyperoxia, poikilocapinc hyperoxia, hypercapnia and
hyperbaric oxygen.
Ventilation in hypoxia: The parameters in the peripheral ventilation equation (Equation

3.16) were adjusted to isocapnic hypoxic data from Bascom et al. (1992). In this
experiment, ventilatory responses to different levels of end tidal PO2 during isocapnia in
humans were measured. End tidal PO2 was held at normoxic level (100 Torr) for the first
10 minutes, which was followed by 20 mins hypoxic exposure at 75, 65, 55, 50, or 45
Torr. PCO2 was held at 1-2 Torr above the resting value. In the simulations, PACO2 was
held constant at the resting level of 39.03 Torr. Then I adjusted the inspired oxygen
fraction to match the experimental oxygen saturation and PO2. Model estimation of
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ventilation at different levels of hypoxia is in agreement with the change in ventilation
observed in the experiments (Figure 3.6). In situations where I would like to simulate CO
exposure at altitude, the lowest (maximum) PO2 may be 75 Torr. So I concentrated on
matching model estimation of ventilation to the change at 75 Torr.
Ventilation in hyperoxia: Becker et al. (1996) measured the ventilatory response to

different levels of hyperoxia. In their study, ventilation in human subjects was measured
after breathing 30%, 50% or 75% O2 for 30 min, while maintaining isocapnia. The
parameters in the central ventilation equation (Equation 3.15) and the brain blood flow
equation coefficients were adjusted to match hyperoxic data. PCO2 was maintained at the
resting value of 39.03 Torr. At higher levels of inspired O2 (50%,75%), the model
estimation matches with the experimental data. At 30% inspired oxygen, the model
estimation is lower than the experimental data. Becker et al. (1996) did not measure the
ventilation at 100% O2. The model application will be mainly in 100% O2 concentration,
so I attempted to adjust my model parameters to match data at higher O2 concentrations
(Figure 3.7). The model estimated ventilation change at 100% O2 is in agreement with
other data from Poulin et al. (1993) and Ren et al. (2002).
In addition to isocapnic hyperoxia, the enhanced model was validated for
poikilocapnic hyperoxia. Nishimura et al. (2007) exposed human subjects to subsequent
stepwise increases from 21% air to 40%, 70% and 100% O2. O2 level at each step was
maintained for ~20 min. They measured arterial PCO2 and ventilation at the end of each
level. This experiment was simulated using the enhanced model and model estimated
changes in ventilation and arterial PCO2 at different levels of hyperoxia were compared
with the experimental data. The model matches the experimental data at high inspired
oxygen concentrations (Figure 3.8). There is a slight mismatch at the lower levels of
inspired O2 concentration. But as the model will be applied only in high O2 inspired
fractions, the parameter values in the ventilation equation were considered to be
appropriate.
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Ventilation in hyperbaric oxygen: Lambertsen et al. (1952,1953,1955) exposed human

subjects to oxygen at 3.5 ATA for ~20 min and measured the ventilatory response and
changes in arterial PCO2. They reported a 25% increase in ventilation and drop in PCO2
of ~ 4-5 Torr compared to the control value (normoxia). Using my enhanced model to
simulate their experiment resulted in an increase in ventilation of 22% and a drop in
arterial PCO2 (ParCO2) of 4.29 Torr. Thus, the estimated changes in ventilation and
ParCO2’s predicted by model are in agreement with the experimental data.
Slopes of Ventilation (Ve) and alveolar PCO2 (PACO2) response curves in normoxia,
hypoxia, and hyperoxia: In order to produce the Ve-PACO2 curves at different alveolar

PO2’s (PAO2=100,50,200 Torr), I maintained the alveolar PO2 at a constant level and the
inspired fraction of CO2 was increased in every simulation from 0% to 3%,5%,6%, or 7%
for 25 min. The slopes and the intercepts for the alveolar PCO2 (PACO2) and minute
ventilation (Ve) curves at each of the maintained PAO2 were calculated and compared
with the experimental values (Table 3.3). The slopes of the Ve-PACO2 curves from my
model simulations are in agreement with the slopes of the Ve-PACO2 curves from other
experiments. I also simulated the experiments of Reynolds et al. (1972) in which
ventilatory response of healthy subjects who breathed 0%, 3%, 5%, 6%, or 7% of CO2 for
25 minutes was determined. At various inspired levels of CO2, I compared the change in
PACO2 with the change in ventilation predicted by my model with the experimental data
and with other mathematical models (Figure 3.9) in the literature simulating the same
experiment (Chiari et al., 1997; Sokhanvar et al., 2005, Grodins et al., 1967, Wolf and
Garner, 2007). The enhanced model was unable to reproduce the transient changes in
ventilation but the steady state responses predicted by the model were in agreement with
the experimental data and steady state data from other mathematical models. As the
application of this model will be in situations where the CO exposure duration will be
atleast 20 mins, the inability of the model to reproduce transient changes in ventilation
may be ignored as a limitation.
Validation of algorithm implemented to include Bohr effects: The algorithms

implementing Bohr effects were validated in the model. Model calculated O2 saturations
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were compared with experimentally measured O2 saturation (SO2) for various values of
PCO2, pH, and %HbCO levels (Doblar, 1977; Roughton and Darling, 1943; Sharan et al,

1989; Severinghaus, 1966; Severinghaus, 1979; Weaver et al., 2009; Whalen et al., 1965;
Zhu and Weiss, 1995). The algorithm estimated O2 saturations are in agreement with the
experimentally measured values (Figure 3.10) for conditions of normoxia, CO hypoxia,
hypercapnia, and hypoxia. Also as seen in figure 3.6a, for a given inspired O2 fraction,
the model estimated arterial SO2 is in agreement with the experimentally measured SO2
for various PO2’s.
DISCUSSION
Model Limitations

The current model was enhanced to simulate and compare the treatment strategies
currently used to treat CO poisoned victims. My previous model (Erupaka et al., 2010)
was modified by adding a two subcompartment brain tissue, dynamics of CO2, control of
ventilation and regulation of cardiac output and blood flow to various tissues. This
modified model was later validated for model estimated variables (ventilation, tissue and
blood PO2, tissue and blood PCO2) in various conditions of normoxia, hypercapnia,
hypoxia, hyperoxia, and hyperbaric oxygen. My enhanced model is the only model
currently available in the literature to estimate O2, CO and CO2 tensions, bicarbonate
levels, pH levels, blood HbCO levels, and MbCO (in heart and skeletal muscle tissues)
levels in all the vascular and tissue compartments in normoxia, hypoxia, CO hypoxia,
hyperoxia, isocapnic hyperoxia and hyperbaric oxygen. This feature of the developed and
validated model to estimate O2, CO and CO2 levels in brain, heart and skeletal muscle
tissue during CO exposures and treatments, will allow me to compare O2 delivery, CO
removal and CO2 levels during different treatments after a CO exposure. In addition to
the limitations discussed in the previous version of this model (Bruce et al., 2008;
Erupaka et al., 2010), there are some limitations to this enhanced model which are
discussed below.
Brain tissue compartment: The brain tissue compartment in this model represents the whole

brain. The brain blood flow values, oxygen consumption and all other parameters used to
model this compartment are for an average human brain. Thus the oxygenation levels
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predicted for this compartment for various simulation conditions represent the PO2’s in the
whole brain. However it is well known that the brain is a highly heterogeneous tissue with
respect to blood flow, oxygen consumption, tissue PO2’s and vasculature (Erecińska and
Silver, 2001; Floyd et al, 2003; Kolbitsch et al., 2002; Leenders et al., 1990). Imaging
studies of CO poisoned victims have reported injury to the basal ganglia, hippocampus, and
cortical white matter. In my study, the goal is to compare O2 delivery to the brain tissue
during the different treatment strategies applied and not to find a correlation between the
tissue PO2 in the various regions (white matter, gray matter, hippocampus, basal ganglia,
and cortex) of the brain with the neurological outcomes or imaging studies. Though it is
desirable to have a brain compartment representing various regions, applying this model to
accomplish the third specific aim should not be considered as a significant limitation.
Myocardial oxygen consumption: Myocardial oxygen consumption (MOC) in the model

is calculated as a function of heart rate (Equation C8, Appendix C of Erupaka et al.,
2010). An increase in work load of the heart in conditions of hypoxic hypoxia (low O2) or
CO hypoxia would result in increased O2 demand and supply to the heart (Erupaka et al.,

2010). In the current model or the previous version of this model, myocardial oxygen
consumption does not increase with increasing work load of the heart i.e., during increase
in cardiac output with CO exposure. A regression relation to predict changes in heart rate
with increasing %HbCO levels using data from Chiodi et al. (1941) was developed. The
regression estimated increases in heart rate were used to increase the resting myocardial
oxygen consumption in the enhanced model. Using this approach greatly underestimated
the tissue PO2’s in the heart at HbCO levels >25%, as the increase in blood flow to the
heart was not sufficient to meet the increased O2 demand. Thus to overcome the problem
of O2 supply and demand mismatch, this regression equation was not implemented in the
final version of the enhanced model. The heart is a rapidly contracting muscle with a high
O2 extraction fraction and MOC at resting state, so in conditions of increased work load

the heart relies on energy production via anaerobic metabolism. My model does not
feature energy production through anaerobic metabolism. In my model, irrespective of
the work load, MOC in the model decreases only as a function of tissue PO2 (Equation
3.22). If the heart rate is known during CO exposures, then changes in MOC can be
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predicted at various stages. However obtaining information on heart rate during high CO
exposures is difficult. Thus in healthy populations the model estimated tissue PO2’s may
assumed to be slight overestimates of the actual values at %HbCO levels greater than
~35% (educated guess based on data from Chiodi et al., 1941).
Prediction of injury: The enhanced model does not directly predict the possibility of

injury after a CO exposure. Despite treatment, neurological and myocardial problems
manifest from CO poisoning. Occurrence of these problems after treatment may either be
due to cellular injuries sustained at the time of exposure, or due to inadequacy of the
therapy administered to sustain high tissue PO2, together with rapid clearance of CO and
other metabolites like CO2. This model can be applied to compare the adequacy of the
treatment administered but currently does not have the capability to predict injury
sustained by the tissues at the time of exposure or before the treatment was applied.
Tissue oxygen thresholds reported in the literature for functional impairments or
occurrences of injury are as follows: Intracellular acidosis is reported to occur at tissue
PO2’s less than 6 Torr (Erecińska and Silver, 2001; Zauner et al., 2002). ECG

abnormalities are seen when myocardial O2 tensions are <5 Torr (Erecińska and Silver,
2001; Zauner et al., 2002). A tissue PO2 of <1.5 Torr would be an indicator of anaerobic
metabolism (Zauner et al.,2002). Binding of CO to cytochrome c-oxidase (CCO) can be
expected when tissue PO2 approaches 1 Torr, thereby inhibiting mitochondrial respiration
(Fisher and Dodia, 1981). Cell death can be inferred when a tissue PO2 of zero is
maintained (Smith et al., 2007). Based on the above thresholds, I can attempt to specify a
criterion to suggest possibility of injury in the tissues. To avoid the influence of tissue
injury on determination of the best treatment, the maximum %HbCO level at which tissue
injury does not occur can be suggested by determining the %HbCO level at which the
PO2’s in the brain and heart tissue start to fall below a certain threshold (PTHO2). But the

%HbCO level determined from this approach will be dependent on the duration and
concentration of CO, health of the subject and intersubject variability. A logistic regression
(model) to develop the prognostic equation of injury using the variables affecting the
incidence of injury like the HbCO levels, duration of exposure, myocardial and cerebral
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tissue PO2’s, metabolic rate, oxygen saturation, blood pH, arterial PCO2, blood lactate
levels and other subject specific variables (age, gender, Hb concentrations and health of the
patient) can be used. But limitations in availability of data currently make this approach
unfit to predict injury. Also in conditions of severe hypoxia, the model does not take in to
account the production of CO2 in the tissues or other metabolites from the anaerobic
metabolic pathway. The best my model can do is determine the time taken in various
tissues to reach the pre CO exposure (control) tissue PO2 values or the values above the
threshold PO2’s (PtO2 > PTHO2). As unconsciousness is reported in CO poisoned subjects at
a %HbCO levels ≥ 40 (Parkinson et al., 2002; Stewart, 1975), I will consider the PO2 in the
tissues at the end of a simulation of CO exposure of levels reaching 40% as PTHO2.
Cerebral blood flow: The blood flow to the brain has been reported to increase during CO

exposure (Benignus et al., 1992; Doblar et al., 1977; Koehler et al., 1984; Langston et al.,
1996; Paulson et al., 1973; Rucker et al., 2002; Santiago et al., 1986). The regression
equation developed in this study to predict percent changes in brain blood flow with
increasing %HbCO, was mostly from animal data. Data for humans were available only up
to HbCO levels less than 20%. During CO exposure, ParCO2 (arterial PCO2) is reported to
increase significantly (Doblar et al., 1977). These increases in ParCO2 will further
contribute to an increase in brain blood flow. The increases in brain blood flow reported in
the experiments were due to the cumulative effect of increased ParCO2 and %HbCO. Also
the aortic body sensitivity to CO is known to be greater in animals when compared to
humans (Lahiri et al., 1981). Thus, using the data from these experiments (Doblar et al.,
1977; Koehler et al., 1984; Langston et al., 1996; Santiago et al., 1986) to predict brain
blood flow resulted in an overestimation of the predicted values in the model (Figure 3.3).
In order to compensate the overestimations, an adjusting factor “ff” (Table 3.1) was
introduced. The value for this parameter “ff” was determined by (trail and error) simulating
various CO exposures and ensuring that the ventilation did not change more than 4% from
the pre CO exposure value (Chiodi et al., 1941; Santiago and Edelman, 1976). A value for
this parameter was chosen from 0-1, e.g., choosing a value of 0.5, decreased the percent
changes predicted in brain blood flow, QBHbCO as a function of %HbCO by 50% (Equation
3.18). For the chosen value, CO exposures of %HbCO levels of 10, 20, 30, 40, and 50 were
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simulated and the % change in ventilation at each %HbCO level from the pre CO exposure
value was calculated. The value of “ff” at which the ventilation did not change more than
4% from the pre CO exposure value for the range of %HbCO levels, was considered as the
value for ff (Table 3.1) in all my simulations.
Effects of HBO2 on shunt fraction (SF): Weaver et al., (2009) reported a decrease in SF

during HBO2 conditions in humans. In the simulations of experiments of weaver et al.
(2009), the values for SF reported in the experiment were used. In their experiments, the
value of SF dropped to zero during HBO2 exposure from a value of 0.15 at normobaric
oxygen. However, the authors report that this observed reduction may not reflect the actual
reduction in SF, due to the limitations in applying the calculations of SF to HBO2
conditions. There have been no other experiments measuring SF in humans and modeling
studies predict (Rasanen et al., 1987) a decrease in SF with increasing inspired O2 fraction.
Thus in this study, for all the HBO2 simulations a value of zero is assumed for SF.
Implementation of hypoxic ventilatory depression: Hypoxia produces an initial rapid

increase in ventilation which is not sustained and declines during the first 30 mins of
hypoxic exposure (Bascom et al, 1992). This biphasic response is referred to as hypoxic
venitilatory depression (HVD). The rapid increase in ventilation is reported to be produced
due to stimulation of peripheral chemoreceptors. The effects of hypoxia on the central
nervous system are reported to promote the decline in ventilation due to various
mechanisms like changes in K+ and Ca2+ channel dynamics, neuromodulators like
adenosine, GABA. In one of the version of the enhanced model, HVD was implemented to
modify the gain of peripheral ventilation component. The gain was modulated as a first
order differential equation of brain tissue PO2 (Zhou et al., 2001; Ursino et al., 2001).
Model predicted ventilatory responses during transient as well as steady state hypoxia were
in agreement with the experimental data (Bascom et al., 1992). However when a CO
exposure resulting in 20% HbCO was simulated, model predicted ventilation decreased
which was not in agreement with the experimental data (Chiodi et al., 1941; Kizakevich et
al., 2000). Thus, to simulate CO hypoxia with appropriate changes in ventilation, HVD was
not implemented in the current version of the enhanced model. The current version of the
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model (without HVD mechanism) is able to predict changes in ventilation which are in
agreement with experimental data of steady state hypoxic hypoxia and CO hypoxia.
Peripheral chemoreceptors are reported to play an insignificant role during CO hypoxia,
atleast for %HbCO <50 (Doblar et al., 1977). Also, changes in ventilation are reported to
correlate with lactate acidosis in brain which occurs at %HbCO levels > 50 (Santiago and
Edleman, 1976). Thus for simulations of CO exposures resulting in %HbCO < 50, inability
to successfully implement HVD will not influence the simulation results. The model lacks
implementation of effects of H+ on ventilation and lactate dynamics. In future,
implementation of these mechanisms in addition to HVD may allow modeling appropriate
changes in ventilation during CO hypoxia. Also, it may be necessary to develop models
which implement HVD to modulate the central and peripheral chemoreceptors gains.

CONCLUSIONS

Overall, the enhanced and validated multicompartment mathematical model can be
applied as a tool to accomplish the third specific aim of “comparing the current treatment
strategies available to treat CO poisoned victims and determine the best treatment strategy
ensuring fastest CO removal and O2 delivery after CO poisoning”. Also, a significant
contribution to the database of mathematical models is made by developing this validated
mathematical model to estimate O2, CO and CO2 levels in various tissues and blood vessels
(brain, heart, skeletal muscle and nonmuscle tissue, arteries, veins, capillaries) for a variety
of exposure conditions like hypoxia, CO hypoxia, hypercapnia, hypocapnia, hyperoxia,
isoapnic hyperoxia, and hyperbaric oxygen.
SUMMARY

Mathematical models of human systems are excellent tools to understand and analyze
physiological mechanisms, especially in situations where experiments either provide
limited information about the physiological process or are unethical. To compare the
current treatment strategies available to treat CO poisoned victims, a previously
developed model (Erupaka et al., 2010) in our lab was enhanced and validated for various
situations. Significant enhancements to the previously published model are addition of a
two subcompartment brain tissue, mass balance equations for CO2, control of ventilation,
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and regulation of blood flow. The enhanced model was validated for various conditions
of changing O2 or CO2 concentrations like hypoxia, hyperoxia, hyperbaric oxygen,
hypercapnia and hypocapnia. The capability of the model to predict brain tissue and
venous PO2’s, ventilation, tissue and blood PCO2’s, tissue and blood pH in various
compartments was assessed and compared with experimental data. Considering the
limited availability and variability of experimental data for the various variables
validated, the model predictions closely represented the trends in the experimental data.
Overall, the enhanced and validated mathematical model can be applied as a tool to
accomplish the third specific aim of “comparing the current treatment strategies available
to treat CO poisoned victims and determine the best treatment strategy ensuring fastest
CO removal and O2 delivery after CO poisoning”.
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Table 3.1: Parameters and their default values
Parameter

Description and references

Value, Units, Reference

Dbvb_on

Ratio of Dbb3O2 (t) and Dbb1O2 (t) +

0.075, none

Dxb

Mean intercapillary distance in brain tissue

0.1, cm, (Bruce et al., 2008)

Fac

Ratio of DiCO2 and DiO2

18, unitless, (Zhou et al.,2007)

ff

Brain blood flow adjustment factor during CO

0.369, unitless

+

exposure
Fvb

Brain tissue volume distribution fraction+

0.2, none

KbO2

PO2 at which MRbO2 decreases by 50%

0.5, Torr, (Erupaka et al.,2010)

kc

Central circulatory delay constant

0.9239, L, (Ursino et al., 2001)

kp

Peripheral circulatory delay constant

0.588,L, (Ursino et al., 2001)

MRbO2/gram

O2 consumption of brain

0.0365*, ml min-1 gm-1(Mintun et
al.,2001 ; Zhou et al., 2007)

PSbav_restO2

Permeability

surface

area

product

of

O2

for

69, ml min-1 Torr-1 gm-1

product

of

O2

for

127, ml min-1 Torr-1 gm-1

arterioles/venules+ in brain
PSbcap_restO2

Permeability

surface

area

capillaries+in brain
0.55, ml min-1 gm-1 (Mintun et

Blood flow of brain tissue

Q b/gram

al.,2001)
RQB

Respiratory quotient for brain tissue

1, unitless, (Zhou et al.,2007)

RQCM

Respiratory quotient for cardiac msucle tissue

0.8, unitless, (Zhou et al.,2007)

RQM

Respiratory quotient for skeletal muscle tissue

0.75, unitless, (Zhou et al.,2007)

RQ

Respiratory quotient for whole body

0.85, unitless, (Zhou et al.,2007)

SCO2

Solubility of CO2 in plasma

8.071x10-4, ml ml-1 Torr-1, (Ursino

B

et al., 2001)

τq

First order time constant for cardiac output

15, sec, (Wolf and Garner, 2007)

τb

First order time constant for brain blood flow

6, sec, (Wolf and Garner, 2007)

Vbt

Volume of brain tissue

Male:

1425g;

Female:1291g

(Steven et al., 2005, Text book)
Volfracb

Fraction of volume of brain tissue compartment

0.04, ml/gm, (Zhou et al.,2007)

attributed to blood

+ See text in section of the chapter entitled “Addition of brain compartment”
*

Values with ‘*’ are in STPD and all other values are in BTPS
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Table 3.2: Experimental data for brain tissue and blood oxygen tensions
Source

Species

PaO2+

PbvO2+

Demchenko et al., 2005

Rat

-

-

Demchenko et al., 2005

Rat

-

-

Demchenko et al., 2005

Rat

-

-

Demchenko et al., 2005

Rat

-

-

Jamieson and Vandenbrenk, 1963

Rat

-

-

Jamieson and Vandenbrenk, 1963

Rat

-

-

Jamieson and Vandenbrenk, 1963

Rat

-

-

Jamieson and Vandenbrenk, 1963

Rat

-

-

Jamieson and Vandenbrenk, 1963

Human
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Lambertsen et al., 1953

Human

Lambertsen et al., 1953

Human

Lambertsen et al., 1953

Human

Lambertsen et al., 1953

Human

Lambertsen et al., 1953

Human

Lambertsen et al., 1953

Human

Lambertsen et al., 1953

Human

Rolette et al., 2000

Rat

Rolette et al., 2000

Rat

Rolette et al., 2000

Rat

Zauner et al., 1995

Cat

Zauner et al., 1995

Cat

Martinez et al., 1999

Rabbit

Martinez et al., 1999

Rabbit

Martinez et al., 1999

Rabbit

Martinez et al., 1999

Rabbit

Charbel et al., 1997

Human

Entrei and Lund, 1986

Swine

Entrei and Lund, 1986

Swine

Entrei and Lund, 1986

Swine

Entrei and Lund, 1986

Swine

PbO2+

Condition*
0.21, 1ATA

25±4

0.3, 1ATA

34±5.5
190
287

1, 2ATA
1, 3ATA
0.21, 1ATA

34±4

1, 1ATA

90±13

1, 2ATA

244±39

1, 3ATA

38

452±68
-

0.21, 1ATA

-

40

-

1, 1ATA

2100

75

-

1, 3.5ATA

-

0.21, 1ATA

-

1, 3ATA

97

34.8±1.1

1740±33

66.4±5.3

97

36.9±1.1

97

41.1±1.3

97
145.1±11.7

-

56.5±4.4

-

40.7±2.3

-

160±22

-

36±4
95

30

27

112.5±9
189±38
378±50
540±29

-

21
-

48.2±2.3
-

-

-

0.21, 1ATA, 2.16% CO2

-

0.21, 1ATA,4.31% CO2

-

0.21, 1ATA, 5.48% CO2

0.3, 1ATA

15.1±1.8

0.15, 1ATA

8.8±0.4

0.10, 1ATA

6.8±0.3

0.3, 1ATA

42±9

0.15, 1ATA

28±5
30±13

0.21, 1ATA
0.12, 1ATA

11±3
8±3

0.10, 1ATA
0.08, 1ATA

6±3
33±11

-

0.21, 1ATA
27.4
64.37
90.6
105.4

0.21, 1ATA
0.35, 1ATA
0.7, 1ATA
1, 1ATA

PbvO2 = Brain venous PO2; PbO2 = Brain tissue PO2; + Torr
*(FIO2, PB); FIO2 = Fractional inspired O2, PB= Barometric pressure, 1ATA=760 Torr
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Table 3.3: Slopes for the VE-PACO2 curves from my model and experiments
Condition
Normoxia, PAO2=100 Torr

slope- model
2.873

Hypoxia, PAO2=50 Torr

4.018

Hyperoxia, PAO2=200 Torr

2.216
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slope range from experiments
2.25±0.19 – 2.90±0.19 (Poulin et
al.,1993)
1.88±0.82 (Honda et al., 1983)
2.4±0.94 (Fatemian and Robbins,
1998)
3.25±0.38 – 4.76±0.37 (Poulin et al.,
1993)
3.59±1.57 (Fatemian and Robbins,
1998)
2.39±0.25 – 2.61±0.31 (Poulin et
al.,1993)
2.14±0.22 (Ren et al., 2000)

Pi CO
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·

VA

V·A

Pi O2 2
PiO
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Q·
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MIXED VENOUS

Pb2o2
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·

PbvO2, PbvCO2

Q VBT
bb Vbb3

bb2

Vb2

B2

Pb1o2

B1

Vb1

3

Vab
Vbb1

Q·B bb1

BRAIN TISSUE

Q·VOT

NON MUSCLE
TISSUE

Vot

Q·OT
Vbot
Q·M

Q·VM
SKELETAL MUSCLE
M2

Vm2

Vbm

M1

Vm1
Q·C

Q·VC
CARDIAC MUSCLE
C2

C1

Vc2

Vc1

Figure 3.1: Architecture of enhanced model.

Vbc

The model consists of seven major

compartments: lungs, arterial blood compartment, mixed venous blood compartment, brain
tissue with two subcompartments, non-muscle tissue, skeletal muscle tissue with two
subcompartments and cardiac tissue with two subcompartments. The brain compartment is
divided into two extravascular subcompartments of volumes (Vb1, Vb2) and three vascular
subcompartments of volumes (Vbb1, Vbb2, Vbb3). Arterial blood enters the vascular
subcompartment bb1 as QB . Solid double arrows indicate blood-tissue gaseous fluxes driven
by partial pressure gradients. Dotted double arrows indicate diffusive gaseous fluxes driven
by concentration gradients of dissolved gases.
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Figure 3.2: Prediction of changes in cardiac output (ordinate) with increasing %HbCO
levels (abcissa). Dashed line represents the linear fit to the experimental data (•) from
Chiodi et al.(1941).
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Figure 3.3: Prediction of changes in brain blood flow (ordinate) with increasing %HbCO
levels (abcissa). Dashed line represents the piece wise linear fit to the experimental data
(•). See text “Addition of regulation of blood flow” for references.
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Figure 3.4: Validation of brain tissue and blood gas (O2, CO2) tensions. Abscissa:
Experimental gas tensions (Table 3.2, References in text “validation of tissue and blood
PCO2). Ordinate: Model predicted gas tensions. The dashed lines are identity lines (IL).
(A) Brain tissue PO2, PbO2 (B) Brain venous PO2, PbvO2 (B) Brain tissue PCO2, PbCO2,
(B) Brain venous PCO2, PbvCO2. Symbols: ‘o’- Hypoxia, ‘•’-Normoxia, ‘x’- Hyperoxia,
‘*’-Hyperbaric Oxygen, ‘◊’- Hypocapnia, ‘∆’-Hypercapnia.
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Figure 3.5: Comparison of model predicted values with experimental data: (i) arterial blood
gas measurements on y-axis of upper panel (A) ParO2 (B) ParCO2 (C) pHar , (ii) mixed
venous blood gas measurements on y-axis of lower panel (D) PmxO2 (E) PmxCO2 (F) pHmx
during different atmospheric pressures on x-axis. Different pressures are: 0.85 ATA air,
0.85 ATA O2, 1.2 ATA O2, 2.0 ATA O2, 2 .5 ATA O2, and 3 ATA O2. Model estimates
are represented with symbols ‘o’ and experimental data with symbols ‘•’. The error bars are
the SD for experimental data (Weaver et al., 2009).
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Figure 3.6: Comparison of: (A) model predicted arterial O2 saturations (SarO2) with
experimentally measured data at various levels of hypoxia (B) model predicted change in
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hypoxia. Model predictions represented by ‘o’ and experiment measurements as ‘•’. The
error bars are the SD for experimental data (Bascom et al., 1992) and PETO2 is the end
tidal PO2.
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(Roughton and Darling, 1943, Weaver et al., 2009; Whalen et al., 1965) and animal
studies (Doblar, 1977; Zhu and Weiss, 1995).
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Chapter 4: Computational analyses of treatments after carbon monoxide (CO)
poisoning in human

Contents of this chapter will be submitted as a manuscript
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INTRODUCTION

Carbon Monoxide (CO) is an odorless, colorless, tasteless gas which is
responsible for a large number of accidental and intentional poisonings reported
throughout the world. CO is generated in toxic amounts by internal-combustion engines,
faulty fossil-fuel heating systems, house fires or explosions in coal mines, and emissions
from modern automobiles or gasoline powered equipment in poorly ventilated spaces.
Exposure to CO concentrations exceeding permissible exposure levels (PEL) of an
average of 50 ppm over 8 hr (EHC, 1979; Raub et al., 1999) is a significant
environmental and occupational health concern. Despite improved efforts in awareness
and prevention, CO poisoning is a severely and frequently overlooked international
problem (Raub et al., 1999). There are approximately 4000 deaths per year, over 40,000
emergency department visits and tens of thousands of people seeking medical attention as
they loose several days to months of normal activity from CO exposure occurring in
United States (Raub et al., 2000; Tucker and Eichold, 2005; Weaver, 1999).
CO produces tissue toxicity by impairing oxygen (O2) delivery to the

tissues. CO is absorbed by the respiratory tract and diffuses through the alveolar-capillary
membrane and enters the blood, following a path similar to that of O2. CO poisoning
causes tissue hypoxia as the binding of CO to the heme (Hb, Mb, CCO) pigments
decreases the blood O2 carrying capacity, reduces O2 availability to tissues, and inhibits
mitochondrial respiration (Piantadosi, 2004). Although CO poisoning does not cause a
fever, other symptoms are similar to those of the flu (including nausea, severe headache,
vomiting). At higher HbCO levels (>10%), the neurological sequelae range from mild
symptoms such as headache, nausea, dizziness, and impaired manual dexterity to severe
symptoms such as confusion, loss of consciousness, and brain damage due to cell death
(Choi, 1983; Ernst and Zibrak,1998; Weaver, 1999; Weaver, 2009). Loss of
consciousness is reported at %HbCO levels >40 (Parkinson et al., 2002; Stewart et al.,
1975). Also, myocardial injury (ECG abnormalities, elevated cardiac injury biomarkers,
myocardial infarction, myocardial dysfunction) and cardiac arrest have been reported in
patients with mild to severe CO poisoning (Anderson et al., 1967; Cosby and Bergeron,
1963; Ernst and Zibrak, 1998; Gandini et al., 2001; Henry et al., 2006; Kalay et al., 2007;
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Middleton et al., 1961;Satran et al,2005; Stewart et al., 1973; Weaver, 2009; Yanir et al.,
2002).
Treatment for CO poisoned victims involves removing the patient from the site of
CO exposure and then administering supplemental O2. O2 hastens the dissociation of CO

from heme proteins (Hb, Mb), thereby improving tissue oxygenation and enhancing
elimination of CO. Choice of the treatment protocol is generally based on the measured
HbCO levels in the venous blood and the state of consciousness of the poisoned victim.

The treatment is with either normobaric hyperoxia (NBO2), where 100% O2 is
administered if the victim is conscious and the HbCO levels in the blood are less than
25%, or hyperbaric hyperoxia (HBO2) where 100% O2 is administered, at high pressures
greater than 1.5 ATA but less that 3.5 ATA (1 atmosphere = 760 mm of Hg), if the victim
is unconscious or the HbCO levels exceed 25%. The half time elimination of CO on
breathing room air, NBO2 and HBO2 at 3 ATA are ~ 320 min, 80 min and 23min,
respectively (Myers et al., 1985). Thus, the choice of the treatment protocol is generally
based on the measured HbCO levels in the venous blood, the state of consciousness of the
poisoned victim and availability of equipment for treatment (hyperbaric chamber). Blood
%HbCO is readily measurable but is thought to be an unreliable measure of poisoning

severity as the symptoms and signs of intoxication correlate poorly with the level of
HbCO measured at the time of hospital arrival. NBO2 therapy is usually continued until

the HbCO levels return to the near normal levels but CO may still be present in the
tissues in the form of MbCO or bound to other heme structures in the cells. Specialized
equipment for administration of HBO2 is not available at all hospitals. Also, treating a
CO poisoned victim with HBO2 is more expensive than treating them with NBO2 and

standardized HBO2 treatment protocols (optimal pressure, duration of treatment, and
required number of sessions) for CO poisoning are currently unavailable and often
debatable (Piantadosi, 2004; Raub et al., 2000; Weaver et al., 2002). However,
mechanisms like improvement of mitochondrial oxidative metabolism and inhibition of
lipid peroxidation are reported to be associated with HBO2 and not seen with NBO2
(Brown and Piantidosi, 1992; Piantadosi, 2004; Thom, 1990)
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Precise set conditions requiring treatment with either NBO2 or HBO2 do not exist,
often leading to disagreement with choice of treatment (Juurlink et al., 2005; Piantadosi,
2004; Raub et al., 2000). Many randomized clinical trials have been conducted to
compare the merits and disadvantages of NBO2 and HBO2 in CO poisoned victims
(Begany, 2001; Ducasse et al., 1995; Gorman, 1999; Isbister et al., 2003; Mathieu et al.,
1996; Raphael et al., 1989; Scheinkestel et al., 1999; Scheinkeste et al., 2004; Thom et
al., 1995; Weaver et al., 2002). Comparison of the treatment outcomes of NBO2 and
HBO2 suggested that the trial results neither confirm nor deny the benefit of HBO2 over
NBO2 (Juurlink et al., 2005; Piantadosi, 2004; Weaver et al., 2002). However, the clinical
trials conducted varied in patient populations, durations and pressures in HBO2 treatment
protocols, durations of treatment with NBO2, severity of poisoning and degree of follow
up (Juurlink et al., 2005). Also, the potential scope of new treatments like normocapnic
NBO2 hyperventilation or normocapnic HBO2 hyperventilation have not been tested in
CO poisoning therapy management. Hyperoxia is reported to increase ventilation and

decrease arterial PCO2 (Nishimura et al., 2007). Decreases in arterial PCO2 is
accompanied by decreases in brain blood flow (Topor et al., 2004), which results in
decreased O2 delivery to the brain tissue during treatment with NBO2 or HBO2 (Figure
4.1). Maintaining isocapnia during NBO2 will eliminate the effects of hypocapnia
induced decreases in brain blood flow (Figure 4.1), thereby increasing oxygen delivery to
the brain. Fisher et al. (1999) and others (Ishida et al., 2007; 1999; Kreck et al., 2001;
Rucker et al., 2002; Takeuchi et al., 2000) have reported (in dogs as well as humans) that
treatment with normocapnic NBO2 increases the rate of CO elimination and improves O2
delivery in CO-poisoned victims. For ethical reasons, the authors had limited HbCO
levels in their subjects (Rucker et al., 2002) to 12% and whether normocapnic NBO2
would be effective in patients with very high levels of HbCO is still unknown.
These ambiguities and variations in the clinical trials or treatment procedures give
rise to many unresolved issues in treatment of CO poisoning (Juurlink et al., 2005;
Piantadosi, 2004). Some of these unresolved issues are to (i) understand the advantages
of NBO2 and HBO2 for a population varying in health status (normal, anemic, coronary
artery disease, etc.), fitness level (athletes, recreationally active, sendentary), severity of
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poisoning (short vs. long or low %HbCO vs. high %HbCO) and intersubject variability
(age, gender, blood volume, etc.) and (ii) suggest standardized treatment regimens for
NBO2 and HBO2 (duration of treatment, number of treatment sessions, optimal pressures,
cost-benefit assessment). The main goal of my study is to compare NBO2, HBO2 and
normocapnic NBO2 to determine the best treatment strategy ensuring fastest CO removal
and O2 delivery after CO poisoning in healthy subjects. To achieve this goal, I will use
the validated mathematical model described in chapter 3. The mathematical model has
many advantages over performing clinical trials, as the model can be used to specify the
treatment regimens, poisoning severity, and health status of the population, thereby
allowing fair comparison among the available therapies to treat otherwise-healthy CO
poisoned victims. As conducting experiments involving high CO exposures is unethical,
the model can be used to simulate and compare the treatments at high %HbCO levels. In
addition to comparing the treatments, various issues (Table 4.1) pertaining to treatments
of otherwise-healthy CO poisoned victims will be addressed in this study.

METHODS

The validated mathematical model used in this study has been described in detail
in chapter 3. This validated model was capable of predicting brain tissue and venous
PO2’s, ventilation, tissue and blood PCO2’s, tissue and blood pH in various compartments
for changing CO, O2 or CO2 concentrations like CO hypoxia, hypoxic hypoxia,
hyperoxia, hyperbaric oxygen, hypercapnia and hypocapnia. The ability of the validated
model to estimate O2, CO and CO2 levels in various tissues and blood vessels (brain,
heart, skeletal muscle and nonmuscle tissue, arteries, veins, capillaries) during CO
exposures and treatments makes it a desirable tool to accomplish the goal of this study.
The mathematical model was used to simulate short (20 min) and long (480 min) CO
exposures in healthy human subjects. At the end of CO exposure, NBO2, HBO2 or
normocapnic NBO2 treatments were simulated. The time varying tissue PO2’s in the
brain, heart and muscle compartments and CO levels in the blood, tissues and body were
analyzed during CO exposures and treatments.
Model description
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The mathematical model used in this study is a significant enhancement of the
previous models developed in our lab (Bruce et al., 2008; Erupaka et al., 2010). This
model consists of a (i) lung compartment (A), (ii) arterial blood compartment (ar), (iii)
two subcompartment brain tissue (b1,b2) with three vascular subcompartments
(bb1,bb2,bb3), (iv) two subcompartment heart tissue (c1,c2) with three vascular
subcompartments (bc1,bc2,bc3), (v) two subcompartment skeletal muscle tissue (m1,m2)
with three vascular compartments (bm1,bm2,bm3), (vi) single nonmuscle tissue
compartment (ot) perfused by single vascular compartment (bot) and (vii) a mixed
venous blood compartment (mx). The three vascular subcompartments surrounding the
tissue compartments represent the arteriole, capillary and venule blood surrounding the
tissue (Bruce et al., 2008; Erupaka et al., 2010). The first tissue subcompartment is
envisioned as tissue perfused extensively by small arterioles and venules in first and the
third vascular subcompartments. The second tissue subcompartment is assumed to be
perfused mostly by capillaries in the second vascular subcompartment. As most of the gas
exchange and energy production takes place in the tissues surrounded by capillaries, the
model estimated O2 levels in the second tissue subcompartments of brain, heart and
skeletal muscle tissue were analyzed in all the simulations. The model predicted tissue
PO2’s in the second tissue subcompartments of brain (Pbt2O2), heart (Pct2O2) and skeletal
muscle (Pmt2O2) were assumed as a correlate of tissue oxygenation and were used to
determine the state of O2 delivery in the tissues during CO exposures and treatments. The
CO levels in the blood (COblood), tissues (COtissue) and body (CObody) during CO exposure

and treatments were calculated from the model using the Equations 4.1-4.3.
COblood = Car COiVar +Cbb COiVbb +Cbc COiVbc + Cbm COiVbm +Cbot COiVbot +Cmx COiVmx .......4.1
COtissue = Cbt COiVbt +Cct COiVct + Cmt COiVmt +Cot COiVot ........................................................4.2
CObody = COblood +COtissue + C ACOiVL .......................................................................................4.3
where, CiCO and Vi are the concentrations of CO and volumes of compartment ‘i’.
Simulation Description

ACSL 11.8 was used to simulate various CO exposures and treatments.
Simulations were performed in double precision and a 30 minute stabilization period was
initiated with every simulation run for the baseline simulation to reach a steady state. The
values for various variables at the end of steady state were considered as the pre-CO
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exposure or control values. The %HbCO levels, Pbt2O2, Pct2O2, Pmt2O2, COblood, COtissue,
CObody, cardiac output ( Q ), and alveolar ventilation ( VA ) were saved for the entire
duration of the simulations to allow analysis of the data. Unconsciousness is reported to
occur in CO poisoned subjects at a %HbCO levels ≥ 40 (Parkinson et al., 2002; Stewart,
1975). Thus to determine the tissue oxygen threshold at which unconsciousness may
possibly occur, a 20 min CO exposure of 6400 ppm of CO resulting in 40% HbCO was
simulated and the PO2’s in the second tissue subcompartments of brain, heart and skeletal
muscle at the end of the exposure were considered as the oxygen thresholds (PTHO2) for
unconsciousness and other functional impairments to occur. Simulations in this study
were designed to test two specific hypotheses. Analysis of the simulation results from
testing these two hypotheses will allow comparison of different treatments and also aid in
understanding of the unresolved issues related to CO poisoning therapies stated in Table
4.1.
Hypothesis 1: I hypothesize that “treating otherwise-healthy CO poisoned victims with
HBO2 after a 6 hr treatment of NBO2 will not have any benefits in improving O2 delivery
and CO removal.” Testing this hypothesis will allow me to compare the merits of NBO2
and HBO2 after CO poisoning occurs. Treatment duration of 6 hr is often considered as
the window of opportunity in the clinical trials for comparing NBO2 and HBO2 (Weaver
et al., 2002). This treatment window of 6 hr interval was suggested by Goulon et al.
(1969) as the opportunity window for maximum benefit from HBO2 therapy. If my
hypothesis is true, then I will determine the maximum duration of NBO2 after which
administered HBO2 therapy may still have a favorable effect in improving O2 delivery to
the tissues and speeding removal of CO from blood and tissues.
Hypothesis 2: I hypothesize that “irrespective of the poisoning severity treating an
otherwise-healthy CO poisoned victim with isocapnic (normocapnic) NBO2 will always
have a favorable effect in improving O2 delivery and enhancing CO removal, when
compared to treating the victim with poikilocapnic NBO2”
Data set used for simulations of CO exposures and treatment protocols
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Benignus et al. (1994) exposed fifteen healthy, male human subjects to high
concentrations of CO for short durations. This data set was used to simulate CO
exposures and three different treatments namely, poikilocapnic NBO2, poikilocapnic
HBO2 and normocapnic NBO2. In this experiment (Benignus et al., 1994), measurements
of age, body weight, height, blood volume, hemoglobin concentration, cardiac output,
initial %HbCO and lung diffusivity coefficient of CO were provided by the investigators
for each subject (Table 4.2). Alveolar ventilation was estimated by the model. Total body
oxygen consumption was calculated as 3.2 ml/Kg. DMCO was varied in proportion to
muscle mass, with a value of DMCO of 0.225 ml/min/Torr/Kg of muscle mass. Values for
all other parameters that were not provided by the investigators have been referenced in
my previous publication (Erupaka et al., 2010). From this data set of 15 subjects, only 6
subjects (S108, S112, S115, S118, S119 and S120) were simulated in this study (Table 1
of Benignus et al., 1994; Table 4.2 of this chapter). Subject 115 (S115) was the subject
with subject specific parameters close to the mean values of the data set. S108 had the
highest cardiac output and S118 had the lowest muscle mass, cardiac output and blood
volume. S112 had the highest muscle mass and S119 had the largest blood volume. S120
was randomly chosen from the data set. Intersubject variability in cardiac output, muscle
mass, blood volume are known to influence the uptake and removal of CO. These
subjects were chosen to test my hypotheses in a range of subjects.
Simulated CO exposures and treatment protocols

To test my hypotheses the validated mathematical model was used to simulate the
following CO exposures and treatments. Simulation sets 1 and 2 were performed to
determine if HBO2 had any merits in removing CO from the body and improving O2
delivery after a NBO2 treatment for 6 hr, irrespective of the duration of CO exposure,
intersubject variability and %HbCO level at the end of exposure. Simulation set 3 was
performed to determine the maximum duration of NBO2 after which administered HBO2
therapy may still have a favorable effect in improving O2 delivery to the tissues and
speeding removal of CO from blood and tissues, irrespective of %HbCO level at the end
of exposure. Simulation set 4 was performed to determine the best treatment strategy
(among the available therapies) to treat otherwise-healthy CO poisoned victims to ensure
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faster CO removal and O2 delivery, irrespective of %HbCO level at the end of exposure.
Among the six subjects simulated, three subjects (S108, S112, S120) had HbCO levels of
~42% during the first CO exposure level (6400 ppm). Simulating the second CO
exposure level of 8000 ppm in these subjects (S108, S112, S120) resulted in HbCO levels
greater than 50%. As the confidence in model’s predictions for HbCO levels greater than
50% is low (See discussion), subjects S115, S118 and S119 were chosen to simulate
different treatments after CO poisoning of varying HbCO levels. Short CO exposures of
(i) 6400, (ii) 8000 ppm and (iii) 10000 ppm of CO for a duration of 20 min were
simulated and the end of CO exposure was followed by different treatment regimens.
Simulation set 1-Short CO exposure followed by NBO2 treatment: Six healthy subjects
(S108, S112, S115, S118, S119 and S120) were exposed to a concentration of 6400 ppm
of CO for a duration of 20 min. The end of CO exposure was followed by a treatment on
100% O2 at 1 ATA (760 Torr) for 360 min (6 hr). In addition, three subjects (S115, S118,
and S119) were also exposed to a concentration of (i) 8000 ppm and (ii) 10000 ppm of
CO for a duration of 20 min and the end of CO exposure was followed by a treatment on

100% O2 at 1 ATA for 360 min. Treatment on NBO2 for 6 hr will be referred as 6 hrNBO2
in the text.
Simulation set 2-Long CO exposure followed by NBO2 treatment: Six healthy subjects
(S108, S112, S115, S118, S119 and S120) were exposed to a concentration of 450 ppm
of CO for a duration of 480 min. The end of CO exposure was followed by a treatment on
100% O2 at 1ATA for 360 min (6 hr).
Simulation set 3-Short CO exposures followed by HBO2 treatment: Three subjects
subjects (S115, S118, and S119) were exposed to a concentration of 6400 ppm of CO for
a duration of 20 min and the end of CO exposure was followed by a treatment on (i)
100% O2 at 1ATA for 120 min (2 hr) followed by 100% O2 at 3 ATA (HBO2) for 90 min
(referred as

2 hr

NBO2-1.5 hrHBO2), (ii) 100% O2 at 1ATA for 180 min (3 hr) followed by

100% O2 at 3 ATA for 90 min (referred as 3 hrNBO2-1.5 hrHBO2) or (iii) 100% O2 at 1ATA
for 240 min (4 hr) followed by 100% O2 at 3 ATA for 90 min (referred as

120

4 hr

NBO2-1.5

hr

HBO2). Also these three subjects were exposed to a concentration of (i) 8000 ppm and

(ii) 10000 ppm of CO for a duration of 20 min and the end of CO exposure was followed
by treatment regimens described above in simulation set 3.
Simulation set 4-Short CO exposures followed by normocapnic NBO2 treatment: Three
subjects subjects (S115, S118, S119) were exposed to a concentration of 6400 ppm of CO
for a duration of 20 min and the end of CO exposure was followed by a treatment on
100% O2 at 1ATA for 360 min, while maintaining isocapnia at the normocapnic level of
the subject (referred as

6 hr

INBO2). For these simulations the alveolar PCO2 was

maintained constant for the duration of treatment at the pre-CO exposure levels
(normoxia, room air). In addition, these three subjects were also exposed to a
concentration of (i) 8000 ppm and (ii) 10000 ppm of CO for a duration of 20 min and the
end of CO exposure was followed by a 6 hr, normocapnic NBO2 treatment.
Data analysis

For each simulation set, the %HbCO levels, COblood, COtissue, CObody, tissue PO2’s
in brain (Pbt2O2), heart (Pct2O2) and muscle tissue (Pmt2O2), cardiac output ( Q ), and
alveolar ventilation ( VA ) were analyzed. All the variables used for analyzing the
simulations to determine the best treatment are defined in Table 4.3.
To determine the state of oxygenation in the tissues during CO exposure and
various treatments the following calculations were made: (i) during a CO exposure, the
duration for which the tissue PO2’s are below the threshold PO2 (PTHO2) for
unconsciousness and other functional impairments to occur (referred as t<PTHO2), (ii)
during a treatment, time taken for the tissue PO2’s in brain, heart and muscle to reach a
value above PTHO2 (referred as tbPTHO2, tcPTHO2, tmPTHO2, respectively), and (ii) during a
treatment, time taken for the tissue PO2’s in brain, heart and muscle to reach a value
above or equal to the pre-CO exposure tissue PO2, PrO2 (referred as tbPrO2, tcPrO2, tmPrO2
respectively). The time taken to reach PrO2’s is computed to determine the suggested
duration of each administered treatment. Among the simulated therapies to treat
otherwise-healthy CO poisoned patients, the treatment strategy in which time taken to
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attain tissue PO2’s above PTHO2 is fastest, will be considered as a therapy ensuring faster
O2 delivery to the tissues. If the time taken to reach tissue PO2’s above PTHO2 is the same

for two or more treatments, then the treatment taking less time to remove CO from the
body will be considered to be the best treatment ensuring faster O2 delivery to the tissues
and CO removal.
To determine the rate of CO removal from the body during various treatments the
following calculations were made: (i) the time taken by a treatment to remove 50% of the
total CO body burden (CObody) at the time of exposure (CObody T1/2), and (ii) the time
taken by a treatment to reach %HbCO levels <10 (T%HbCO<10). A 10% HbCO level was
chosen as no adverse effects of CO have been reported at these levels. CObody T1/2 is
calculated to determine the treatment ensuring fastest CO removal from the body.
T%HbCO<10 is computed to determine the minimum duration of each administered
treatment. Also, the CO washout curves (CObody) were fit to exponential functions to
determine the time constants of these curves. The early (τe) and late (τl) time constants of
these CO washout curves after short and long CO exposures were determined to compare
the washout times during different treatments and CO exposures. To calculate the early
and late time constants of CO washout curves, these curves were fit to a exponential
function of the form Aebt+Dect using least squares method in Matlab, version 6.5. In the
exponential functions, 1/b (τe) and 1/c (τl) are the early and late time constants. A and D
are the magnitudes of the early (Ge) and the late (Gl) exponential decay functions. Early
and late time constants of CO washout curves were determined only for the treatments,
where the CO washout curves followed an exponential function.

RESULTS

The main goal of my study is to compare NBO2, HBO2 and normocapnic NBO2 to
determine the best treatment strategy ensuring fastest CO removal and O2 delivery after
CO poisoning in healthy subjects. The validated mathematical model was used to

perform simulation sets 1-4 to achieve this goal. Unconsciousness is reported to occur in
CO poisoned subjects at a %HbCO levels ≥ 40 (Parkinson et al., 2002; Stewart, 1975).

Prior to analyzing the results of the simulation sets 1-4, a CO exposure resulting in
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HbCO’s ≥ 40% was simulated. Thus to determine the tissue oxygen threshold at which
unconsciousness may possibly occur, a 20 min CO exposure of 6400 ppm of CO
resulting in ≥40% HbCO was simulated in six Benignus’s subjects (S108, S112, S115,
S118, S119 and S120). The PO2’s in the second tissue subcompartments of brain, heart
and skeletal muscle at 40% HbCO levels were assumed as the tissue oxygen threshold
(PTHO2) at which unconsciousness and functional impairments may possibly occur. From
the results of these simulations in six subjects, PTHO2 was determined as 15 Torr. A tissue
PO2 below PTHO2 in the brain tissue is assumed to cause unconsciousness and tissue PO2
below PTHO2 in the heart and skeletal muscle tissue is assumed to cause functional
impairments. Unconsciousness is reported at a cerebral venous PO2 of 16-20 Torr
(Purves, 1972). Thus, a value of 15 Torr for PTHO2 in the brain is a reasonable
assumption for unconsciousness to occur in a CO poisoned victim.
Results of simulation set 1: In this simulation set, 6 subjects were exposed to a
concentration of 6400 ppm of CO for a duration of 20 min followed by a treatment on
NBO2 for 6 hr (6 hrNBO2). For the same inspired CO concentrations, the %HbCO levels in
the subjects at the end of exposure ranged from 34%- 45% (Table 4.4). The durations for
which the PO2’s were below the threshold PO2 (PTHO2) were calculated for the brain
(tb<PTHO2), heart (tc<PTHO2) and muscle (tm<PTHO2) tissues. Also the time taken to reach
PO2’s above the threshold values and the pre-CO exposure tissue PO2’s (PrO2) were
calculated for the brain (tbPTHO2, tbPrO2), heart (tcPTHO2, tcPrO2) and muscle (tmPTHO2,
tmPrO2) tissues. In 3 (S108, S112, S120) of the 6 subjects tb<PTHO2 was ~3 min,
suggesting a possibility of occurrence of unconsciousness at the end of CO exposure in
these subjects. The mean±SD values for tc<PTHO2 and tm<PTHO2 in 5 of the 6 subjects
were 4.3±2.7 and 4.5±2.5 min, respectively. These values suggest that except in S119
(t<PTHO2=0, i.e., during CO exposure, PO2 in the brain was never below 15 Torr), there is
a possibility of occurrence of functional impairment in the heart and muscle tissues. The
mean±SD values for tbPTHO2, tcPTHO2, and tmPTHO2 are 1.2±0.5, 3.7±2.4, and 4±1.2 min,
respectively. Thus during treatment with

6 hr

NBO2, the PO2’s in all the vital tissues are

above PTHO2 in ~4 min for an otherwise-healthy CO poisoned subject with an average
%HbCO level of 40. It should be noted that at ~4 min, though the PO2’s in all the vital
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tissues are above PTHO2, the body burden of CO (CObody) is still greater than 50% (Table
4.5). Also, the PO2’s in the brain, heart and muscle tissues reach PrO2’s within 4.8±0.4,
4.2±0.3, and 2.8±0.1 hr respectively (Table 4.5). The %HbCO levels after 4.8 hr of
treatment on NBO2 immediately after end of CO exposure is ~4.5%. The CObody T1/2 and
T

%HbCO<10

values are 1.4±0.2 and 2.8±0.1 hr, respectively (Table 4.5). Also after short

CO exposures resulting in higher %HbCO values followed by a treatment on

6 hr

NBO2,

the PO2’s in the brain, heart and muscle tissues are above PTHO2 and PrO2 levels and the
%HbCO levels are less than 10 at the end of the treatment (Table 4.5). These results
(Table 4.5-4.6A-C) suggest that in healthy subjects poisoned by short CO exposures, the
O2 levels and CO levels in the body are restored to control or pre-CO exposure values

within 6 hr of treatment on NBO2.
Results of simulation set 2: In this simulation set, 6 subjects were exposed to a
concentration of 450 ppm of CO for duration of 480 min (8 hr) followed by

6 hr

NBO2

treatment. The mean %HbCO level at the end of exposure is ~42% (Table 4.4). In five of
the 6 subjects t<PTHO2 at the end of exposure was greater than 0 in all the tissues,
suggesting a possible occurrence of unconsciousness and functional tissue impairments in
these subjects. In one subject S 119, tb<PTHO2 at the end of exposure was equal to 0. In
the same subject, tc<PTHO2 and tm<PTHO2 at the end of exposure was greater than 0 ,
suggesting a possible occurrence of functional impairments in the tissues. The mean±SD
values for tb<PTHO2, tc<PTHO2 and tm<PTHO2 in these subjects were 84±38 min (5
subjects), 168±69 min (6 subjects) and 209±98 min (6 subjects), respectively. The
mean±SD values for tbPTHO2, tcPTHO2, and tmPTHO2 are 1.6±0.75, 10.5±9, and 4.7±1.4
min, respectively. When compared to short CO exposures, though the tissue PO2’s are
below PTHO2 for a longer duration in long CO exposures, during treatment with 6 hrNBO2,
the PO2’s in all the vital tissues are above PTHO2 in ~11 min for the otherwise-healthy CO
poisoned subjects with an average %HbCO level of 42. It should be noted that at ~11
min, though the PO2’s in all the vital tissues are above PTHO2, the body burden of CO
(CObody) is still greater than 50% (Table 4.5). Also, the PO2’s in the brain, heart and
muscle tissues reach PrO2’s within 5 ±0.3, 4.4±0.4, and 3±0.3 hr respectively (Table 4.5).
The %HbCO levels after 5 hr of treatment on NBO2 immediately after end of CO
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exposure is ~3.5%. The CObody T1/2 and T

%HbCO<10

values are 1.4±0.2 and 3.0±0.2 hr

respectively (Table 4.5). These results (Table 4.5) suggest that in a healthy subject
poisoned by long CO exposures, the O2 levels and CO levels in the body are restored to
control or pre-CO exposure values within 6 hr of treatment on NBO2.
Analysis of results from simulation sets 1 and 2, suggests that administering
HBO2 after

6 hr

NBO2 will have no additional benefits of improving O2 delivery and CO

removal in healthy subjects exposed to long or short durations of varying CO
concentrations. Thus, for HBO2 to have merit in treating a CO poisoned victim, this
treatment may have to be applied within

6 hr

NBO2. To determine the maximum duration

of NBO2 after which administered HBO2 therapy may still have a favorable effect in
improving O2 delivery to the tissues and speeding removal of CO from the body,
simulation set 3 was performed.
Results of simulation set 3: In this simulation set, three subjects were exposed to CO
levels of three different concentrations (6400, 8000, and 10000 ppm) for a duration of 20
min (See Table 4.6A-C for %HbCO levels). At the end of CO exposure, the subject was
treated with one of the three different treatment protocols: (i) 2 hr NBO2 followed by 1.5
hr HBO2 at 3 ATA (2 hrNBO2-1.5 hrHBO2), (ii) 3 hr NBO2 followed by 1.5 hr HBO2 at 3
ATA (3NBO2-1.5HBO2) or (iii) 4 hr NBO2 followed by 1.5 hr HBO2 at 3 ATA (4 hrNBO21.5hr

HBO2). The variables useful in assessing the state of O2 delivery in the tissues and CO

removal from the body during the treatments (6

hr

NBO2,

2 hr

NBO2-1.5

hr

HBO2, and

3hr

NBO2-1.5 hrHBO2) after different severities of CO poisoning are listed in Table 4.6A-C.

In all the simulations of set 3, the treatment for the initial two hours after end of CO
exposure was on NBO2 and hence the tbPTHO2, tcPTHO2, and tmPTHO2 were not calculated
for this simulation set (as they would be similar to that of

6 hr

NBO2 ). Thus in this

simulation set, the criterion for determining the best treatment is based on CObody T1/2 and
T

%HbCO<10

and T

(as values for tbPTHO2, tcPTHO2, and tmPTHO2 are the same). The CObody T1/2

%HbCO<10

values for treatment with

values with treatment on

4 hr

NBO2-1.5hrHBO2 were not different from the

6 hr

NBO2 (Table 4.6A-C). Also, the goodness of fit for the CO

washout curves (CObody) to fit the exponential functions (Aebt+Dect) was statistically
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poor. Thus, the early and late time constants were not calculated for this simulation set.
On analysis of the results from this simulation set, the maximum duration of NBO2 after
which administering HBO2 therapy may still have a favorable effect in improving O2
delivery to the tissues and speeding removal of CO from the body is suggested as 3 hr for
%HbCO levels <50. For CO poisonings resulting in %HbCO levels >50, the maximum
duration of NBO2 can be suggested as 3 hr. Thus for any severity of poisoning when
compared to

6hr

NBO2, treatments on

2hr

NBO2-1.5 hrHBO2 suggests faster removal of CO

from the tissues and the maximum duration of NBO2 after which administering HBO2
therapy may still have a favorable effect in speeding removal of CO from the body is
suggested as 3 hr.
Results of simulation set 4: This simulation set was performed to test my hypothesis that
“irrespective of the poisoning severity treating an otherwise-healthy CO poisoned victim
with isocapnic (normocapnic) NBO2 will always have a favorable effect in improving O2
delivery and enhancing CO removal, when compared to treating the victim with
poikilocapnic NBO2”. Three subjectswere exposed to three different concentrations of
CO levels (6400, 8000, and 10000 ppm) for a duration of 20 min and the end of CO

exposure was followed by a treatment with NBO2 for 6 hr while maintaining isocapnia at
the normocapnic level of the subject (6 hrINBO2). The durations for which the PO2’s in the
tissues are less than PTHO2 (tc<PTHO2) is greater for the higher %HbCO levels and the
values for tbPTHO2 are similar for all the treatments for any severity of poisoning (Table
4.6A-C). For %HbCO levels <50, the values for tcPTHO2 are smaller in 6 hrINBO2 than all
other treatments, suggesting faster O2 delivery to cardiac tissues during 6 hrINBO2. It is to
be noted that tbPrO2 in

2 hr

NBO2-1.5 hrHBO2 is always less than tbPrO2 in

indicating a smaller suggested treatment duration in

6 hr

INBO2,

2 hr

NBO2-1.5 hrHBO2. Simulation

results (Table 4.6A-C) suggests that for an otherwise-healthy CO poisoned subject with
any degree of poisoning severity, 6 hrINBO2 is the best treatment strategy to ensure faster
CO removal from the body when compared to treatments on
hr

HBO2 or

4 hr

6 hr

NBO2,

3 hr

NBO2-1.5

NBO2-1.5 hrHBO2. Thus, treating an otherwise-healthy CO poisoned victim

with 6hrINBO2 is the best treatment to be administered.
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Overall analysis of results from simulation sets 1-4 suggests that treating an
otherwise-healthy human subject with hyperbaric oxygen immediately after a treatment
on normobaric oxygen for 6 hr, may not have any benefits of improving oxygen delivery
to the tissues or removal of CO from the body. Also, normocapnic normobaric oxygen
(INBO2) treatment seems to be a promising therapy to allow fast removal of CO from the
body and thereby improve oxygen delivery to the tissues. In cases of high CO exposures
(%HbCO >50%), treating an otherwise-healthy subject with HBO2 (followed by <4 hr of
treatment on NBO2) or normocapnic NBO2 is suggested. In cases of CO exposures of
%HbCO <50, treating an otherwise-healthy subject with INBO2 is suggested.

DISCUSSION

In this study, a validated mathematical model was used to compare O2 delivery
and CO removal during three treatments namely NBO2, HBO2 and INBO2 administered
after varying severities of CO poisoning in healthy subjects. The time varying tissue
PO2’s in the second compartments of the brain, heart and skeletal muscle were assumed
as correlates of state of oxygenation during CO exposure and treatments. The time taken
by the treatment to remove 50% of the CO from the body and to reach %HbCO
levels<10% were the criterion to determine the efficacy of a treatment to remove CO
during the course of the treatment.
Treatment for short vs. long CO exposures: A 6 hr, NBO2 treatment was simulated

immediately after short or long CO exposures in 6 healthy subjects. The inhaled
concentrations of CO were intended to achieve similar %HbCO levels in a given subject
at the end of exposure irrespective of the duration of the exposure. In 3 (S108, S112,
S120) of the 6 subjects, similar %HbCO levels were reached at the end of short and long
CO exposures. At the end of short CO exposures, the model predicted that 3 of the 6

subjects may be unconscious and 5 of the 6 subjects may have mild functional
impairments. At the end of long CO exposures, 5 out of 6 subjects are predicted to be
unconscious and 6 subjects may have severe functional impairments (as the tissue PO2’s
< 15 Torr for a longer duration). Despite similar %HbCO levels compared to a long
duration CO exposure, less CO diffuses into the tissues and the increases in cardiac
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output and blood flow to other tissues is faster (due to rapidly increasing %HbCO) during
a short CO exposure (Bruce et al, 2008; Erupaka et al., 2010). Thus, the values for
tb<PTHO2, tc<PTHO2 and tr<PTHO2 were larger during long CO exposures compared to
short CO exposures.

During treatment on

6 hr

NBO2, time taken to reach tissue PO2’s

above PTHO2 were greater in a treatment followinglong CO exposure compared to the
short CO exposure (especially heart tissue). Prior to treatment, the tissue was hypoxic for
a longer duration in long CO exposure. During CO exposure, the model predicted PCO2’s
in the cardiac and muscle tissue compartments are increasing. Greater extent of
accumulation of metabolites like CO2 in the tissues and decreases in pH as a consequence
of prolonged tissue hypoxia may be a contributing factor for larger values of tPTHO2 in
long CO exposures. Irrespective of the duration of exposure, the times taken to reach
PrO2’s in the tissues were similar during treatment on 6 hr NBO2 for a short or a long CO
exposure. During treatment on 6 hr NBO2, removal of CO from the body followed by long
and short CO exposures was not different (Table 4.5). As the O2 delivery to tissues and
CO removal from the body was similar during treatment on 6hrNBO2 followed by short or

long CO exposure, other treatments (6 hrINBO2,

2 hr

NBO2-1.5 hrHBO2, etc), were not

simulated for a long CO exposure.
Suggested tissue specific treatments: In this study, oxygen delivery to the brain, heart and

muscle tissues during various treatments after varying levels of poisoning severity (Table
4.6A-C) were assessed. For an otherwise- healthy CO poisoned subject, irrespective of
the poisoning severity, the time to reach PTHO2 are similar in all treatments. However,
treatment on

2

hr

NBO2-1.5

hr

HBO2 has the advantage of availability of larger

concentrations of dissolved O2 when compared to treatments with 6 hrNBO2 or 6 hrINBO2.
The advantage of enhanced O2 delivery with treatment on 6 hrINBO2 over treatment with 6
NBO2 or other treatments (2

hr

hr

NBO2-1.5

hr

HBO2,

3 hr

NBO2-1.5

hr

HBO2,

4 hr

NBO2-1.5

hr

HBO2) are due to greater blood flows to the tissues and hyperventilation during

isocapnia (Figure 4.1).

Poikilocapnic hyperoxic treatments are accompanied with

decreases in blood flow due hypocapnia and hyperoxia induced vasoconstriction.
Maintaining isocapnia at the normoxic levels eliminates the effects of hypocapnia
induced decreases in blood flow, thereby improving O2 delivery to the tissues.
Considering the difficulty and cost of administering any HBO2 treatment (especially
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within 2 hr of NBO2),

6 hr

INBO2 seems to be the suggested treatment of choice. At the

end of treatment, when compared to

6 hr

NBO2, treatment with

4hr

NBO2-1.5 hrHBO2 seems

to improve O2 delivery to the brain tissues but not the heart or skeletal muscle tissues,
thereby suggesting advantages of using HBO2 to treat unconscious subjects or subjects
showing symptoms of neurological impairments on admission (Table 4.6A-C). For the
same level of CO poisoning severity administering 6 hrINBO2 allows faster O2 delivery to
the heart and muscle tissues when compared to treatment with
hr

HBO2, or

6 hr

NBO2

3hr

NBO2-1.5

4 hr

NBO2-1.5 hrHBO2 (Table 4.6A-C). This could be due to faster removal of

CO2 and CO from the tissues containing myoglobin due to increased blood flows and

increased ventilation in isocapnia compared to poikilocapnia. Thus, subjects showing
cardiovascular abnormalities on admission should be treated with

6 hr

INBO2 to ensure

faster O2 delivery to the heart tissues.
Suggested treatments for fast CO removal: The goal of any treatment administered after
CO poisoning is to improve tissue oxygenation and enhance elimination of CO. Except

for treatment on room air, administering NBO2, INBO2 or HBO2 rapidly increases the
tissue PO2’s during treatment. Irrespective of the duration and severity of poisoning, the
maximum time taken by the tissues to reach PO2’s above PTHO2 is ~30 min (Table 4.5,
4.6A-C). But the half time elimination of CO on breathing room air, NBO2 and HBO2 at
3 ATA are ~ 320 min, 80 min and 23 min, respectively (Myers et al., 1985). Considering
the difficulty of administering HBO2 immediately after CO poisoning, emphasis of
determining an efficient treatment should be based on its capability to quickly remove
CO. In this study among the treatments compared (Table 4.5, 4.6A-C) for any level of

poisoning severity in a healthy subject, the treatment with the fastest CObody T1/2 and T
%HbCO<10

was found to be for

6 hr

INBO2. A %HbCO of 10 was chosen as the adverse

effects of exposure at these levels are reported to be minimal in humans (Rucker et al.,
2002; Stewart, 1975). This treatment allows faster elimination of CO due to
hyperventilation and increases in blood flow, when compared to other treatments
analyzed in this study.
Suggested treatments for otherwise healthy CO poisoned subjects: Analysis of simulation

sets 1-4, suggests that INBO2 is the best treatment available to ensure fast O2 delivery and
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removal of CO from the body. For high %HbCO levels, my study confirms the findings
of Fisher et al. (1999) and Rucker et al. (2002) for otherwise-healthy CO poisoned male
subjects. Treatment with

2 hr

NBO2-1.5hrHBO2 also improves O2 delivery and enhances

removal of CO from the body. But the superiority of INBO2 is established over HBO2
considering the limited availability of hyperbaric chambers in hospitals, cost of
administering HBO2, complications like barotrauma, claustrophobia arising from
hyperbaric treatment (Juurlink et al., 2005) and faster removal of CO in INBO2 when
compared to HBO2. It may also be hypothesized that maintaining isocapnia at levels 2-3
Torr greater than normocapnia (i.e., hypercapnic NBO2) will prove to be more beneficial
in ensuring fast O2 delivery and removal of CO from the body as the increase in blood
flow and ventilation will be greater in hypercapnic NBO2 when compared to
normocapnic NBO2. I also hypothesize that hypercapnic HBO2 or normocapnic HBO2
will be highly beneficial in CO poisoning cases with high %HbCO levels as it would
have the advantage of availability of high concentrations of dissolved O2 in addition to
increases in blood flow and ventilation. However, in CO poisoned patients with
depressed ventilation or cardiovascular impairments at the time of hospital admission,
INBO2 may not be the suggested treatment (reasons discussed below).
Anticipated suggestions for treating high risk CO poisoned populations:

Groups

especially susceptible to the hypoxic stress of CO exposure would potentially be
individuals with anemia (decreased hemoglobin content) (Penney, 1988; Weaver et al.,
2002) and individuals with cardiovascular or coronary artery diseases (Penney, 1988;
Raub et al., 2000; Satran et al., 2005; Stewart et al., 1973). These groups are assumed to
be at increased risk because of the anticipated reduced (O2 delivering) capacity to
accommodate hypoxic stress caused due to CO. In these patients, the regulatory
mechanisms are already activated in basal conditions to compensate the dysfunction and
depending on the severity additional compensation during CO exposure may be difficult.
Based on the simulation results, it is suggested that the anemic patient populations should
be treated with INBO2. Compared to NBO2, the increases in blood flow to vital organs
(like brain and heart) and ventilation are greater in INBO2.

Despite decreased O2

delivering capacity due to low hemoglobin levels, treating anemic populations with
INBO2 compared to NBO2 will increase O2 delivery and CO removal (Figure 4.1).
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However, treatment with INBO2 is not suggested for CO poisoned patients with
cardiovascular or coronary artery diseases. This is because during INBO2 treatment, there
is an increased work load on heart as the cardiac ouput and myocardial blood flow is
increased (Figure 4.1). This increased workload may lead to myocardial injury in these
patient populations during treatment. Thus it is anticipated that NBO2 or HBO2 may be a
better treatment than INBO2.
Also, there is evidence that healthy humans who are chronically or acutely
exposed to CO under high work loads or physical stress (like exercise) have an increased
risk for morbidity and mortality (Koskela, 1994; Stern et al., 1981). Groups exposed to
CO during exercise are at increased risk of tissue injury, because the hypoxic stress on

tissues due to increased O2 demands (increased O2 consumption) will increase. Also in
conditions of exercise, there is increased uptake of CO due to increases in blood flow to
the tissues and ventilation. In these populations, if the patients do not exhibit
cardiovascular abnormalaties or depressed ventilation at the time of hospital admission,
then INBO2 may be the preferred treatment over NBO2 or HBO2.
Other populations susceptible to hypoxic stress of CO exposure are the fetus,
pregnant women (Penney, 1988; Weaver et al., 2002), and patients with obstructive lung
diseases, cerebrovascular and peripheral vascular diseases. For patient populations with
cerebrovascular and peripheral vascular diseases, INBO2 may be the preferred treatment
over NBO2 due to the advantage of increased cerebral oxygenation (Figure 4.1). Patients
with obstructive lung diseases should be treated with either NBO2 or HBO2, as INBO2 is
accompanied with increases in ventilation. In these patient populations flow of air in and
out of the lungs is either impaired or limited and additional increases in ventilation during
treatment on INBO2 may have deletorious effects. The effects of INBO2 on the human
fetus and pregnant women are not known. Thus it would be difficult to suggest a
treatment for these patient populations.
Limitations of the study: The foremost limitation of this study is lack of availability of

experimental data to compare tissue O2 levels in various tissues during high CO
exposures and various treatments. Model predictions of possibility of occurrence of
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unconsciousness or functional impairments are based on PTHO2 estimated by the model
for tissues representing an average brain, heart or skeletal muscle. The model estimated
times for t< PTHO2, tPTHO2 or tPrO2 during different CO exposures and treatments may
either be an overestimate or underestimate in certain regions of the brain, heart or muscle
tissues (cortex, gray matter, endocardium, epicardium, lower limb muscles, etc) with
statistically significant differences in blood flow, oxygen consumption, capillary density,
etc. Considering this limitation, I interpret my results with acknowledging the fact that
the values for PTHO2, t< PTHO2, tPTHO2 or tPrO2 may be poor approximations of the actual
values.
During CO exposures, cardiac output and blood flow to tissues (brain, heart and
muscle) increases as a function of %HbCO (Equations 3.18-3.17 of Chapter 3). These
increases in blood flow are attributed to the vasodilatatory effects of CO. Also, during
treatment it is not known if the hyperoxia and hypocapnia induced vasoconstriction,
compensates the vasodilatatory effects of CO. The regression equations were developed
from animal and human data during or at the end of CO exposure (Chapter 3).
Contribution of CO to increases in blood flow during various treatments is not known.
Rucker et al. (2002) compared brain blood flow during NBO2 and INBO2 in humans after
a CO exposure resulting in ~10 %HbCO. The blood flow in this study decreased during
the normocapnic treatment but the fall was not rapid, indirectly suggesting the possibility
of the presence of vasodilatatory effect of CO during treatment. However the contribution
of CO to increases in blood flow at 10% HbCO may be smaller compared to a high
%HbCO level (>25). For very high %HbCO levels (>50), the estimates of blood flows
from the regression equations may be overestimating the increases in blood flow. Thus
the uptake and removal of CO during CO exposure and treatment for the highest
exposure level in this study may be underestimating the values for CObody T1/2, T%HbCO<10,
t< PTHO2, tPTHO2 or tPrO2.
In this study O2 delivery and CO removal was compared in healthy, adult, male
subjects exposed to different concentrations and durations of CO. Treatments to ensure
fast O2 delivery and CO removal were suggested for otherwise-healthy CO poisoned,
adult, male subjects. I hypothesize that the suggested treatments in this study will be
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applicable to (i) otherwise-healthy CO poisoned, adult, nonpregnant, female subjects, (ii)
anemic subjects, (iii) otherwise-healthy, elderly CO poisoned subjects, and (iv) subjects
with coronary artery disease, cerebrovascular or peripheral vascular diseases.
Applicability of the suggested treatments to enhance O2 delivery or CO removal in other
populations like the fetus, infants, children, pregnant women and patients with
obstructive lung diseases is not predictable due to the complexity involved in the
adaptation mechanisms in these groups. Also variations in treatments like administering
<100% O2 (in ambulance), room air (removing victim from site of CO exposure) or
HBO2 at lower atmospheric pressures have not been simulated in this study. Even if these
variations were simulated, the treatments suggested in this study will still be the best
therapies to treat otherwise-healthy CO poisoned subjects.

CONCLUSIONS

The main goal of my study was to compare NBO2, HBO2 and normocapnic NBO2 to
determine the best treatment strategy ensuring fastest CO removal and O2 delivery after
CO poisoning in healthy subjects. A validated mathematical model was used to compare

these treatments after exposure to CO of different durations and concentrations. Among
the treatments compared, analysis of my simulation results suggests that normocapnic
normobaric oxygen (INBO2) is the best treatment available to ensure fast O2 delivery and
removal of CO from the body. Physicians and care givers should consider treating
otherwise-healthy CO poisoned victims with normocapnic normobaric oxygen instead of
poikilocapnic normobaric oxygen. Also, clinical trails should be conducted comparing
the merits of treating CO poisoned victims with NBO2 and INBO2.

SUMMARY

Carbon Monoxide (CO) is responsible for a large number of accidental and
intentional poisonings reported throughout the world. CO produces tissue toxicity by
impairing oxygen (O2) delivery to the tissues. Treatments for CO poisoned victims
involve administering supplemental O2 at normal (NBO2) or high pressures (HBO2). The
merits of NBO2 or HBO2 with regards to improving O2 delivery to the tissues and
removing CO from the body during the treatments are not known. In this study, I use a
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validated mathematical model to compare O2 delivery and CO removal during three
different treatments (NBO2, HBO2 and isocapnic NBO2). In my simulations, these
treatments are administered immediately after exposure to long or short durations of
varying CO concentrations. Analysis of the results of various simulations of treatments
followed after varying severities in CO poisoning suggests that among the treatments
compared, isocapnic NBO2 is the most efficient therapy to ensure faster O2 delivery to
the tissues and CO removal from the body.
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Table 4.1: Questions related to CO poisoning treatments
1. Are there any merits of treating otherwise-healthy CO poisoned subjects with
HBO2 after a 6 hr treatment of NBO2?
2. For otherwise-healthy CO poisoned subjects, what is the maximum duration of
NBO2 after which administered HBO2 therapy may still have a favorable effect
in improving O2 delivery to the tissues and speeding removal of CO from blood
and tissues?
3. For otherwise-healthy CO poisoned subjects, are there any benefits of treating
with normocapnic NBO2 over poikilocapnic NBO2?
4. Among the therapies available (NBO2, HBO2, normocapnic NBO2) to treat
otherwise-healthy CO poisoned subjects, which is the best treatment strategy
that will ensure fastest CO removal and O2 delivery during treatment?
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Table 4.2: Subject specific parameters
Cardiac
output
Muscle
Blood
( Q ),
mass (VM), +DMCO,
volume
*MRO2,
(VB), L
ml/min/Kg L/min
Kg
ml/min/Torr
Subject
115
240
6.6
5.1
31.8
7.19
108
194
7.5
4.0
28.0
6.34
112
320
6.7
5.3
38.8
8.80
118
167
5.1
3.5
25.6
5.81
119
285
6.9
6.9
36.2
8.20
120
231
5.8
4.4
31.3
7.08

* Total body oxygen consumption; + Muscle diffusion coefficient of CO
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Table 4.3: Symbols and Definitions
Symbol

Definition

PTHO2

Threshold PO2, the PO2 below which unconsciousness or other functional
impairments in the tissues may occur.

t<PTHO2

Before treatment, duration for which PO2 is below PTHO2 in the brain tissue

t<PTHO2

Before treatment, duration for which PO2 is below PTHO2 in the heart tissue

t<PTHO2

Before treatment, duration for which PO2 is below PTHO2 in the muscle tissue

tbPTHO2

Time taken by a treatment to reach a PO2 above PTHO2 in the brain tissue

tcPTHO2

Time taken by a treatment to reach a PO2 above PTHO2 in the heart tissue

tmPTHO2

Time taken by a treatment to reach a PO2 above PTHO2 in the muscle tissue

PrO2

Control or pre-CO exposure tissue PO2.

tbPrO2

Time taken by a treatment to reach a PO2 above PrO2 in the brain tissue

tcPrO2

Time taken by a treatment to reach a PO2 above PrO2 in the heart tissue

tmPrO2

Time taken by a treatment to reach a PO2 above PrO2 in the muscle tissue

COblood

Total CO blood burden (CO in all vascular compartments of the model)

COtissue

Total CO tissue burden (CO in all the tissue compartments of the model)

CObody

Total CO body burden (CO in the blood and tissue compartments and the
lungs)

CObody T1/2

Time taken by a treatment to remove 50% of the total CO body burden

T %HbCO<10

Time taken by a treatment to reach %HbCO levels <10
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Table 4.4: %HbCO levels at the end of CO exposure
Subject

*Short, %HbCO
115
108
112
118
119
120

37.48
42.01
44.79
39.40
34.04
43.74

+

Long, %HbCO
40.72
42.97
44.21
41.66
38.61
43.67

* Short CO exposure = 6400 ppm, 20 min; + Long CO exposure = 450 ppm, 480 min
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Table 4.5: O2 delivery and CO removal during 6 hr NBO2 treatment
Variable (Mean ±SD)

*Short exposure

%HbCO
tbPrO2, min
tcPrO2, min
tmPrO2, min
CObody T1/2 , min
T %HbCO<10, min
τe, min
Ge
τl, min
Gl

40.2±4.1
286±23
250±18
166±7.1
84.1±11
167±7.9
40.2±6.5
80.9±18
149±17
417±81

+

Long exposure
41.9±2.1
303±19
265±23
180±16
83.9±11
179±14
43.9±6
97.6±22
151±18
459±101

* Short CO exposure = 6400 ppm, 20 min; + Long CO exposure = 450 ppm, 480 min
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Table 4.6 A: O2 delivery and CO removal during different treatments for subject, S115
Variable

#

Treatment*

T1

T2

T3

T4

T1

T2

T3

T4

T1

T2

T3

T4

312

127

184

139

340

135

185

159

360

139

186

182

272

200

245

165

296

210

253

190

320

210

260

210

176

128

168

111

199

131

186

135

225

133

187

157

0

0

0

0

4

4

4

4

7

7

7

7

1.4

1.4

1.4

1.4

8

8

8

8

10

10

10

10

1.3

1.3

1.3

1.3

9

9

9

9

10

10

10

10

0

0

0

0

3

3

3

4

16

16

16

18

1.5

1.5

1.5

1

15

15

15

5

35

35

35

35

1.5

1.5

1.5

3

6.5

6.5

6.5

22

15

15

15

3

91.

92.

92.

66.

85.

85.

85.

67.

78.

78.

78.5 69.4

0

0

8

6

6

6

4

1

0

143

175

120

202

152

191

142

222

158

tbPrO2, min
tcPrO2, min
tmPrO2, min
tb<PTHO2 ,min
tc<PTHO2 ,min
tm<PTHO2 ,min
tbPTHO2, min
tcPTHO2, min
tmPTHO2, min

$

%HbCO=37.5

CObody T1/2 ,
8
min
T %HbCO<10, 175
min

&

%HbCO=46.7

%HbCO=56.8

198

163

*T1= CO exposure followed by treatment on NBO2 for 6 hr (6 hrNBO2)
*T2= CO exposure followed by treatment on NBO2 for 2 hr followed by 1.5 hr (90 min)
treatment on HBO2 at 3ATA (2 hrNBO2-1.5 hrHBO2).
*T3= CO exposure followed by treatment on NBO2 for 3 hr followed by 1.5 hr (90 min)
treatment on HBO2 at 3ATA (3 hrNBO2-1.5 hrHBO2).
*T4= CO exposure followed by treatment on isocapnic NBO2 for 6 hr (6 hrINBO2)
#

Exposure to 6400 ppm of CO for 20 min

$

Exposure to 8000 ppm of CO for 20 min

&

Exposure to 10000 ppm of CO for 20 min

140

Table 4.6B: O2 delivery and CO removal during different treatments for subject, S118
Variable

#

Treatment*

T1

T2

T3

T4

T1

T2

T3

T4

T1

T2

T3

T4

272

126

184

135

300

132

185

154

315

134

186

163

254

197

244

145

280

205

247

198

300

208

257

209

164

129

186

99

187

128

185

115

200

127

184

130

0

0

0

0

4.5

4.5

4.5

4.5

7.5

7.5

7.5

7.5

6

6

6

6

9

9

9

9

11

11

11

11

4

4

4

4

9.5

.5

9.5

9.5

10.

10.

10.5 10.5

5

5

tbPrO2, min
tcPrO2, min
tmPrO2, min
tb<PTHO2 ,min
tc<PTHO2 ,min

$

%HbCO=39.4

&

%HbCO=48.9

%HbCO=59

tm<PTHO2 ,min
tbPTHO2, min
tcPTHO2, min

0

0

0

0

4

4

4

4

15

15

15

17

6

6

6

4

10

10

10

6

15

15

15

13

4

4

4

4

9.5

9.5

9.5

9

10.

10.

10.5 11

5

5

68

67.

tmPTHO2, min
80.
CObody T1/2 ,
2
min
T %HbCO<10, 159
min

80.

80.

52.

74.

74.

74.

53.

6

6

5

5

6

6

8

137

160

94

182

144

182

141

67.8 54.5

8
199

149

190

153

*T1= CO exposure followed by treatment on NBO2 for 6 hr (6 hrNBO2)
*T2= CO exposure followed by treatment on NBO2 for 2 hr followed by 1.5 hr (90 min)
treatment on HBO2 at 3ATA (2 hrNBO2-1.5 hrHBO2).
*T3= CO exposure followed by treatment on NBO2 for 3 hr followed by 1.5 hr (90 min)
treatment on HBO2 at 3ATA (3 hrNBO2-1.5 hrHBO2).
*T4= CO exposure followed by treatment on isocapnic NBO2 for 6 hr (6 hrINBO2)
#

Exposure to 6400 ppm of CO for 20 min

$

Exposure to 8000 ppm of CO for 20 min

&

Exposure to 10000 ppm of CO for 20 min
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Table 4.6C: O2 delivery and CO removal during different treatments for subject, S119
Variable

#

Treatment*

T1

T2

T3

T4

T1

T2

T3

T4

T1

T2

T3

T4

309

126

184

140

340

135

185

160

350

137

186

180

261

193

236

160

295

203

241

182

315

207

249

205

170

128

185

170

200

131

186

130

225

135

187

153

0

0

0

0

1.5

1.5

1.5

1.5

5

5

5

5

0

0

0

0

4

4

4

4

7

7

7

7

3.5

3.5

3.5

3.5

7

7

7

7

9.5

9.5

9.5

9.5

0

0

0

0

1

1

1

1

7

7

7

8

0

0

0

0

2.5

2.5

2.5

2

10

10

10

9

2

2

2

2

3.5

3.5

3.5

3.5

10

10

10

11

103

103

103

73

97

97

97

73.

90

89.

89.8 74.2

tbPrO2, min
tcPrO2, min
tmPrO2, min
tb<PTHO2 ,min
tc<PTHO2 ,min
tm<PTHO2 ,min
tbPTHO2, min
tcPTHO2, min
tmPTHO2, min

$

%HbCO=34

CObody T1/2 ,
min
T %HbCO<10, 179
min

&

%HbCO=42.3

%HbCO=51.4

5
145

180

122

209

155

195

145

8
232

163

203

167

*T1= CO exposure followed by treatment on NBO2 for 6 hr (6 hrNBO2)
*T2= CO exposure followed by treatment on NBO2 for 2 hr followed by 1.5 hr (90 min)
treatment on HBO2 at 3ATA (2 hrNBO2-1.5 hrHBO2).
*T3= CO exposure followed by treatment on NBO2 for 3 hr followed by 1.5 hr (90 min)
treatment on HBO2 at 3ATA (3 hrNBO2-1.5 hrHBO2).
*T4= CO exposure followed by treatment on isocapnic NBO2 for 6 hr (6 hrINBO2)
#

Exposure to 6400 ppm of CO for 20 min

$

Exposure to 8000 ppm of CO for 20 min

&

Exposure to 10000 ppm of CO for 20 min
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NBO2

INBO2

↓ Brain blood flow: due to O2
breathing causing
cerebrovascular
vasoconstriction

↓ Brain blood flow: due to O2
breathing causing
cerebrovascular
vasoconstriction

↑ Brain tissue PCO2

↑ Brain tissue PCO2

↑ Ventilation

↑ Ventilation

↓Arterial PCO2

No change or slight rise in
arterial PCO2

↓Brain tissue PCO2

↑ Brain tissue PCO2*
↑ Ventilation*: resulting in
improved CO removal.

↓Brain blood flow: due to
decreasing arterial PCO2,
resulting in decreased cerebral
O2 delivery

↑ Brain blood flow*: resulting
in increased cerebral O2
delivery

↓Cardiac output: due to
decreasing arterial PCO2,
resulting in decreased O2
delivery

↑ Cardiac output *: resulting in
increased O2 delivery

Figure 4.1: Poikilocapnic normobaric oxygen (NBO2) vs. Isocapnic normobaric oxygen
(NBO2). * INBO2 is administered using a mixture of 98% O2 + 2% CO2 and inspiration
of CO2 is accompanied with increases in brain blood flow, brain tissue PCO2’s, and
ventilation.
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Chapter 5: Conclusions and Future work
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CONCLUSIONS

In my dissertation, I have applied validated mathematical models (Erupaka et al.,
2010, second specific aim) of human systems to understand and analyze physiological
mechanisms in situations where experiments either provide limited information about the
physiological process (first specific aim) or are unethical (third specific aim). I
hypothesized that “accurately estimating the amount of CO bound to myoglobin during
and after CO inhalation will (i) allow improving the accuracy of CO-rebreathing methods
to determine hemoglobin mass and (ii) aid in suggesting treatments ensuring fast CO
removal from the body.” As determination of amount of CO bound to myoglobin is
diffcult because non-invasive measurements of MbCO are not possible, a mathematical
model was enhanced to address knowledge gaps in the literature. My dissertation has
given me the opportunity to (i) analyze CO-rebreathing techniques used to estimate total
hemoglobin mass, (ii) develop and validate a multicompartment model to compare O2
delivery and CO removal during different treatments administered after CO poisoning
and (iii) analyze treatment protocols for otherwise-healthy CO-poisoned subjects.
My project 1 (first specific aim) is the first study to determine the sources
of errors in the existing CO rebreathing methods to estimate hemoglobin mass, MHb.
Inaccuracies in estimation of volume of CO bound to myglobin were determined as the
major source of error. The existing CO rebreathing methods are used to estimate MHb to
determine the effects of adaptation to exercise training, environmental stresses, illness or
trauma. Also, reference ranges of MHb are developed for athletic and clinical purposes.
The errors in estimation of hemoglobin mass from the current CO rebreathing methods
were in the range of 2%-6% depending on the blood site sampled, CO rebreathing
method applied, and intersubject variability. These errors suggest that in order to compare
the mean MHb values among different studies and to develop accurate reference ranges
for MHb, information about the source of error and the approximate magnitude of errors
associated with each CO rebreathing method and sampling site should be considered.
Thus, determining the magnitude and sources of errors in the existing CO rebreathing
methods to estimate MHb is vital in interpreting and comparing the results of different
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studies done in clinical and sports medicine. Also, if the errors in estimation of MHb are
small then significant changes in MHb can be easily detected with a smaller population
size, whereas a larger population is needed to detect significant changes with a method
which has larger errors. Using a validated mathematical model to estimate the amount of
CO bound to myoglobin during and after CO inhalation aided in improving the accuracy

of CO-rebreathing methods to determine hemoglobin mass. Based on the simulation
results, I have suggested modifications to the existing CO rebreathing methods to
estimate total hemoglobin mass with low errors (Protocols Bmodified and Pmodified). The
proposed modifications to these methods were to use the suggested (i) regression
equations to estimate volume of CO bound to myoglobin, (ii) Tsample’s, and (iii) blood
sites. I have also proposed a new CO rebreathing method to estimate hemoglobin mass
with low errors (Protocol N). In this study, I have made an attempt to understand the
reasons for variability in the values reported in the literature for hemoglobin mass (MHb)
estimates and mixing times from CO rebreathing studies differing in methods, durations
of CO rebreathing, intial dose of CO administered and recruited subjects. I have also
suggested optimal blood sites and sampling times to estimate hemoglobin mass with low
errors. Making use of the optimal sampling time and blood site to obtain estimates of
hemoglobin mass will make the CO rebreathing methods less inconvenient to the subject,
and inexpensive. Following suggestions for shorter CO rebreathing durations will make
these procedures easy to perform. In conclusion, estimating hemoglobin mass with
modified versions of the existing CO rebreathing methods or the proposed new method
will be less inconvenient to the subject, inexpensive, reliable, accurate, easy to perform
and will make comparison of hemoglobin mass among different studies possible.
The mathematical model developed in my project 2 (second specific aim) is a
significant contribution to the database of mathematical models. Significant
enhancements made to my previous upgraded model (Erupaka et al., 2010) are addition
of: (i) brain compartment (Figure 3.1), (ii) mass balance equations for CO2, (iii) control
of ventilation, (iv) regulation of blood flow: cardiac output, cerebral blood flow,
myocardial blood flow, skeletal muscle tissue and non-muscle tissue blood flow with
changes in arterial O2 saturation (SO2), PO2, PCO2, %HbCO and (v) Bohr effect on O2
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dissociation curve and Haldane effect on CO2 dissociation curve. Regression relations to
predict cardiac output and cerebral blood flow during high CO exposure levels
(%HbCO>30) were developed. Regression relationships to predict cardiac output and
brain blood flow during hyperoxic and hyperbaric conditions were developed as a
function of arterial PO2 and PCO2’s. This developed multicompartment model has the
capability to estimate O2, CO and CO2 tensions, bicarbonate levels, pH levels, blood
HbCO levels, and MbCO levels (in myoglobin containing tissues) in all the vascular and

tissue compartments in normoxia, hypoxia, CO hypoxia, hyperoxia, isocapnic hyperoxia
and hyperbaric oxygen. Furthermore, reliable measurements of tissue oxygenation, PtO2,
in healthy human tissues (brain, heart and skeletal muscle) are difficult to make. To
assess the quality of treatment (NBO2 or HBO2) administered to CO-poisoning patients, it
is difficult to conduct large, controlled, randomized treatment clinical studies on CO
poisoned victims. Thus, a better approach would be to use a validated mathematical
model to estimate CO burden in different tissues (brain, heart, skeletal muscle) for
various CO exposures and treatment sessions. Determination of PtO2 in the human brain,
heart, and skeletal muscle tissues by the model, during CO exposure and treatment will
provide valuable information on tissue oxygenation as noninvasive measurement of these
values is difficult.
In project 3 of my dissertation, the most important issues (like comparision of
merits of hyperbaric O2, normobaric O2 and iscocapnic normobaric O2) pertaining to
treatments of otherwise-healthy CO poisoned victims were addressed. Long and short CO
exposures followed by treatment on normobaric O2 (NBO2) were simulated in healthy
adult subjects. Also simulations of varying levels (%HbCO= 37.5, 47, 57) of short CO
exposures followed by 6 hr on NBO2, 2 hr on NBO2 followed by 1.5 hr on HBO2, 3 hr on
NBO2 followed by 1.5 hr on HBO2, 4 hr on NBO2 followed by 1.5 hr on HBO2, or 6 hr
on NBO2 with maintaining isocapnia at normocapnic levels were administered.
Administering HBO2 after 6 hr on NBO2 did not have any merit in improving O2 delivery
or CO removal after long and short CO exposures in healthy, adult subjects. The
maximum interval of NBO2 after which administering HBO2 had the benefit of
improving O2 delivery to the tissues and CO removal from the body was 4 hr.

147

A treatment protocol is optimal only if it can provide sustained high tissue PO2’s,
together with rapid clearance of CO and other metabolites. The time taken to reach a PO2
above the threshold PO2 was similar in all the treatments. However, the time taken to
reach the resting PO2 was shorter in normocapnic normobaric O2 (INBO2) treatments.
Also the time taken to reach %HbCO levels <10, was shorter for INBO2 treatment. For
any severity of poisoning, administering normocapnic normobaric oxygen was beneficial
in improving CO removal and oxygen delivery, when compared to poikilocapnic
normobaric oxygen. In all the simulations for HbCO levels <50%, during treatment with
INBO2, the HbCO levels are <10% and the tissue PO2’s also reach the control values
(PO2’s prior to CO exposure) withing 3 hrs of treatment. Thus for %HbCO’s less than 50,
the normocapnic normobaric O2 treatment duration can be reduced to 3 hrs for otherwise
healthy CO poisoned subjects. Approximately normocapnic normobaric oxygen therapy
can be administered by using a gas mixture of 2-3% of CO2 in O2. The other best
alternative to INBO2 treatment is treating the otherwise healthy CO poisoned subjects
with NBO2 for 2 hr followed by 1.5 hr on HBO2 (based on its availability). Also
compared to poikilocapnic normobaric O2, hyperbaric O2 treatment will always be
benefical in improving tissue O2 delivery and CO removal to the otherwise-healthy CO
poisoned subjects, provided it is administered within 6 hrs of administration of NBO2.
Based on the analysis of my simulations, I have proposed a treatment protocol
(normocapnic normobaric oxygen) which enhances CO removal from the body and
improves oxygen delivery after any severity of CO poisoning in healthy adults. This
treatment was reported to improve O2 delivery and enhance CO removal in humans for
%HbCO levels <15. During normocapnic NBO2 treatment, my simulation results confirm
improved O2 delivery and enhanced CO removal in humans for HbCO levels up to 50%.
Physicians should consider the benefits of administering normocapnic NBO2 over
poikilocapnic NBO2. However it should be noted that this therapy cannot be expected to
reverse cell injury or prevent sequelae (neurological or myocardial) that may have
occurred before the end of CO exposure. I have also suggested anticipated optimal
treatments for “high risk” populations, but these suggestions were based on
understanding of physiology and may have to be tested through simulations. Comparison
of isocapnic treatments with poikilocapnic treatments have helped me in understanding
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the role of CO2 during treatments and suggest new treatment strategies (hypercapnic
normobaric oxygen, normocapnic or hypercapnic hyperbaric oxygen) for treating CO
poisoned victims. Irrespective of the poisoning severity, the suggested normocapnic
normobaric oxygen therapy ensures fast removal of CO from the body, improves O2
delivery to the tissues, and is easy and affordable to administer.
In this dissertation suggestions made for improving (i) CO rebreathing methods to
estimate hemoglobin mass and (ii) treatments for fast CO removal in otherwise healthy
CO poisoned populations are based on analysis of predictions from validated

mathematical models. However, the findings from this study should be confirmed by
conducting experiments. Experiments should be conducted to estimate hemoglobin mass
using the suggested CO rebreathing methods and the estimated hemoglobin mass from
these studies should be compared with the measurements made from the gold standard
radioactive techniques. Also, physicians should conduct trials comparing normocapnic
normobaric oxygen treatments with poikilocapnic normobaric oxygen and hyperbaric
oxygen treatments in CO poisoned subjects.

149

FUTURE WORK

1. Conduct experiments in human subjects to estimate hemoglobin mass using the
three CO rebreathing protocols suggested in this dissertation. These experiments
should be conducted to ensure the validity of the conclusions made in my
dissertation that using the modified versions of the existing CO rebreathing
methods (Protocols Bmodified and Pmodified) or the newly proposed CO rebreathing
method (Protocol N) to determine hemoglobin mass, the variability in the estimated
values of hemoglobin mass will be negligible for a given subject. Also, the
hemoglobin mass estimated from protocols Bmodified, Pmodified, and N can be
compared to a known hemoglobin mass of a subject determined from any other
method (except from a CO dilution technique), to verify the results of my model
simulations that determination of hemoglobin mass from the CO rebreathing
methods proposed (protocols Bmodified and Pmodified and N) in this study result in low
errors.
2. Conduct clinical trials on patients with similar poisoning severities and symptoms
randomized to receive poikilocapnic normobaric oxygen and normocapnic
normobaric oxygen. In the literature, clinical trials comparing poikilocapnic
normobaric oxygen and normocapnic normobaric oxygen have not been conducted.
Prior to conducting clinical trials in humans, experiments to determine a better
treatment for CO poisoned victims can be done in human like species e.g.,
monkeys. In these species, different treatments can be compared after a short (20
min) and long (8 hr) duration CO exposures resulting in HbCO levels upto 40%.
My simulation results suggest that compared to poikilocapnic normobaric oxygen,
normocapnic normobaric oxygen improves O2 delivery and CO removal during
treatment. Based on my simulation results, I suggest that these experiments should
be conducted to compare the merits of poikilocapnic normobaric oxygen and
normocapnic normobaric oxygen after CO poisoning occurs. Data concerning to (i)
time taken for %HbCO levels to reach < 10% after treatment is administered, (ii)
occurrence of myocardial abnormalities (ECG abnomalities, arrythimias etc.)
during treatment, (iii) blood flow during treatments, (iv) blood gases and O2
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content during the treatments (v) neuropsychological tests after treatments and (vi)
volume of CO exhaled during treatments should be recorded. The information from
determining the time taken for %HbCO levels to reach < 10% and volume of CO
exhaled during treatments will allow comparision of a treatment’s efficiency to
remove CO. The product of blood flow and oxygen content can be used as measure
of O2 delivery during the treatments. Also, the results from neuropsychological
tests and myocardial performance tests may furthur assist in determining the state
of oxygenation during treatments. In these clinical trials, continual statistical
assessment of collected data should be done. If the statistical assessments favour a
particular type of treatment, then the trial should be stopped and the physicians
should be encouraged to administerd the favoured treatment.
3. Apply mathematical model to compare NBO2, HBO2, normocapnic NBO2,
hypercapnic NBO2 and hypercapnic HBO2 therapies to determine the best
treatment strategy ensuring fastest CO removal and O2 delivery after CO poisoning
of varying severities in healthy populations consisting of young, middle aged, and
elderly male and nonpregnant female subjects. Determine the sensitivity of these
different treatments to intersubject variability in specific parameters like blood
volume, cardiac output, muscle mass, ventilation, and fitness level.
4. Enhance and validate the model by implementing compensatory mechanisms
accompanied with high altitude living, anemia, and by implementing disease states
associated with impaired oxygen delivery, e.g., coronary artery diseases,
cerebrovascular diseases or peripheral vascular diseases. Generally in patients with
coronary artery diseases, there is decreased blood flow to the heart due to narrowed
or blocked arteries. In my model, the blood flow to the myocardium can be reduced
depending on the degree of blockage and myocardial oxygen tensions and body CO
burden can be predicted during CO exposure and treatments. Then I can use the
enhanced and validated mathematical model (suitable for simulating the disease
state) to compare NBO2, HBO2, normocapnic NBO2, hypercapnic NBO2 and
hypercapnic HBO2 therapies to determine the best treatment strategy ensuring
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fastest CO removal and O2 delivery after CO poisoning of varying severities in
these populations consisting of young, middle aged, and elderly male and
nonpregnant female subjects.
5. Compare CO dose to myocardium with occurrence of abnormal features in ECG
(ElectroCardioGram). Myocardial hypoxia during CO exposures has been reported
to produce changes in ECG (S-T segment elevation, QT dispersion, T wave
changes). The extent to which the CO load (HbCO and MbCO levels) contributes
to ECG alterations seen in CO poisoning victims is unknown. Assessing the
correlations between the occurrence of predicted peak MbCO and HbCO levels
with occurrence of abnormalities in ECG will aid in understanding the CO
poisoning related increased risk of cardiac injury during treatments.
6. Develop and validate a multicompartment brain model representing different
regions of the brain (cortex, white matter, gray matter, basal ganglia, and
hippocampus) and assess the state of oxygenation in these regions during CO
exposures and treatments.
7. Enhance the model further by implementing anaerobic metabolic pathways to
understand energy production and utilization during CO induced hypoxic stress.
Introduce interactions of cytochrome c oxidase with CO. Cytochrome c oxidase is
also known to bind reversibly with CO. Understanding the contribution of this
protein will further enhance the knowledge database for CO toxicity. Improve
control of ventilation in the model by implementing effects of changes in H+ ions
on ventilation. Also implement lactate dynamics to determine lactate threshold for
anaerobic metabolism to occur.
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